Stem Cell Marker OCT3/4 in Biology and Diagnostics of Germ Cell Tumors by Jong, J. (Jeroen) de
  
 
Stem Cell Marker OCT3/4 in Biology 
and Diagnostics of Germ Cell Tumors 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Printed by PrintPartners Ipskamp, Enschede. 
 
Coverdrawing by Anoek & Jeroen de Jong, detail of the front page from “Exercitationes de 
Generatione Animalium” (1651) by William Harvey. 
 
The research described in this thesis was performed in the LEPO laboratory, Erasmus MC, 
Rotterdam and supported by an Erasmus MC Translational Research grant. 
 
ISBN 978-90-9022351-3 
© 2007 Jeroen de Jong
  
 
Stem Cell Marker OCT3/4 in Biology 
and Diagnostics of Germ Cell Tumors 
 
Stamcel marker OCT3/4 in de biologie en diagnostiek van kiemceltumoren 
 
 
 
 
 
Proefschrift 
 
 
 
 
 
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de 
rector magnificus 
Prof.dr. S.W.J. Lamberts 
en volgens besluit van het College van Promoties 
 
 
 
 
De openbare verdediging zal plaatsvinden op 
woensdag 14 november 2007 om 13.45 uur 
 
 
 
 
door 
Jeroen de Jong 
geboren te Vlaardingen 
 
  
 Promotiecommissie 
 
Promotoren:  Prof.dr. L.H.J. Looijenga 
   Prof.dr. J.W. Oosterhuis 
 
Overige leden: Prof.dr. R. Fodde 
   Prof.dr. J.A. Grootegoed 
   Prof.dr. C.H. Bangma 
  
 
 
 
 
 
 
“Ik hoop dat ik het nog mag meemaken, jongen.” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ter nagedachtenis aan opa Ouweschoen 
 
 CONTENTS 
 
1 General introduction 
Based on: Stem cell marker OCT3/4 in tumor biology and germ cell 
tumor diagnostics: history and future. Critical Reviews in Oncogenesis, 
12 (3-4): 171-203 (2006) 
Scope of this thesis 
2 Diagnostic value of OCT3/4 for pre-invasive and invasive 
 testicular germ cell tumours 
 Journal of Pathology, 206: 242-249 (2005) 
3 A 40-year old woman with a progressive periventricular 
 white matter lesion 
 Brain Pathology, online August 2007 (printed version January 2008) 
4 Immunohistochemistry on testicular biopsies is mandatory for 
carcinoma in situ diagnosis: OCT3/4 as informative marker 
manuscript in preparation 
5 Differential methylation of the OCT3/4 upstream region 
in primary human testicular germ cell tumors 
Oncology Reports, 18: 127-132 (2007) 
6 JKT-1 is not a human seminoma cell line 
 International Journal of Andrology, 30 (4): 350-365 (2007) 
7 Characterizion of the first seminoma cell line TCam-2: 
biology and functional pathways  
 submitted for publication 
8 SOX17 instead of SOX2 as partner of POU5F1 (OCT3/4) in  
normal and malignant embryonic germ cells 
 submitted for publication 
9 General discussion 
10 Summary & samenvatting 
Curriculum vitae 
Publications 
Appendix of colour figures 
Abbreviations 
Dankwoord 
9
22
33
49
55
69
83
109
129
147
165
173
174
175
190
191
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
 
Jeroen de Jong & Leendert H.J. Looijenga. Stem cell marker OCT3/4 in tumor biology and 
germ cell tumor diagnostics: history and future. Critical Reviews in Oncogenesis, 12 (3-4): 
171-203 (2006)
General introduction & Scope of this thesis 
 11
INTRODUCTION 
 
Pluripotency is regarded as the hallmark of embryonic stem (ES) cells. The ability of these 
cells to differentiate into all three germ layers during embryogenesis, which give rise to 
specialized tissues and organs, is the requisite to form complex multi-cellular organisms. 
In addition, this pluripotency is transmitted through the germ line to the next generation. 
Although the concept of pluripotency was already implied in William Harvey’s 
postulation “Ex ovo omnia” in the 17th century, the mechanisms regulating pluripotency 
on the molecular level have only been partly elucidated nowadays. Based on results from 
the past 17 years, transcription factor OCT3/4 is currently regarded as one of the key 
regulators of pluripotency.1,2 The central role of OCT3/4 in keeping cells in an 
undifferentiated pluripotent state and preventing differentiation has been a major focus in 
stem cell research. In germ cell development prolonged expression of OCT3/4 is tightly 
linked to malignant transformation and the genesis of germ cell tumors of adolescents and 
young adults. A detailed overview of the role of OCT3/4 during normal embryogenesis is 
provided and translated to its current status in the study of germ cell tumorigenesis. 
 
 
HISTORY AND STRUCTURAL TRAITS 
 
Initially, OCT3/4 was identified in nuclear extracts of undifferentiated cells of the murine 
embryonal carcinoma (EC) cell line F9 and designated nuclear factor A3 (NF-A3).3 
Subsequently, different names have been used for this protein as OCT34,5, OCT46,7 and a 
combination of the previous, OCT3/48.  
The OCT3/4 transcription factor belongs to a family of octamer binding proteins that 
specifically bind to the conserved ATTTGCAT motive in transcriptional control elements 
of genes.9 The octamer motive is recognized by the highly charged POU domain10 in the 
OCT3/4 protein, from which the gene name POU5F1 (POU family of transcription 
factors, class 5, factor 1) is derived. On the DNA level the POU domain consists of two 
subdomains: a C-terminal homeodomain and an N-terminal POU-specific region 
separated by a short non-conserved linker.11 The human POU5F1 gene has been mapped 
to chromosome 6p21 and consists of 5 exons from which two alternative splice variants 
can be transcribed.12,13 In most reports, only the long splice variant, isoform A, is studied, 
however recently there has been increased interest in the short splice variant, isoform 
B.14-16 This last isoform is localized in the cytoplasm and is unable to activate or repress 
transcription of OCT3/4 responsive genes in contrast to isoform A.15 Because of a 
polymorphism at the initiating codon, not all individuals can form the isoform B protein.12 
Therefore, the biological function of the human OCT3/4 isoform B mRNA and protein 
remain to be established. 
Next to the POU5F1 gene six pseudogenes have been identified in the human genome.17,18 
These pseudogenes can be transcribed, but a protein will never be formed. 
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FUNCTION OF OCT3/4 EXPRESSION IS CELL TYPE DEPENDENT 
 
The presence of OCT3/4 is vital for the formation of pluripotent stem cells during 
embryogenesis as shown in a mouse knock-out study by Nichols et al.19 OCT3/4 deficient 
embryos develop to blastocyst-like structures with a normal cell number at the site of the 
prospective inner cell mass (ICM), but after implantation no homozygous mutant embryos 
are found. The ICM cells of these embryos are not pluripotent and are restricted to 
differentiation along the extra-embryonic trophoblast lineage during in vitro 
propagation.19 Tightly regulated expression levels of OCT3/4 dictate pluripotency and 
differentiation. In mouse ES cells with inducible OCT3/4 regulation, Niwa et al 20 showed 
that a 50% decrease in expression levels resulted in trophectodermal differentiation, 
whereas a 50% increase initiated upregulation of primitive endoderm and mesoderm 
markers. This confirms the previous results from Palmieri et al 21 who described OCT3/4 
protein expression to appear higher in the newly forming primitive endoderm than that 
seen in the ICM population of murine blastocysts. In addition, Botquin et al 22 found a 
transient 2.5 fold increase in OCT3/4 mRNA levels after 1 day of retinoic acid induced 
differentiation of murine EC cells through a hypoblast-like stage. Differentiation along 
the trophectodermal lineage as a result of OCT3/4 downregulation was recently also 
shown by RNA interference (RNAi) targeting the OCT3/4 mRNA in mouse and human ES 
cell lines.23-26 Besides expression in undifferentiated cell types in early development, 
OCT3/4 is also present in migrating primordial germ cells (PGCs). These cells are not 
pluripotent in vivo but committed to gametogenesis after they reach the developing 
gonads. Conditional gene targeting during murine PGC migration indicates that loss of 
OCT3/4 presence leads to apoptosis instead of differentiation to trophectoderm.27 This 
suggests that OCT3/4 has a function in survival of these cells during migration. However, 
conditional gene targeting by the same strategy as in vivo in cultured embryonic germ 
cells derived from 8.5dpc PGCs leads to trophectodermal differentiation instead of 
apoptosis.27 This is consistent with the observation that cultured human PGCs can give 
rise to pluripotent stem cells capable of forming embryonic bodies that contain cells of all 
three germ layers.28 How the function OCT3/4 exerts in a certain cell type is intrinsic to 
that cell or is dependent on its niche remains to explored further. The mechanism and 
pathway by which OCT3/4 promotes survival in PGCs and how this is linked to its role in 
pluripotency is unknown at the moment. 
 
 
ROLE IN NORMAL DEVELOPMENT 
 
The role of OCT3/4 in early mammalian development has first been recognized in the 
mouse4,5,7,29 and was subsequently studied in human14,30,31, bovine32,33, porcine33, marsupial34  
and monkey35 embryogenesis. In general, expression patterns are the same in all 
mammals, however there are some marked and significant differences, especially in the 
early stages of embryogenesis and gametogenesis. The interspecies differences in early 
embryogenesis could be expected because of species-specific timing of activation of 
embryonic transcription when transition from oogenetic to embryonic control of 
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development is initiated and the cells of the embryo begins to synthesize their own 
mRNA and protein, thereby replacing the mRNA and protein pool maternally inherited 
from the oocyte.36,37 Besides the variation between species, there are also inconsistencies 
between studies on the same animal. 
Expression of OCT3/4 in human embryogenesis was first reported in 1995 by Abdel-
Rahman et al 30 using murine-based degenerate primers for RT-PCR on embryos at the 1-
cell to blastocyst stages. These embryos were not suitable for assisted reproduction 
because of retarded development and were therefore available for research. Throughout 
development, from unfertilized oocyte to blastocyst, OCT3/4 expression was detected. To 
clarify the distribution pattern of OCT3/4 in human blastocysts, Hansis et al 31 examined 
mRNA expression in ICM and trophectoderm cells of blastocysts discarded for in vitro 
fertilization due to anomalous morphology. Blastocysts were halved, creating a 
trophectoderm part and a mixed ICM/trophectoderm part and the OCT3/4 expression 
levels were found to be significantly higher in the ICM/trophectoderm compared to the 
trophectoderm samples. In addition, the size of the ICM was well correlated with the 
OCT3/4 mRNA levels, indicating a rather similar level in each individual ICM cell. 
Recently, Cauffman et al 14 performed a large study on OCT3/4 mRNA and protein 
expression in a series of 36 oocytes of various maturity and 112 normally developing pre-
implantation embryos at the level of single blastomeres, morulas, blastocysts, or ICM and 
trophectoderm samples. Oocytes and cleavage stage embryos revealed a variable 
expression pattern, concomitant with a pure cytoplasmic localization of the protein. 
During compaction, the variability in expression faded away indicating embryonic 
OCT3/4 expression and the protein appeared in the nucleus implying biological activity. 
In blastocysts, transcripts and protein were present at approximately the same levels in 
ICM and trophectoderm, which is in contrast to the previous study by Hansis et al 31, 
expression profiling by Adjaye et al 38 and studies in murine embryos21,33, but consistent 
with studies in bovine and porcine embryos32,33. In Rhesus monkey the study by Mitalipov 
et al 35 points to a position in between where early blastocysts have OCT3/4 expression in 
the trophectoderm that diminishes quickly as these blastocysts expand and hatch. 
Immediately after implantation, it is not possible to follow the fate of OCT3/4 positive 
cells in human embryos. Studies in the mouse using mRNA in situ hybridization5 and 
transgenic mice expressing green fluorescent protein under control of the OCT3/4 
promoter39, indicate that OCT3/4 expression becomes restricted to the epiblast until the 
beginning of gastrulation when it is downregulated in an anterior to posterior manner, 
after this only PGCs express OCT3/4. These cells move through the primitive streak and 
invade the definitive endoderm, parietal endoderm and allantois. The fate of the PGCs in 
the allantois is uncertain, however the PGCs from the definite endoderm are incorporated 
into the hindgut pocket and migrate to the developing gonadal ridges.40 After the PGCs 
have reached the genital ridge, they are called gonocytes.41 In the human embryo this 
stage is reached in the sixth week of development42 and these cells have been studied from 
terminated pregnancies as early as 8 weeks.43 In the developing testis these OCT3/4 
positive gonocytes are initially located in the lumen, there they change ultrastructural 
features and move to the basal lamina, where they are called prespermatogonia, which are 
OCT3/4 negative.41,44 Gradually, the number of OCT3/4 positive cells decreases with time, 
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although they can occasionally be detected in neonatal testes.44 In normal human adult 
testis and spermatogenesis no OCT3/4 positive cells are present45 in contrast to adult 
mouse testis in which Gidekel et al 46 detected OCT3/4 positive spermatogonia A with a 
self-made antibody. 
In the female gonad, OCT3/4 protein expression decreases after ~24 weeks of gestation.47 
At term and in the ovaries of neonates, hardly any positive germ cells were detectable. In 
addition to oogonia, OCT3/4 was occasionally seen in the cytoplasm of early oocytes, but 
was never detectable in cells involved in folliculogenesis.47,48 
 
 
THE PLURIPOTENCY NETWORK 
 
Maintaining cells in an undifferentiated state requires fine-tuning of an intricate network 
of cellular factors that prevents the cell from entering any of the differentiation lineages. 
Tightly controlled expression levels of OCT3/4 have been shown essential in keeping cells 
undifferentiated and pluripotent.20 Besides OCT3/4, a number of other embryonic stem 
cell specific proteins have been identified that contribute to the so-called “stemness” of 
pluripotent cells.38,49-56 Among these are well-characterized transcription factors as 
NANOG and SOX2.57-59 SOX2 (SRY-related HMG box 2) is an HMG domain-containing 
transcription factor that shows an expression pattern similar to OCT3/4 during early 
embryogenesis.59 The HMG-domain and homeodomain DNA binding sites are frequently 
adjacent or in close proximity to each other and their co-evolution suggest a role for 
specialized SOX/POU protein complexes.60 Indeed, for OCT3/4 and SOX2 this protein 
interaction during DNA binding has been confirmed.60,61 In addition, Boyer et al 62,63 
demonstrated by chromatin immunoprecipitation combined with DNA microarrays 
(ChIP-on-chip) that 65% of OCT3/4 direct downstream target genes in human ES cells are 
also regulated by SOX2. Comparative location analysis in mouse ES cells indicated that 
OCT3/4 and SOX2 targets overlap substantially.62,63 This strengthens the functional 
partnership of OCT3/4 and SOX2. Among the target genes are OCT3/4 and SOX2 
themselves and the SOX2-OCT3/4 protein complex regulates OCT3/4 and SOX2 gene 
expression.64 Transcriptional regulation of NANOG gene expression is also dictated by 
joined OCT3/4 and SOX2 binding.65,66 The homeobox transcription factor NANOG is 
required to maintain pluripotency in mouse epiblast and ES cells and RNA interference 
induced downregulation of NANOG in human ES cells leads to extra-embryonic 
endoderm and trophectoderm differentiation.67,68 NANOG exerts its function in a close 
relationship to OCT3/4 and SOX2 as NANOG regulates more than 90% of the OCT3/4-
SOX2 direct downstream gene targets.62 The interdependency is further exemplified by 
the need for OCT3/4 and NANOG to function in parallel in maintaining ES cell self-
renewal and that neither is dispensable nor capable of compensating the role of the 
other.69  
Unravelling the regulation of all components in the pluripotency network is a laborious 
task that requires high through-put screening techniques as well as detailed functional 
analyses of each individual factor. Many studies have focussed on the major players 
OCT3/4, SOX2 and NANOG as discussed above. However, other known “stemness” factors 
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as REX1/ZFP4270, CRIPTO-1/TDGF171, STELLAR/DPPA372 and ESG1/TLE173 are just a 
few examples of the many components whose functional role remains to be established. 
An approach to dissect the pluripotency network is to classify each component based on 
its relation to OCT3/4. This generates three classes: the first containing the upstream 
factors that bind to the regulatory elements of the OCT3/4 gene either activating or 
repressing transcription. Almost all of these factors bind in one of the four conserved 
regions upstream of the OCT3/4 gene (Figure 1).74  The second class consists of proteins 
physically interacting with the OCT3/4 protein and the final class is formed by 
downstream target genes that are directly activated or repressed by binding of OCT3/4 to 
the octamere DNA sequence. Of course, these classes will show some overlap because of 
positive and negative feedback mechanisms and proteins that can bind to OCT3/4 protein 
and its DNA sequence. The bulk of factors identified thus far are repressed downstream 
targets of OCT3/4 like transcription factors involved in developmental processes in human 
and murine embryogenesis.62,63 A large screen on the physical interaction of OCT3/4 with 
other proteins has only been performed in murine ES cells by Wang et al 75. Using affinity 
purification under native conditions of OCT3/4, NANOG and REX1 amongst others, 
followed by mass spectrometry, physically associated protein partners were identified and 
a protein interaction network was constructed. As OCT3/4 also regulates its own gene 
expression, the identified protein partners are potential upstream regulators of OCT3/4 
expression either indirectly via the OCT3/4 protein, directly by binding to the DNA, or 
via both ways. Remarkable was the absence of the well-characterized OCT3/4 protein 
partner SOX2, especially since SOX2 has direct functional contact with the NANOG 
protein in activation of the REX1 gene.70 Another factor that was previously reported as a 
physical partner for OCT3/4 is the early trophectodermal marker CDX2 that reciprocally 
represses OCT3/4 target genes.76 CDX2 was also not present in the protein interaction 
network.75 In mouse embryonic stem cells, it was found that β-CATENIN, a component of 
the WNT signalling pathway, is required for maintenance of undifferentiated ES cells and 
can physically interact with OCT3/4.77 This adds to the view of WNT signalling being 
involved in virtually every aspect of embryonic development and controlling homeostatic 
self-renewal in a number of adult tissues.78 Besides the OCT3/4 protein partners that can 
indirectly influence OCT3/4 transcription, a relatively small number of transcription 
factors has been identified that bind directly to the transcription regulation elements of 
the OCT3/4 gene. As discussed above, OCT3/4, NANOG and SOX2 are the most 
prominent factors during the maintenance of pluripotency. Another class of factors that 
has been shown to positively or negatively regulate OCT3/4 transcription, consists of the 
orphan nuclear receptors for which specific ligands have not yet been defined like 
steroidogenic factor-1 (SF1; ELP; NR5A1)79,80, liver receptor homologue 1 (LHR1; FTF; 
NR5A2)81, COUP transcription factors ARP-1, EAR-2 and EAR-382-84, TR2 (NR2C1)85, and 
germ cell nuclear factor (GCNF; NR6A1)86. This last factor recruits DNA 
methyltransferase DNMT3A for OCT3/4 gene silencing.87 Nuclear receptors with a 
defined ligand are the retinoic acid receptors (RAR; isoforms α, β and γ) and the retinoid 
X receptors (RXR; isoforms α, β and γ) that have been shown to direct early 
embryogenesis, testis development and meiotic timing.88-91 They bind retinoic acid and 
can form heterodimers. Three of these heterodimers, RARα:RXRα, RARβ:RXRα and 
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FIGURE 1. Transcriptional regulation of the OCT3/4 gene and targets of OCT3/4 protein. For clarity the 
well-established name OCT3/4 is used in this figure, however the official gene name is POU5F1. 
Transcription of the OCT3/4 gene is regulated by a large number of proteins that bind to conserved regions 
(CR1 to CR4) in the upstream region of the gene. Which factors will bind depends on the stage of 
embryonic development, cell type and environment of the cells involved. The binding site for NOBOX 
(between CR1 and CR2) is only present in the murine OCT3/4 gene, whereas, in theory, the other factors 
can bind in both the mouse and human gene. However, most of the functional studies have been performed 
in mouse and await confirmation in human cells. Activation of OCT3/4 expression will generate mRNA that 
can be alternatively spliced in human generating two proteins, OCT3/4A and OCT3/4B. The biological role 
of OCT3/4B is unknown at the moment. The OCT3/4A protein can bind to several other proteins, but so far 
again most of these interactions have only been studied in mouse. In addition, OCT3/4A binds to 
transcriptional control elements and activates or represses expression of a large number of genes. Besides 
regulating its own expression by binding to conserved region four (CR4) upstream the OCT3/4 gene, 
OCT3/4A regulates genes involved in differentiation and pluripotency of which a selected number from 
human and mouse data is presented here. Finally, OCT3/4A binds in the vicinity of a number of miRNAs 
and is therefore likely to influence their expression. (Figure 1 colour image on page 177) 
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RARβ:RXRβ specifically bind and activate the OCT3/4 promoter in a ligand-dependent 
manner.82,88 This stimulation is antagonized by COUP transcription factors ARP-1 and 
EAR-3 that down regulate OCT3/4 promoter activity, whereas the DNA-binding 
specificity proteins SP1 and SP3 are also involved in this interaction.82,83,92 Recently 
identified upstream regulators of OCT3/4 expression are newborn ovary homeobox gene 
(NOBOX)93, hypoxia-inducible factor 2α (HIF-2α)94 and a member of the spalt-like 
protein family SALL495. SALL4 activates OCT3/4 expression by direct DNA binding and 
physical protein interaction with OCT3/4 and NANOG.75,96 In addition, SALL4 co-
occupies NANOG genomic sites in embryonic germ cells suggesting a similar NANOG-
SALL4 partnership as OCT3/4-SOX2.96  
Next to downstream target genes whose mRNA expression is under control of the OCT3/4 
protein, expression of specific members of a class of small non-coding RNAs known as 
microRNAs (miRNAs) is likely to be regulated by OCT3/4. MiRNAs are ~22 nucleotide 
RNAs that use antisense complimentarity to inhibit translation of specific mRNAs to 
protein. Recent studies of expression patterns and functional roles have implicated specific 
miRNAs in complex genetic pathways regulating embryogenesis, hematopoiesis, neuronal 
differentiation and Hox-mediated development (see Pasquinelli et al 97 for review). DNA 
binding sites for OCT3/4, NANOG and SOX2 were found in the vicinity of a small 
number of miRNAs (Figure 1).62 An additional piece of evidence for a functional 
relationship between OCT3/4 and expression of certain miRNAs is the co-occupation of 
the presumed promoter of mir-301 by OCT3/4, NANOG and SOX2 and the presence of 
mir-301 in human ES cells.62,98 Finally, RNAi silencing of DICER1, an RNAse III enzyme 
involved in the cytoplasmic processing of miRNAs, suppresses OCT3/4 as well as NANOG 
and SOX2 mRNA and protein expression, and DICER1 knock-out embryos develop to the 
blastocyst stage with an OCT3/4 negative ICM.99,100 In contrast, DICER-null mouse ES 
cells generated by conditional gene targeting express OCT3/4 at normal levels, but cannot 
differentiate both in vivo and in vitro.101 
So far, mainly the nuclear factors that function in maintaining pluripotency have been 
identified. The extra-cellular signals and their intracellular pathways that disturb this 
intricate pluripotency network and lead to differentiation need further exploration. A 
schematic model of OCT3/4 regulation, its protein partners and downstream target genes 
is presented in Figure 1. Most of the evidence of the included factors comes from murine 
ES cells or transgenic mice and awaits to be investigated in human experimental systems. 
In addition, the factors can be cell-type specific and most functional studies have focussed 
on ES cells; however OCT3/4 regulation and function can be substantially different in for 
example PGCs. 
 
 
EPIGENETIC REGULATION OF THE OCT3/4 GENE 
 
Next to the binding of factors on transcription regulatory elements as described above, 
gene expression during normal development is also tightly regulated by epigenetic 
modifications, including cytosine (CpG) methylation and histone modification, including 
acetylation.102 A model for OCT3/4 gene silencing was recently proposed by Feldman and 
Chapter 1 
 18 
co-workers103 who described a sequence of inactivation. First, factors like GCNF bind for 
transient inactivation, followed by deacetylation and subsequently DNA methylation 
catalysed by de novo methyltransferases DNMT3A and possibly DNMT3B, which are 
recruited to the promoter through involvement of effectors as G9A and HDAC (HDAC2 is 
a direct binding partner of the OCT3/4 protein75; see Figure 1). This methylation step 
brings an irreversible repression of OCT3/4 expression preventing reactivation of the gene 
and dedifferentiation of cells. 
Methylation of the OCT3/4 upstream region has been studied in several human and 
murine tumor-derived and ES cell derived cell lines. In mouse ES cells, Hattori et al104 
showed the hypomethylation of this region and compared it to trophoblast stem cells and 
mouse liver cells which were hypermethylated. In addition, they showed that in vitro 
methylation suppressed OCT3/4 enhancer/promoter activity in a reporter assay; a defect 
in the methylation machinery resulted in the ectopic expression of OCT3/4, and the 
demethylating agent 5-aza-2'-deoxycytidine could induce aberrant OCT3/4 expression in 
trophoblast stem cells. This possibly indicates to dedifferentiation of these cells.104,105 In 
cloned mouse embryos the OCT3/4 promoter undergoes gradual demethylation during 
pre-implantation development and inefficient demethylation of the OCT3/4 promoter is 
associated with developmental retardation at early cleavage stages.106 In the malignant 
equivalent of ES cells, the embryonal carcinoma (EC) cells, it was already demonstrated in 
1993 that inhibition of OCT3/4 expression in retinoic acid-induced differentiated murine 
EC cells is achieved through changes in methylation status, chromatin structure and 
transcriptional activity of the OCT3/4 upstream regulatory region.107 These results were 
confirmed by independent studies.8,108 Loss of  OCT3/4 expression during differentiation of 
a human EC-derived cell line (NTera2) was found to be correlated with increased 
methylation in the OCT3/4 upstream region.109 This correlation was also found in human 
ES cells.110 
 
 
OCT3/4 IN ADULT STEM CELLS 
 
Expression of OCT3/4 in ES cells, EC cells and PGCs was proven in multiple independent 
studies. A consistent triad of hypomethylation of the gene promoter region, high 
expression of OCT3/4 mRNA and abundant presence of the protein in the nucleus of these 
cells, has been reproduced repeatedly by different approaches like RT-PCR, micro-array 
expression profiling, Western blotting and immunohistochemistry. However, it is still a 
matter of debate if OCT3/4 expression is restricted to these aforementioned cells. Already 
in 1992, Takeda et al 12 reported expression of both splice variants in normal human heart, 
kidney, liver, spleen and placenta. It is also interesting that in this study the transcripts 
were picked up from a cDNA bank of adult human pancreatic islets. Recently, an 
accumulating pile of articles has been published reporting OCT3/4 expression in normal 
adult tissues and various tumors and cell lines. This increased focus on OCT3/4 has been 
triggered by the concept of adult stem cells, which are tissue specific stem cells with the 
capacity for self-renewal and tissue regeneration.111-113 The current hypothesis is that 
asymmetrical division of a stem cell generates a new stem cell and a multipotent 
General introduction & Scope of this thesis 
 19
progenitor cell, which is restricted to differentiation to cell types within a particular 
organ. These tissue specific stem cells or their multipotent progenitor cells can give rise to 
tumor formation when the homeostasis of self-renewal and tissue regeneration is 
disturbed either by intrinsic properties of the cells themselves, i.e. mutations, or by 
changes in the microenvironment, i.e. the stem cell niche.111,112 Although progress has 
been made in identifying specific cell populations within tumors that can give rise to new 
tumors in transplantation experiments, there remains debate whether these are the true 
adult stem cells and how to further define and characterize them.112,114 
 
 
A MARKER FOR GERM CELL TUMORS OF ADOLESCENTS AND ADULTS 
 
Human germ cell tumors (GCTs) form a heterogeneous group that can mimic various 
stages of intra-uterine development. Recently, we proposed to classify these tumors into 
five subtypes based on anatomical site, phenotype, age of presentation, cell of origin, 
genomic imprinting pattern, genotype and animal model.123 This classification is adopted 
by the World Health Organisation and includes: type I: teratomas and yolk sac tumors of 
neonates and infants; type II: seminomatous and nonseminomatous tumors of adolescents 
and adults; type III: spermatocytic seminomas of elderly men; type IV: dermoid cyst; type 
V: hydatidiform mole.124 The first three types can arise in the testis from immature germ 
cells.  
Testicular germ cell tumors of adolescents and adults, the seminomas and non-seminomas, 
belong to the type II tumors and are the most common malignancies in Caucasian men in 
the second to fourth decade of life.125 They develop from PGCs/gonocytes that are 
malignantly transformed and are located in the seminiferous tubules where normally 
spermatogenesis takes place. These precursor cells of the invasive tumors are known as 
carcinoma in situ (CIS)126 or intratubular germ cell neoplasia unclassified (ITGCNU)124 and 
are normally not found in adult testis. The invasive tumors themselves may exhibit a wide 
spectrum of histological subtypes, ranging from seminoma to various non-seminomatous 
elements: EC, teratoma, choriocarcinoma, and yolk sac tumor.124 Seminoma cells are 
similar to embryonic germ cells, i.e. PGCs or gonocytes, based on morphology, marker 
expression profile and differentiation capacity.123 The malignant counterpart of ES cells, 
EC cells are in principle pluripotent, and thus able to differentiate into several lineages 
analogous to normal embryonic development (Figure 2). Besides the testis, type II GCTs 
can also be found in the ovaries and extragonadal sites, primarily in the midline of the 
body.123 A major feature that set these tumors aside from all other solid tumors is their 
extreme sensitivity to radiotherapy and chemotherapy resulting in a high curability of 
approximately 95%.127,128 This response to DNA damage reflects the embryonic origin of 
these tumors as ES cells are characterized by the absence of G1 arrest after induction of 
DNA damage.129 Type II GCTs have a distinct chromosomal constitution with the gain of 
12p as the hallmark of all invasive tumors. Gain of chromosome 12, including 12p, is also 
found upon prolonged culturing of human ES cells suggesting a selective advantage of 
increased dosage of the short arm of chromosome 12 for the propagation of 
undifferentiated human ES cells in vitro as well as tumor cell proliferation in vivo.130  
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FIGURE 2. OCT3/4 (POU5F1) expression in normal embryogenesis and type II testicular GCT development. 
Developmental stages and cell types that are OCT3/4 positive are represented in grey. The developmental 
stages and cell types of GCTs are in bold/italic and grouped with their embryonic counterpart. Starting at 
the precursor lesion carcinoma in situ (CIS), black arrows represent the development into the various extra-
embryonic and embryonic histological elements. Seminoma has a limited differentiation capacity and can 
only form trophoblastic giant cells (not depicted in this scheme), however seminoma cells can be 
reprogrammed to embryonal carcinoma cells. Embryonal carcinoma is pluripotent and can give rise to all 
three germ layers. In addition, embryonal carcinoma can give rise to malignant germ cells that have a more 
mature phenotype than gonocytes as these germ cells also express TSPY. 
 
In contrast to somatic cells, murine ES cells show predominantly loss and reduplication 
during in vitro culturing leading to uniparental disomy.131 In human ES cells uniparental 
disomy has not been reported so far, but the repeatedly reported chromosomal instability 
leading to predominantly gain of sequences favours the establishment of uniparental 
disomy.132 Interestingly, uniparental disomy is also found in type II GCTs.133 Although its 
presence was explained by a possible fusion of an early germ cell and a sperm, recent own 
unpublished data indicate that this model cannot be true, because uniparental disomy is 
also found in ovarian type II GCTs, which can never be the result of sperm fusion. 
Expression of OCT3/4 in testicular GCTs on mRNA level was reported in 2002 by 
Palumbo et al 134 who showed expression in seminoma and EC and absence in 
differentiated elements teratoma and yolk sac tumor. PCR-amplified sequences were 
examined by restriction enzyme digestion and were specific for the OCT3/4 gene 
transcript and not for the OCT3/4 pseudogenes. The value of OCT3/4 as an 
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immunohistochemical marker in clinical pathology has been recognized since 2003 when 
Looijenga et al 45 published an extensive study on OCT3/4 protein expression in a multi-
tumor tissue microarray analysis covering over 100 different tumor categories and 3600 
individual cancers. They verified that the OCT3/4 protein is specific for particular cell 
types of germ cell tumors. In the testis, the protein was only present in CIS, seminoma and 
EC, and absent in differentiated tumor elements as teratoma, yolk sac tumor and 
choriocarcinoma. In addition, expression was absent in normal adult testis including the 
germ cell lineage. In the ovary, OCT3/4 expression was confined to dysgerminomas, 
which are the seminomatous equivalent of the female gonad as shown by expression 
profiling.135 The precursor lesion of dysgerminoma in the dysgenetic gonad, i.e. 
gonadoblastoma, was also found to be positive for OCT3/4 in accordance to its testicular 
equivalent CIS. Finally, four germ cell tumors in the midline of the brain showed positive 
staining of the EC and germinoma (seminoma of the brain) cells. Comparison of 
chemosensitive and chemoresistant germ cell tumors showed no difference in staining 
pattern.45  
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SCOPE OF THIS THESIS 
 
The studies presented in this thesis focus on the role of OCT3/4 in germ cell 
tumorigenesis and its value as a diagnostic marker for germ cell tumors in clinical 
pathology. An immunohistochemical marker applied for diagnostic purposes has to fulfill 
a number of criteria. First, it has to be reliable, reproducible and robust. Second, the 
expression pattern in normal tissues, both adult and during development, must be 
precisely determined in order to correctly interpret immunohistochemical results. 
Therefore, the expression pattern of different OCT3/4 antibodies was investigated in a 
consecutive series of diagnostic samples. Special attention was given to diagnostic 
challenging cases in which OCT3/4 is mandatory to come to the final diagnosis. Next to 
patient samples, OCT3/4 is used to establish the nature of cell lines as proper in vitro 
model systems for germ cell tumors. 
The parallels between normal embryonic development and germ cell tumor development 
are used to come to a deeper insight into the origin and progression of these tumors. The 
central role of OCT3/4 in maintaining pluripotency and restricting differentiation serves 
as a starting point for investigation. Epigenetic modification of the promotor region of 
OCT3/4 is investigated in the context of expression regulation. Finally, the shift in 
function from gatekeeper of pluripotency in stem cells to survival factor in germ cells is 
linked to a cell specific protein partner. 
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ABSTRACT 
 
Human testicular germ cell tumours of adolescents and adults (TGCTs), the seminomatous 
and non-seminomatous germ cell tumours, show morphological and biological similarities 
to normal embryonic development, presumably determined by their supposed cell of 
origin, the primordial germ cell/gonocyte. Based on this knowledge, OCT3/4, also known 
as POU5F1, was recently defined as a diagnostic marker for these tumour types. In the 
adult testis, positive immunohistochemistry for OCT3/4 is an absolute indicator for the 
presence of the TGCT precursor carcinoma in situ/intratubular germ cell neoplasia un-
differentiated (CIS/ITGCNU), seminoma, and/or embryonal carcinoma. Several studies 
have confirmed this observation, using the same polyclonal antibody. The present study 
demonstrates the usefulness of OCT3/4 immunohistochemistry in a diagnostic setting of a 
consecutively collected series of more than 200 testicular tumours and over 80 testicular 
biopsies. 
Moreover, it is shown that a monoclonal antibody directed against OCT3/4 is as 
informative as the polyclonal antibody, both in immunohistochemistry and in western 
blot analysis. The antibodies are robust and applicable with different methods of 
pretreatment and storage of tissue. This allows routine application of this diagnostic 
marker. 
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INTRODUCTION 
 
Testicular germ cell tumours of adolescents and adults (TGCTs) - seminomas and non-
seminomas - are the most common malignancies in Caucasian men in the second to fourth 
decades of life [1]. These tumours can be treated effectively using surgery, irradiation, and 
chemotherapy, resulting in 5- and 10-year survivals in the range of 90–95%. Despite this 
good prognosis, a major concern is the annual increase in incidence of 2–5% [2]. 
Invasive TGCTs exhibit a wide spectrum of histological types, ranging from seminoma to 
various non-seminomatous elements: embryonal carcinoma, teratoma, choriocarcinoma, 
and yolk sac tumour [3]. Seminoma cells are similar to embryonic germ cells, most likely 
primordial germ cells (PGCs) or gonocytes. Embryonal carcinoma is the malignant 
counterpart of embryonic stem cells, in principle pluripotent, and thus able to 
differentiate into all three germ lineages. This histological spectrum mimics embryonal 
development to a certain extent (see ref 4 for a review). 
Despite the palette of histological appearances of TGCTs, they all originate from a 
common precursor, known as carcinoma in situ (CIS) [5] or intratubular germ cell 
neoplasia unclassified (ITGCNU). Recent findings regarding the expression of embryonic 
traits, and the high expression of the cell cycle regulators that are typical of embryonic 
mitotic germ cells in CIS cells, support the hypothesis that these cells originate from 
PGCs/gonocytes (see ref 6 for a review). So far, all known markers of CIS cells are also 
found in immature germ cells [7]. This hampers the applicability of these markers at an 
early age, particularly if a delay or block of maturation of germ cells is expected, for 
example in the case of cryptorchidism or gonadal dysgenesis [8]. The presence of 
immature germ cells may result in overdiagnosis of CIS, and therefore possibly 
overtreatment. 
To detect CIS by means of immunohistochemistry, the markers c-KIT [9] and PLAP [10] 
have been used for more than a decade. One of the most recent markers is OCT3/4, also 
known as POU5F1. This transcriptional regulator is expressed in undifferentiated, pluri-
potent cells including embryonic stem cells and germ cells, both mouse [11–13] and 
human [14,15]. Knock-out mice are non-viable, because they fail to form a pluripotent 
inner cell mass, but instead consist primarily of cells committed to the trophoblast lineage 
[16]. Inhibition of expression of this gene in mouse and human embryonic stem cells 
results in a similar type of differentiation induction to trophectoderm [17,18]. In contrast, 
recent data show that PGCs without OCT3/4 do not differentiate, but undergo apoptosis 
[19]. This indicates that the role of OCT3/4 in embryonic stem cells and PGCs is different. 
We showed that expression of OCT3/4 in TGCTs is highly similar to the pattern found 
during normal development. In fact, testicular parenchyma containing CIS, as well as 
seminoma and embryonal carcinoma cells, contained mRNA of this gene, while it was 
absent in differentiated non-seminomas [20]. Subsequently, we demonstrated, by using a 
polyclonal antibody, that OCT3/4 protein is detectable in the cell types also positive for 
the mRNAs [21]. We applied immunohistochemistry to a large series of solid tumours 
(organized in tissue microarrays, TMAs) and found that OCT3/4 is a specific marker for 
CIS, seminoma, and embryonal carcinoma. In addition, its expression was also found in 
gonadoblastoma (the CIS counterpart of dysgenetic gonads), dysgerminoma, and 
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germinoma (the seminomatous tumours of the ovary and midline of the brain, 
respectively). No correlation between treatment response and OCT3/4 staining was 
observed. None of the non-germ cell tumours investigated expressed the protein, except 
for three isolated cases [21]. Subsequently, these findings were confirmed by different 
studies [8,22–27] (see Table 1). In addition, Baker and Oliva recently reviewed the value 
of diagnostic markers in ovarian tumours, in which again OCT3/4 was concluded to be 
suitable for identifying dysgerminomas and ovarian embryonal carcinomas [28]. 
Here we report on our diagnostic experience of using immunohistochemistry for OCT3/4 
on a consecutive series of more than 200 testicular cancers. Moreover, the applicability for 
the diagnosis of CIS in testicular biopsies is shown. We demonstrate that, in addition to 
the polyclonal antibody, which has been used in various studies, a suitable monoclonal 
antibody is now available that is informative for both immunohistochemistry and western 
blotting. The monoclonal antibody assures infinite availability of OCT3/4 for clinical 
pathology and research. The diagnostic value of OCT3/4 immunohistochemistry is 
exemplified by the presentation of two patients. One presented with an unusual tumour 
in the brain and the other with a highly necrotic tumour in the retroperitoneal region. 
The positive staining of the neoplasms for OCT3/4 led to their recognition as germ cell 
tumours and the patients were treated successfully. 
 
TABLE 1. Chronological summary of published data on OCT3/4 in germ cell tumours at the mRNA and 
protein levels 
  Germ cell tumours 
   Pre-invasive  Invasive  Metastatic 
     Seminomatous  Nonseminomatous  
Reference Method SpA CIS GB SE GE DG SpSE EC YST MTE ITE CHC EC SE 
Looijenga et al. [21] IHC - + + + + + - + - - - -   
Gidekel et al. [24] IHC + +  +    +       
Sperger et al. [22] Microarray    +    + -      
Rajpert-De Meyts  [8] IHC - + + +   - +       
Jones et al. [25] IHC    +   - + - - - -   
Almstrup et al. [23] Microarray  +  +    +       
Cheng et al. [26] IHC   +   +   - - -    
Cheng et al. [34] IHC             + + 
Jones et al. [27] IHC  +             
All immunohistochemical studies were performed with a polyclonal goat anti-human OCT3/4 antibody 
(C20, sc 8629; Santa Cruz Biotechnology, Santa Cruz, CA, USA), except for Gidekel et al, where a self-made 
rabbit anti-mouse OCT3/4 antibody was used. 
IHC = immunohistochemistry; SpA = spermatogonium A; CIS = carcinoma in situ; GB = gonadoblastoma;   
SE = seminoma; GE = germinoma; DG = dysgerminoma; SpSE = spermatocytic seminoma; EC = embryonal 
carcinoma; YST = yolk sac tumour; MTE = mature teratoma; ITE = immature teratoma; CHC = 
choriocarcinoma. 
 
 
MATERIALS AND METHODS 
 
Sample handling and characterization 
Use of tissues for scientific purposes was approved by the institutional review board (MEC 
02.981). The samples were used according to the ‘Code for proper secondary use of human 
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tissue in The Netherlands’, as developed by the Dutch Federation of Medical Scientific 
Societies (FMWV) (version 2002). 
A total of 223 testicular tumours were consecutively collected in the south-western part of 
The Netherlands, in collaboration with urologists and pathologists. Representative parts of 
the tumour (and adjacent tissue, if available) were snap-frozen in liquid nitrogen or fixed 
in 10% formalin overnight for paraffin wax embedding. Tumours were diagnosed 
according to the WHO classification, supported by immunohistochemistry using 
antibodies directed against germ cell/placental alkaline phosphatase (PLAP), α-fetoprotein 
(AFP), human chorionic gonadotropin (hCG), the stem cell factor receptor c-KIT, and 
cytokeratin 8 (CAM5.2). CD30 was used on a selected series. In addition, 81 open surgical 
biopsies from 56 adults with primary infertility or a history of TGCT were evaluated for 
Johnson score and the presence of CIS. 
 
Immunohistochemistry 
Immunohistochemistry with anti-OCT3/4 antibodies was performed on paraffin wax-
embedded tissue sections of 3 μm thickness. Endogenous peroxidase activity was 
inactivated by incubation in 3% H2O2 for 5 min. Antigen retrieval was carried out by 
heating sections in 0.01 M sodium citrate (pH 6.0) under high pressure up to 1.2 bar. 
Endogenous biotin was blocked using an avidin/biotin blocking kit (SP-2001; Vector 
Laboratories, Burlingame, CA, USA). The sections were incubated for 2 h at room 
temperature with a polyclonal goat anti-human OCT3/4 antibody (sc-8629; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) directed against the COOH terminus of the protein. 
This antibody is used in almost all studies of OCT3/4 and germ cell tumours (Table 1). The 
antibody was diluted 1 : 1000. Subsequently, a biotinylated horse anti-goat secondary 
antibody (BA-9500; Vector) diluted 1 : 200 was applied and bound antibody complex was 
visualized using the horseradish peroxidase (HRP) avidin–biotin complex method. 
Sections were counterstained with haematoxylin. 
A monoclonal antibody against the N-terminus of human OCT3/4 (sc-5279; Santa Cruz 
Biotechnology) was compared with the polyclonal antibody using a 1 : 1000 dilution in 
the same assay as described above. As a secondary antibody, a biotinylated rabbit 
antimouse antibody was used (E0413; Dako, Glostrup, Denmark). Detection and 
counterstaining were as described above. 
To compare the staining pattern of the monoclonal and polyclonal anti-OCT3/4 
antibodies, immunohistochemistry was performed on parallel paraffin wax sections. In 
addition, both antibodies were used at a dilution of 1 : 4000 on parallel, 4 μm thick and 
acetone-fixed, frozen tissue sections. 
Initial OCT3/4 staining of the brain tumour from patient 2 was performed on limited 
paraffin waxembedded material that was left after a large panel of markers was tested. 
Therefore, only a small fragment containing tumour cells was present. To improve this 
result, a negative control slide was reused for OCT3/4 immunohistochemistry using the 
monoclonal antibody. 
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Immunofluorescence 
Fluorescent immunohistochemistry was performed on acetone-fixed frozen tissue sections 
of 4 μm thickness and cytospins of cell lines. The monoclonal anti-OCT3/4 antibody was 
incubated 1 : 2000 for 1 h at room temperature. Subsequently, a secondary FITClabelled 
goat anti-mouse antibody (1090-02; Southern Biotechnology Associates, Birmingham, AL, 
USA) was incubated for 30 min. Counterstaining was done with Vectashield (Vector)/ 
DAPI (Sigma Chemical Co, St Louis, MO, USA). 
 
Cell culture 
The human cell lines Tera1 [29], 2102Ep [30], NT2 [31], and NCCIT [32], all of which 
were derived from embryonal carcinomas, were grown in a 5% humidified incubator until 
80% confluency was reached. Cells were incubated with trypsin–EDTA, harvested, and 
cytospins were prepared. 
 
Protein isolation 
Tissue from frozen sections containing normal testis, embryonal carcinoma, yolk sac 
tumour, mature teratoma and seminoma, and pellets from cell lines Tera1, 2102Ep, NT2, 
and NCCIT were used to extract protein. Samples were washed in cold PBS and 
centrifuged at 0 ◦C for 5 min at 1500 rpm. Lysis buffer (1× PBS, 1% Nonidet P40, 0.5% 
sodium deoxycholate, 0.1% SDS) including protease inhibitors (1 836 153 complete mini 
cocktail; Roche Diagnostics, Mannheim, Germany) was added. Samples were sonicated 
and centrifuged at 0 ◦C for 10 min at 14 000 rpm. Protein lysates were stored at - 80 ◦C. 
 
Western blot 
Samples of 20 μg protein were run on a 10% SDSpolyacrylamide gel, blotted on a PVDF 
membrane for 1 h, and incubated with a primary antibody overnight at 4 ◦C (anti-Oct3/4 
monoclonal and polyclonal antibody both diluted 1 : 1000). HRP-labelled secondary 
antibody was incubated for 1 h at room temperature. After washing, ECL western blotting 
detection reagents (RPN2109; Amersham Biosciences, UK) were added for 5 min and the 
blots exposed. After scanning, the blots were stripped and re-probed with anti-β-actin (1 : 
5000) as a loading control. 
 
 
RESULTS 
 
Immunohistochemistry 
To test the diagnostic use of OCT3/4, immunohistochemistry was performed using the 
polyclonal antibody on a series of consecutively collected cases. In total, 209 testicular 
germ cell tumours were investigated after radical orchidectomy: three spermatocytic 
seminomas and 206 TGCTs (110 pure seminomas, 50 pure non-seminomas, and 46 
combined tumours, the latter containing both a seminoma and a non-seminoma 
component). Mean age and range in major tumour groups were according to the 
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literature. None of the three spermatocytic seminomas or 14 non-germ cell tumours [five 
B-cell lymphomas, three Leydig cell tumours, three embryonal rhabdomyosarcomas, one 
sarcoma, one carcinoid, and one metastatic renal carcinoma (clear cell type)] stained for 
OCT3/4. In contrast, all seminoma and embryonal carcinoma components were positive. 
CIS cells in the adjacent parenchyma of seminomas, non-seminomas, and combined 
tumours were all consistently positive. This was also true for intratubular seminoma (n = 
29) and embryonal carcinoma (n = 18). There was a sharp transition between positive and 
negative cells, coinciding with the border of CIS, seminoma, and embryonal carcinoma 
with adjacent tissue. The CIS and seminoma cells showed highly consistent and strong 
nuclear staining, whereas in embryonal carcinoma cells, diffuse cytoplasmic staining was 
seen in addition to the nuclear staining. Representative examples are shown in Figures 1A 
and 1B (seminoma in Figure 1A; seminoma and embryonal carcinoma in Figure 1B). 
Fluorescent detection confirmed this cytoplasmic staining to be absent in seminoma 
(Figure 1C) and CIS, and specific for embryonal carcinoma (Figure 1D). Because 
cytoplasmic staining was never seen in the negative controls, and was only found together 
with nuclear presence of the protein, we regard cytoplasmic staining to be an intrinsic 
characteristic of embryonal carcinoma. Based on morphological and immunohisto-
chemical data, no CIS, seminoma or embryonal carcinoma cell was found to be negative. 
This pattern of staining is in agreement with our previous observations, in line with the 
published data of others (Table 1). 
 
FIGURE 1. OCT3/4 immunohistochemistry 
using different embedding, fixation, and 
detection methods. (A) Nuclear staining 
(brown) of seminoma cells with a mono-clonal 
antibody. (B) Embryonal carcinoma and 
seminoma incubated with a polyclonal 
antibody. Note the cytoplasmic staining in the 
angio-invasive embryonal carcinoma (arrows) 
compared with the clear cytoplasm of 
intratubular seminoma cells. Both slides are 
from formalin-fixed and paraffin wax-
embedded tissue. Images C–F show FITC-
labelled fluorescence with the monoclonal 
antibody as the primary step. Nuclear staining 
is in blue (DAPI) and OCT3/4 localization in 
green (FITC). (C) Frozen tissue from a 
seminoma. (D) Frozen tissue from an 
embryonal carcinoma. Note the difference in 
cytoplasmic staining pattern between 
seminoma and embryonal carcinoma cells. 
Cytospin preparations of (E) pluripotent 
embryonal carcinoma-derived cell line NT2 
and (F) nullipotent 2102Ep. Note the OCT3/4-
negative cells located at the periphery of the 
aggregates.  
(Figure 1 colour image on page 178) 
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Besides the different tumour samples, four embryonal carcinoma-derived cell lines were 
investigated. All cell lines showed strong nuclear and faint cytoplasmic staining with both 
enzyme-based and fluorescent immunohistochemistry. Remarkably, all cell lines 
contained a number of cells without positive nuclear OCT3/4 staining. This heterogeneity 
was clearly greater in the pluripotent NT2 cell line (41% OCT3/4-negative) than in 
nullipotent cell lines [2102Ep (9%), NCCIT (18%), and Tera1 (14%)], possibly due to 
spontaneous differentiation (Figures 1E and 1F). OCT3/4-negative cells were pre-
dominantly located at the borders of cell aggregates, which is consistent with 
differentiation [33]. 
Next to the analysis of orchidectomy specimens (see above), a series of consecutively 
collected testicular biopsies was included. These were taken because of infertility or a 
history of TGCT. In total, 81 biopsies from 56 patients were included. Based on both 
morphology and immunohistochemistry for OCT3/4, CIS was found in open surgical 
biopsies in four patients: two had a prior TGCT of the contralateral testis and two 
presented with infertility. A clinically occult seminoma was diagnosed in the biopsy from 
another patient with prior TGCT. In addition, in two patients with a palpable testicular 
node, the excision biopsy showed seminoma in both cases. 
 
Comparison of the monoclonal and polyclonal antibodies 
Because of the, by definition, finite availability of a polyclonal antibody, and possible 
differences between batches, we studied the suitability of a commercially available 
monoclonal antibody directed against OCT3/4. In parallel, this monoclonal and the 
polyclonal antibody used to date (also see above) were compared using immuno-
histochemistry on both frozen and formalin-fixed, paraffin wax-embedded tissue, and 
western blot analysis. Both antibodies showed a similar pattern in both approaches, 
without background staining (data not shown). Western blot analysis was performed on 
total protein extracted from normal testis, seminoma, and the various histological types of 
non-seminoma, as well as the TGCT-derived cell lines (Figure 2A). These results are in 
accordance with the immunohistochemical data. The presence of the two bands around 
the expected size of 43 kD, corresponding to the longer OCT3/4 variant [13], is currently 
under investigation. 
 
Robustness of the polyclonal and monoclonal antibodies for immunohistochemistry 
To check the stability of the polyclonal and monoclonal antibodies for immuno-
histochemistry, the following procedure was performed repeatedly (n = 4). Undiluted 
antibody was frozen at −20 ◦C, thawed, used for immunohistochemistry, and again stored 
at −20 ◦C. Staining results did not decrease after multiple cycles. Immunohistochemistry 
results for frozen acetone-fixed, paraffin wax-embedded, formalin-, formaldehyde- and 
Bouin (Figure 2B)-fixed material and pretreated by microwave or high pressure were all 
successful, and suitable for diagnostic purposes.  
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Demonstration of the clinical value of OCT3/4 immunohistochemistry 
The clinical value of immunohistochemistry for OCT3/4 in the diagnosis of solid tumours 
is demonstrated by the following two cases. 
 
Case 1 
A 37-year-old male presented with pain in the left flank for 1 year, related to an 
abdominal mass extending from the diaphragm to the aortic bifurcation with involvement 
of the left kidney and retroperitoneal lymphadenopathy. The patient showed small 
testicles on ultrasound. Serum LDH was strongly elevated up to 3568 U/l (normal: 0–449), 
while hCG levels were elevated to 29.5 IU/l (normal: 0–1.9). Guided biopsies showed large 
areas of necrosis and fibrosis with fields and strands of closely packed neoplastic cells with 
intermingling of lymphocytes. The malignant cells had round nuclei with prominent 
nucleoli and intermediate to large amounts of clear cytoplasm. The morphological 
differential diagnosis was: seminoma, Ewing/small blue round cell tumour and lymphoma. 
Immunohistochemically, the tumour cells showed very weak cytoplasmic and focally 
membranous staining for c-KIT (Figure 2C), while scattered cells were positive for keratin 
8 (not shown). No staining was found in tumour cells for PLAP, hCG, CD30, AFP, CD99, 
desmin, CD21, CD45, EMA, and TDT. The lymphocytes were positive for CD45. The 
tumour cells were consistently positive for OCT3/4 (Figure 2D), from which the diagnosis 
of seminoma was made and the patient was accordingly treated with chemotherapy. 
During standard chemotherapy, there was a rise in AFP levels, unusual for a seminoma. A 
nonseminomatous component was therefore suspected and the patient underwent 
retroperitoneal lymph node dissection (RPLND) and nephrectomy of the involved left 
kidney. In addition, his left testis, which showed microlithiasis on ultrasound, was 
removed. AFP levels normalized and no viable tumour tissue was found in the RPLND, 
kidney or testis specimens. After a rise in hCG level to 5.8 IU/l suggesting residual 
tumour, his right testis was removed; again, no tumour tissue was found and hCG 
normalized. Two and a half years after the initial diagnosis, the patient has no signs of 
recurrent disease. 
 
Case 2 
A 40-year-old female presented with visual disturbances, followed by slowly progressive 
left-sided motor and sensory disturbances. She also suffered from memory disturbances 
and was mildly spatially and temporally disorientated. A T2 weighted MRI scan showed a 
large area of high signal intensity in the periventricular white matter of the right more 
than the left occipital region and the corpus callosum, without enhancement on T1 
weighted images after gadolinium administration and without mass effect. A tumour was 
considered unlikely and an acute demyelinating encephalomyelopathy was suspected. 
Repeated cerebrospinal fluid examination showed mononuclear pleiocytosis (10 cells per 
cubic mm; normal value: <3 cells), without tumour cells. Flow cytometry showed 
predominantly reactive T-lymphocytes, without evidence of tumour cells. A CT scan of 
the thorax and abdomen did not reveal any abnormalities. The CSF-serum IgG index was 
normal and oligoclonal bands were absent. No evidence of vasculitis or an inflammatory 
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disease was found, and treatment with steroids was ineffective. A stereotactic biopsy of 
the intracerebral lesion showed blast-like neoplastic cells within a mononuclear infiltrate 
(Figure 2E). A wide panel of markers including those for a primary central nervous system 
lymphoma was applied: CD3, CD4, CD5, ALK-1, CD19, CD20, CD79a, CD45, CD30, S100, 
MELAN-A, HB45, CD68, CD43, PLAP, hCG, AFP, and CD56 all showed no staining; 
there was some punctate keratin positivity and no final diagnosis was made. At first, her 
condition stabilized, but after a few months it deteriorated further and an MRI scan 
showed increasing focal areas of enhancement. Immunohistochemistry for OCT3/4 
(Figure 2F) revealed the tumour to be a germinoma and she was treated with whole brain 
irradiation. Follow-up MR imaging showed disappearance of the enhancement and her 
condition improved, although focal deficits remained present. One and a half year after 
treatment, her condition is stable. 
 
FIGURE 2. (A) Western blot analysis 
for OCT3/4 in different testicular 
germ cell tumours, derived cell lines, 
and normal testis. Note the specificity 
for seminoma and embryonal 
carcinoma. (B) OCT3/4 immuno-
histochemistry on Bouin-fixed tissue 
showing  positive staining of CIS. (C, 
D) Retroperitoneal tumour with 
extensive necrosis from patient 1 
showing weak cytoplasmic, focally 
membranous staining for c-KIT in red 
(C, positive cells indicated with 
arrows) and distinct brown nuclear 
staining for OCT3/4 (D). (E, F) 
Tumour localized in the brain of 
patient 2, with scattered cells with 
clear cytoplasm and prominent 
nucleoli (E) with positive staining for 
OCT3/4 (F). (Figure 2 colour image on 
page 179) 
 
 
 
 
DISCUSSION 
 
After our initial publication [21] showing the sensitivity and specificity of OCT3/4 
immunohistochemistry for the detection of a number of specific histological variants of 
human germ cell tumours, the results were largely confirmed in subsequent studies, both 
by immunohistochemistry with the same polyclonal antibody and at the mRNA level 
(Table 1). The first study included an extensive multi-tumour tissue microarray covering 
more than 100 different tumour categories and 3600 individual cancers. Strong nuclear 
expression was found in seminomatous tumours, irrespective of anatomical localization 
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(like germinoma and dysgerminoma), and embryonal carcinoma, and their common 
precursor cell CIS (as well as gonadoblastoma), whereas the differentiated components of 
nonseminomas (yolk sac tumour, teratoma, and choriocarcinoma) were consistently 
negative. No correlation with chemotherapy sensitivity or resistance was found. Since 
then, it has been demonstrated that OCT3/4 immunohistochemistry is of value to 
diagnose metastatic seminoma and embryonal carcinoma [34]. The antibody applied in the 
different studies reported so far is of polyclonal origin, generated in goat. Therefore, 
availability of this antibody is finite. Here we have demonstrated for the first time that 
similar results can be obtained using a mouse monoclonal antibody, the availability of 
which is unlimited. These antibodies give the same results in immunohistochemistry and 
western blot analysis. Both antibodies appear to be robust and highly stable, and the 
immunohistochemical detection method is relatively insensitive to pretreatment and poor 
quality of the tissue samples. That OCT3/4 is indeed of additional value in clinical 
pathology compared with the other available markers is demonstrated by the two cases 
reported in this paper. One of these patients had an unusual presentation of a germinoma 
(seminoma of the brain) and the other patient had a highly necrotic retroperitoneal 
seminoma, and both were successfully treated as such. OCT3/4 was the only positive 
marker found, even when applied on a slide used previously as a negative control. The 
negativity of the other markers could be due to the absence of these markers in the tissue 
under investigation and/or poor quality of the tissue. 
The value of using immunohistochemistry for OCT3/4 to screen for CIS in testicular 
parenchyma biopsies taken in the context of an outpatient andrology clinic is also 
presented. The data again demonstrate the usefulness of OCT3/4 immunohistochemistry 
for the diagnosis of these pre-invasive cancer cells. It must be kept in mind that the 
presence of OCT3/4-positive cells in testicular parenchyma of patients below the age of 1 
year does not justify the diagnosis of CIS [7], in particular when a germ cell maturation 
delay or block is expected. For this specific application, additional criteria have to be 
developed. Recently, Tai et al [35] reported OCT3/4 protein expression in some cells in 
the basal layer of human skin, corresponding in their hypothesis to the presence of adult 
stem cells. To verify these results, we incubated a total of 20 skin sections from five 
different individuals with the same monoclonal OCT3/4 antibody; no positive cells were 
found and this discrepancy remains to be resolved. 
The data on OCT3/4 are also highly interesting from the biological point of view. An 
oncogenic driving force of OCT3/4 in the pathogenesis of TGCTs has been suggested based 
on mouse studies [24]. This conclusion was drawn from results obtained with experiments 
using mouse embryonic stem cells, which have various expression levels of OCT3/4. These 
cells give rise to so-called teratocarcinomas, which are not the proper animal model for 
TGCTs (see ref 36 for a review). In addition, it has been shown that the effect of OCT3/4 
on a PGC and an embryonic stem cell is indeed different [19]. The fact that, in TGCTs, 
OCT3/4 expression mimics the pattern found during normal development (ie no OCT3/4 
expression is detected in the differentiated non-seminomatous components) supports the 
model that OCT3/4 is under the control of physiological expression machinery and is not 
an oncogene in its classical sense. Our findings and those of others are in line with 
OCT3/4 expression being influenced by neither ploidy nor parental genome composition 
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[37]. In fact, TGCTs originate from an erased PGC/gonocyte [38] and are consistently 
aneuploid [39]. It remains to be established whether epigenetic modifications have a 
regulatory role in the expression of OCT3/4 in TGCTs, as indicated in mouse cells [40]. 
In conclusion, we have demonstrated the diagnostic value of OCT3/4 immuno-
histochemistry for CIS, seminoma, and embryonal carcinoma in a clinical setting. Use of 
the monoclonal antibody is preferable for this application. 
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CLINICAL HISTORY 
 
A 40-year-old female presented with blurred vision and diplopia, followed by slowly 
progressive left-sided motor and sensory disturbances. She also suffered from memory loss 
and mild spatial and temporal disorientation. A T2 weighted MRI (Figure 1A) showed a 
large area of high signal intensity (indicated by arrows) in the periventricular white 
matter of the right more than the left occipital region and the corpus callosum, without 
enhancement on T1 weighted images (Figure 1B), There was no mass effect. A tumor was 
considered unlikely, and acute demyelinating encephalomyelopathy (ADEM) was 
suspected. Repeated cerebrospinal fluid (CSF) examinations showed a mononuclear 
pleocytosis (10 cells per cubic mm, normal value: <3 cells), without immunohistochemical 
evidence of tumor cells; tumor markers HCG, AFP and CEA were not elevated. Flow 
cytometry showed predominantly reactive T-lymphocytes, but again no evidence of 
tumor cells. CT scan of thorax and abdomen did not reveal any abnormalities. The CSF-
serum IgG index was normal, and oligoclonal bands were absent. No evidence of a 
vasculitis or an inflammatory disease was found. Treatment with steroids proved 
ineffective. 
Brain Pathology Case of the Month - August 2007 
printed version January 2008 
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MICROSCOPIC DESCRIPTION 
A stereotactic biopsy of the intracerebral lesion showed blast-like neoplastic cells within a 
mononuclear infiltrate (Figure 2A). The rounded tumor cells contained a large centrally 
located nuclei. A wide panel of markers including those for carcinoma, melanoma and 
primary central nervous system lymphoma was applied: CD3, CD4, CD5, ALK-1, CD19, 
CD20, CD79a, CD45, CD30, S-100, MELAN-A, HMB45, CD68, CD43, PLAP, hCG, AFP 
and CD56, all found to be negative; there was some punctuated NCL5D3 (low molecular 
weight keratins 8 and 18) positivity (Figure 2B). No final diagnosis could be made.  
 
Subsequently, the marker OCT3/4 became available, which has proven to be specific for 
certain histological types of germ cell tumors (6), including seminomatous tumors and 
embryonal carcinoma. This has been confirmed in multiple independent studies (1) (for 
review). 100% of tumor cell nuclei present in the biopsy of the above mentioned patient 
clearly stained positive for OCT3/4 (Figure 2C). Because only a small number of tumor 
cells were present in this slide and no biopsy material was left anymore, OCT3/4 was also 
applied to a slide previously found to be negative by immunohistochemistry for another 
unrelated marker. Again all tumor nuclei stained positive for OCT3/4 without any 
background. Recently, the stem cell factor receptor c-KIT was also applied on a previously 
negative slide and the cytoplasm of some tumor cells was stained positive (Figure 2D). 
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DIAGNOSIS 
Diffusely infiltrating germinoma 
 
 
ADDITIONAL TREATMENT AND CLINICAL PROGRESS 
 
After the lesion was diagnosed as a germinoma, the patient was treated with whole brain 
irradiation in fractions of 1.6 Gy, to a total dose of 44.8 Gy. Follow-up MRI showed 
disappearance of the enhancement and her condition improved, although focal deficits 
remained present. Three years after treatment she had a relapse which was treated with 
chemotherapy (bleomycin-etoposide-cisplatin) with good respons. One year later a second  
relapse occurred 
 
 
DISCUSSION 
Germinomas are tumors of germ cell origin and represent the brain counterpart of 
testicular seminoma. They are relatively rare and represent 0.4-3.4% of all primary 
intracranial tumors, although in Northeast Asia this is significantly higher, up to 9% (4). 
Like other extragonadal germ cell tumors, germinomas occur primarily in the midline, 
with the region of the pineal gland being the most common site, followed by the 
suprasellar compartment (8). They occur predominantly in children with a peak incidence 
around 12 years of age (4).  
Depending on anatomical localization, patients with a germinoma may present with a 
range of neurological, endocrine and psychiatric symptoms. Pineal region tumors often 
compress the cerebral aqueduct, resulting in progressive hydrocephalus, and invade the 
tectal plate, producing a paralysis of upward gaze and convergence known as Parinaud 
syndrome. Suprasellar germ cell tumors compress the optic chiasm, resulting in visual loss, 
and present with endocrinopathy due to pituitary failure with diabetes insipidus, retarded 
growth and sexual maturation (8). Cure rates for this tumor exceed 90% at 10 years, and 
limitation of treatment-related late morbidity is therefore essential (7).  
In this case, the characteristic radiological features of a germinoma were absent (3, 5). 
There was no mass effect, i.e. compression of pre-existent anatomical structures by growth 
of a solid tumor, and no enhancement after gadolinium administration. Instead, the tumor 
was diffusely infiltrating the surrounding tissue and followed the contours of the 
ventricular system. In addition, the marker placental alkaline phosphatase (PLAP) usually 
present in germinomas (2) was negative and diagnosis was made on nuclear OCT3/4 
staining, which has proven to be a valuable marker in diagnosis of germ cell tumors (6, 1). 
Chapter 3 
 54 
REFERENCES 
1. De Jong J, Stoop H, Dohle GR, Bangma CH, Kliffen M, Van Esser JWJ, Van den 
Bent M, Kros JM, Oosterhuis JW, Looijenga LHJ (2005) Diagnostic value of 
OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J Pathol 
206:242-249.  
2. Felix I, Becker LE (1990) Intracranial germ cell tumors in children: an 
immunohistochemical and electron microscopic study. Pediatr Neurosurg 16:156-
162.  
3. Fujimaki T, Matsutani M, Funada N, Kirino T, Takakura K, Nakamura O, Tamura 
A, Sano K (1994) CT and MRI features of intracranial germ cell tumors. J 
Neurooncol 19:217-226.  
4. Jennings MT, Gelman R, Hochberg F (1985) Intracranial germ-cell tumors: natural 
history and pathogenesis. J Neurosurg 63:155-167.  
5. Kanagaki M, Miki Y, Takahashi JA, Shibamoto Y, Takahashi T, Ueba T, Hashimoto 
N, Konishi J (2004) MRI and CT findings of neurohypophyseal germinoma. Eur J 
Radiol 49:204-211.  
6. Looijenga LHJ, Stoop H, De Leeuw HPJC, De Gouveia Brazao CA, Gillis AJM, Van 
Roozendaal KEP, Van Zoelen EJJ, Weber RFA, Wolffenbuttel KP, Van Dekken H, 
Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, 
Oosterhuis JW (2003) POU5F1 (OCT3/4) identifies cells with pluripotent potential 
in human germ cell tumors. Cancer Res 63:2244-2250.  
7. Rogers SJ, Mosleh-Shirazi MA, Saran FH (2005) Radiotherapy of localised 
intracranial germinoma: time to sever historical ties? Lancet Oncol 6:509-519.  
8. Rosenblum MK, Matsutani M, Van Meir EG (2000) CNS germ cell tumours. In: 
World Health Organization Classification of Tumours. Pathology and genetics of 
the tumours of the nervous system, Kleihues P, Cavenee WK (eds.), pp. 208-214, 
IARC Press: Lyon.  
 
 
  
 
  
  57
Immunohistochemistry on testicular biopsies is 
mandatory for carcinoma in situ diagnosis: 
OCT3/4 as informative marker. 
 
Jeroen de Jong1,*, Niels van Casteren1,2,*, Hans Stoop1, Gert J. Dohle2, J. Wolter Oosterhuis1, 
Leendert H.J. Looijenga1 
 
1Department of Pathology and 2Urology, Erasmus MC-University Medical Center Rotterdam, Josephine Nefkens Institute, 
Daniel den Hoed Cancer Center, The Netherlands. 
*These authors contributed equally to the work. 
 
 
ABSTRACT 
 
Carcinoma in situ (CIS) is the common precursor of all type II testicular germ cell tumours 
(TGCTs), i.e. seminomas and nonseminomas, the most frequent solid cancer in Caucasian 
adolescent and young adult males. Although CIS can be detected with a surgical testicular 
biopsy, the rareness of TGCTs does not justify testicular biopsies in the general 
population. However, specific risk factors for TGCTs have been identified, including 
infertility, cryptorchidism, and more recently bilateral testicular microlithiasis. 
Individuals with these characteristics more often have a testicular biopsy taken for 
diagnostic purposes than the general male population. This gives an opportunity to 
diagnose CIS at an early stage, allowing early treatment, thereby preventing development 
of an invasive cancer. However, CIS is difficult to identify using morphology alone, 
especially when it is focal and spermatogenesis is (still) present.  
We performed a retrospective study using the Dutch pathological database (PALGA) on 
patients diagnosed for an invasive TGCT after orchidectomy, who earlier underwent a 
testicular biopsy because of infertility or microlithiasis, and signed out as non-malignant. 
A total of 21 men fulfilled these criteria. In 19 patients new haematoxylin-eosin (H&E) 
slides of the biopsies were examined using morphology alone as well as 
immunohistochemistry for OCT3/4 (next to PLAP and c-KIT) by a pathologist specialized 
in TGCTs. This revealed CIS in four cases and an invasive tumour in two (6/19=31.6%). 
Using immunohistochemistry, an additional four cases of CIS were identified, 
demonstrating an added value of immunohistochemistry of 21.1%. In three patients, this 
diagnosis could have prevented a second gonadectomy, leading to life long hormonal 
androgen substitution. Three out of nine negative biopsies contained less than 30 tubules, 
and should therefore have been classified as insufficient for histological diagnosis.  
This study demonstrates that in a routine pathology setting immunohistochemistry is 
mandatory for the diagnosis of CIS of the testis. Based on staining intensity, it is 
recommended  that  OCT3/4  is  applied  on  formalin-fixed  tissue  and  PLAP or c-KIT on  
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Bouin-fixed tissue. False negative cases can be due to heterogeneous distribution of CIS in 
the testis, favouring taking two biopsies. Application of this protocol will allow early 
diagnosis, and therefore treatment by local low-dose irradiation, to prevent the 
development of an invasive cancer. This will save the patients the heavier treatment for 
an invasive cancer, and will preserve hormonal function of the treated testis in the 
majority of cases. 
 
 
INTRODUCTION 
 
Carcinoma in situ (CIS), also referred to as Intratubular Germ Cell Neoplasia Unclassified 
(ITGCNU) is currently accepted as the precursor of all testicular germ cell tumours of 
adolescents and young adults (TGCTs), i.e., the seminomas and nonseminomas, which we 
refer to as type II TGCTs1,2. The CIS cell is the malignant counterpart of a primordial germ 
cell/gonocyte, which develops in utero. The invasive TGCT will manifest itself after 
puberty. The life-time risk for TGCT is similar to the identified incidence of CIS in a 
population of young males who died of other reasons than a TGCT3. This indicates that all 
CIS will eventually progress to an invasive cancer and that no spontaneous regression 
occurs1. In other words, there is a time window for early diagnosis of CIS, which is of 
clinical value for various reasons. Diagnosis and treatment of CIS can prevent 
development of an invasive TGCTs, which carries the risk of metastasized disease, 
requiring irradiation or chemotherapy and sometimes extensive surgery4. Patients with 
isolated CIS can be cured using local low dose irradiation only, which spares the hormonal 
function of the tesis in the majority of cases1. Some patients at risk for type II TGCTs like 
those with fertility problems undergo testicular biopsies, in others a biopsy is taken to 
diagnose CIS, for example patients with a contralateral TGCT, bilateral testicular 
microlithiasis or cryptorchidism5-11 Although CIS is virtually always found in the 
parenchyma adjacent to a TGCT in orchidectomy specimens, it is reported that in 
testicular biopsies, without an invasive tumour, CIS is missed in approximately 0.5 
percent12,13. This has been attributed to heterogeneous distribution of CIS throughout the 
testis14. Because of this, Dieckmann et al proposed to take two-sited surgical biopsies from 
a single testis which improves the diagnostic yield with 18 percent15. Besides the putative 
heterogeneous histological distribution16,17 CIS can also be difficult to identify in H&E 
stained sections when limited to a few seminiferous tubules that have retained some 
spermatogenesis. Recently, application of immunohistochemistry using specific antibodies 
has significantly increased the sensitivity and specificity of diagnosing CIS, because of the 
identification of (novel) highly specific and sensitive markers. OCT3/4 (POU5F1) is one of 
the best examples in this context18,19. This transcription factor is regarded as one of the key 
regulators of pluripotency19,20, and inhibits apoptosis in early germ cells21. OCT3/4 is 
expressed in CIS, seminoma and embryonal carcinoma cells. All CIS, seminoma and 
embryonal carcinoma cells have a consistent strong nuclear staining for this marker. No 
OCT3/4 staining is found in normal adult testis.  
In this study we assessed the additional value of OCT3/4 immunohistochemistry 
compared to standard morphological investigation for the diagnosis of CIS in patients with 
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a proven type II TGCT, who earlier underwent a testicular biopsy from the same testis 
because of infertility, bilateral testicular microlithiasis, or an earlier TGCT in the 
contralateral testis. In all cases CIS was not recognized in the biopsy. New H&E slides 
were examined by an expert pathologist and complemented with immunohistochemical 
stainings for OCT3/4, PLAP and c-KIT. 
 
 
MATERIALS AND METHODS 
 
Patient selection 
Since 1971 a national pathology database (PALGA) has been used in the Netherlands, 
which covers all (70) academic and non-academic pathology departments. PALGA 
registers histo- and cytopathology using this nation-wide network. 
A database search was performed to identify patients who underwent a testicular biopsy 
and later in life developed a TGCT. This screening resulted in 121 patients fulfilling these 
criteria. The findings in the original biopsies consisted of twelve cases with CIS (9.9%), 88 
invasive TGCTs (72.7%; 55 seminomas and 33 nonseminomas) and 21 cases in which no 
malignant cells were seen (17.4%). The original paraffin blocks of the latter were collected 
from 10 pathology departments involved throughout the Netherlands, including a total of 
28 biopsy specimens from 20 patients (nine bilateral, 11 unilateral). From one patient no 
material could be retrieved. The indications for performing a testicular biopsy were 
obtained from the original pathology report. Because of ethical restrictions, related to 
privacy protection, to the use of data derived from PALGA, it was not possible to obtain 
additional patient information, other than mentioned in the pathology report. 
 
Immunohistochemistry & evaluation 
Three micron thick tissue sections were cut of all the retrieved blocks and stained with 
haematoxylin and eosin (H&E). The slides were evaluated by a pathologist experienced in 
TGCT pathology (J.W.O.). In addition, parallel sections were stained using immuno-
histochemistry for c-KIT, PLAP, and OCT3/4, as described before 18 . Endogenous 
peroxidase activity was inactivated by incubation in 3% H2O2 for 5 min. Antigen retrieval 
was carried out by heating sections in 0.01 M sodium citrate (pH 6.0) for formalin-fixed 
tissue or 0,001M EGTA/0,01M Tris/HCl (pH9.0) for Bouin-fixation, under high pressure 
till 1.2 bar for all three antibodies. Endogenous biotin was blocked using an avidin/biotin 
blocking kit (SP-2001; Vector Laboratories, Burlingame, CA, USA). For OCT3/4 
immunohistochemistry sections were incubated for 2 h at room temperature with a 
monoclonal OCT3/4 antibody (sc-5279; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
directed against the NH2 terminus of the protein. The OCT3/4 antibody was diluted 
1:1000. Subsequently, a biotinylated rabbit anti-mouse secondary antibody (E0413; Dako, 
Glostrup, Denmark) diluted 1:200 was applied and bound antibody complex was 
visualized using the horseradish peroxidase (HRP) avidin-biotin complex method. 
Sections were counterstained with haematoxylin. PLAP and c-KIT immuno-
histochemistry was performed as described earlier22. 
Chapter 4 
 60 
The biopsy samples were blinded prior to evaluation, and the presence of CIS was scored 
first on the H&E stained sections and subsequently on the OCT3/4, PLAP and c-KIT 
stained slides. These immunohistochemically stained slides were compared to asses 
differences in staining pattern between these techniques. 
To asses if a reliable diagnosis could be made, according to the recommendations of 
Nieschlag23, the total number of seminiferous tubules was counted. The orchidectomy 
specimens were diagnosed according to the 2004 WHO classification24. 
 
 
RESULTS 
 
In 21 out of the 121 patients (17.4%) morphological investigation of an H&E stained 
histological section of the testicular biopsy performed in a routine pathology department 
revealed no CIS or invasive type II TGCT, although all 21 subsequently developed an 
ipsilateral TGCT, confirmed by orchidectomy specimen evaluation. The biopsies were 
taken between 1981 and 2003, and the mean age at time of biopsy was 29.1 years (range 
16 to 36 years). The biopsy indication is shown in Table 1. The mean age at time of 
orchidectomy was 33.2 (range 19 to 44 years), and the mean time span between the 
original biopsy and the orchidectomy in these patients was 52.4 months (range 9.3 to 
156.5 months). We were able to obtain paraffin blocks from twenty patients. In one of 
these the paraffin block lacked residual material. In total we were able to re-evaluate 
testicular biopsies from 19 patients. Pathological examination of the 21 orchidectomy 
specimens revealed 13 seminomas, six nonseminomas, one CIS-only and one burned out 
tumour with CIS in the adjacent parenchyma (Table 1). Four patients had a history of 
unilateral TGCT, in three of them a biopsy was performed because of infertility. 
Re-evaluation by an expert in germ cell tumour pathology (J.W.O.) showed, based on 
morphological examination of newly cut slides of the same paraffin blocks used for the 
initial evaluation, that malignant cells were present in six out of the 19 patients (31.6%, 
i.e., four CIS (one of them with a previous TGCT), and two invasive seminomas. In three 
other biopsies (15.8%) the histology was recognized as suspicious for the presence of CIS, 
although it could not be diagnosed with certainty. Immunohistochemistry was deemed 
necessary before coming to a definitive diagnosis. In addition to the six cases diagnosed on 
H&E morphology alone, immunohistochemistry for OCT3/4, PLAP and c-KIT identified 
four more cases (10 out of 19 cases, 52.6%), including the three cases identified as 
suspected. In other words, an experienced pathologist in TGCT pathology is able to 
correctly diagnose CIS in 60.0% of the cases and 90.0% including those classified as 
suspicious. One patient (case no. 7 in Table 1; Figure 1) underwent three successive 
biopsies within a period of 1.5 year for unknown reasons. While based on the H&E 
stained sections no CIS was identified, both originally and in the review, OCT3/4 
immunohistochemistry demonstrated CIS in the second and third biopsy. In four cases, 
the biopsy samples (patients no. 1, 8, 11, and 15 in Table 1) were negative for CIS on H&E 
evaluation and contained 30 tubules or less. Therefore, these biopsies are in principle not 
appropriate to allow diagnosis, because of the risk of false negative findings. However, 
immunohistochemistry demonstrated CIS in one of them. 
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TABLE 1. Patient characteristics with initial pathological evaluation and revision results. 
Case no. 
A
ge at biopsy     (years) 
H
istory 
Fixative 
A
ge at orchidectom
y 
Initial biopsy diagnosis 
N
ew
 H
&
E 
D
iscordance initial diagnosis 
and new
 H
&
E 
O
CT3/4 
D
iscordance new
 H
&
E and 
O
CT3/4 
O
rchidectom
y diagnosis 
1 36 azoospermia F 38 bilateral JS 8-9 no CIS  -  L: SE 
2 32 bilateral orchidopexy 
azoospermia 
B 39 R: hypospermatogenesis, 
some SCOS tubules, 
Leydig cell hyperplasia 
no CIS  -  R: EC + TE  
3 31 orchidopexy, infertility, 
oligospermia 
B 32 R: SCOS, focal 
hypospermatogenesis 
JS 2-3 
suspect  +  R: SE 
4 35 azoospermia B 44 bilateral 
hypospermatogenesis 
no CIS  -  R: SE 
5 28 R: orchidopexy , 
azoospermia 
B 39 bilateral JS 9-10 no CIS  -  R: SE 
6 27 infertility F 39 bilateral JS 3 CIS L + R + L : +, 
R : + 
 R: SE 
7 30 R: orchidectomy 
chemotherapy BEP + 
RPLND, azoospermia 
B+F 33 3 biopsies:  
maturation arrest  
1: no CIS 
2: no CIS 
3: no CIS
 1: -, 
2: +, 
3: + 
+ L: SE 
8 33 - F 34 bilateral JS 9-10 no CIS  L: -  L: SE 
9 28 azoospermia F 34 bilateral SCOS, severe 
spermatogenesis arrest 
R: micro 
invasive SE 
+ R: +  R: SE 
10 34 orchidopexy, 
azoospermia 
B 37 bilateral oligospermia, 
atrophy, Leydig cell 
hypoplasia 
no CIS  -  R: TE 
11 29 bilateral testicular 
microlithiasis 
B 29 bilateral JS 10 no CIS  -  L: SE 
12 28 R: orchidectomy for 
TGCT, infertility 
F 31 L: hypospermatogenesis, 
Leydig cell hyperplasia 
CIS + +  L: SE 
13 24 R: NS, azoospermia F 28 L: 30 % SCOS, some 
spermatozoa 
suspect  +  L: SE 
14 34 azoospermia F 38 L: JS 9 no CIS  -  L: SE 
15 28 - F 29 R: fibrosis, necrosis no CIS  -  R: EC + 
YST 
16 31 infertility F 34 bilateral JS 7 CIS + L: -, 
R + 
 R: SE 
17 31 azoospermia, normal 
gonadotrophins 
F 36 L: maturation arrest CIS + +  L: CIS 
18 29 - . 30 R:  infection, suspicious 
for sarcoidosis 
no material    R: NS 
19 29 - B 33 R: JS 2, areas with JS 6-7 no material     R: CIS + 
burned out 
SE 
20 16 R: TE F 19 L: JS 10 suspect  +  L : NS 
21 21 - F 21 L: reactive connective 
tissue, no testis in this 
biopsy 
NS + +  L : NS 
Legend: JS=Johnsen score; SCOS=Sertoli cell only syndrome; BEP=Bleomycin/Etoposide/Cisplatin; 
RPLND=Retroperitoneal Lymph Node Dissection; F=formalin ; B=Bouin’s fixative ; L=left ; R=right; 
CIS=carcinoma in situ; NS=nonseminoma; EC=embryonal carcinoma; SE=seminoma; YST=yolk sac tumour; 
TE=teratoma 
 
In our study Bouin-fixated biopsy specimens showed a weaker nuclear OCT3/4 staining 
compared to formalin-fixated specimens (data not shown). This is in contrast to our earlier 
study, in which no difference of fixative on OCT3/4 immunohistochemistry was found18. 
Most likely this is due to the duration of fixation. This was not seen for both the non-
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nuclear markers c-KIT and PLAP. In spite of the weaker staining intensity for OCT3/4, no 
difference was seen in the amount of CIS identified compared to c-KIT and PLAP. 
 
 
FIGURE 1. A) Histology of an open surgical biopsy of the testis stained with H&E (25x) (patient 7, Table 1). 
It was identified as suspected, but not proven to contain CIS; B) Higher power of suspected lesion (H & E 
100x); C) Histology of the same biopsy stained immunohistochemical for OCT3/4 (25x). The region with 
positive cell is indicted in the square; D) Higher power of suspected lesion (OCT3/4, 100x); Only three 
tubules contained OCT3/4 positive cells (brown); E) PLAP immunohistochemistry of the same region, 
confirming the presence of CIS cells (red). (Figure 1 colour image on page 181) 
 
Twelve out of the 121 patients (9.9%) were correctly diagnosed with CIS on the testicular 
biopsy during the initial morphological investigation using morphological analysis alone, 
and were subsequently treated by orchidectomy. These patients had a mean age of 28.1 
year at time of orchidectomy (range 18-38). The mean age of patients at time of 
orchidectomy diagnosed with CIS and of those in whom CIS was initially missed was not 
significantly different, respectively 28.7 vs. 28.1 (p=0.77).  
 
 
DISCUSSION 
 
This is the first study to describe the additional value of immunohistochemistry for 
diagnosing CIS in testicular biopsies in a nation-wide setting. The findings are in line with 
the conclusions based on epidemiological observations that CIS will always develop into 
an invasive tumour, and no spontaneous regression occurs25. Therefore, diagnosis of CIS is 
an indication for treatment. Our study shows that evaluation of standard H&E stained 
section of biopsy material, CIS is overlooked and that the use of immunohistochemistry is 
mandatory.  
In 1983, placental like alkaline phosphatase (PLAP) was the first marker used in the 
detection of seminomas. Since then other markers as c-KIT, AP2-gamma and OCT3/4 
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followed20,26-28. Currently, OCT3/4 is best characterized and a reliable marker in TGCT 
diagnostics and 100% of the cells of CIS, seminoma and embryonal carcinoma have strong 
nuclear staining18,19,29. In contrast to PLAP which is positive in 93-98% of the cases and 
the frequent finding of only focal c-KIT positivity in CIS29,30, Jones et al  reported on the 
extra diagnostic yield of OCT3/4 staining in a retrospective study in 6 out of 157 patients31. 
Two out of these six patients were younger than 16 months and therefore the clinical 
importance of this finding can be questioned, as OCT3/4 positive cells found in normal 
testis of neonates32,33 do not always implicate neoplastic transformation of germ cells. Our 
study, including clinical follow-up, is based on revision of testicular biopsies of 19 patients 
who developed a TGCT after an initial CIS negative biopsy. By examination of H&E 
stained slides alone six biopsies were scored positive for CIS or invasive TGCT (31.6%). 
Additional immunohistochemistry for OCT3/4, PLAP and c-KIT identified four additional 
positive biopsies making an extra diagnostic yield of 21.1 percent. Our results show that 
10 out of 19 biopsies (52.6%) were initially incorrectly diagnosed and that additional 
immunohistochemistry is mandatory to come to a correct diagnosis. The development of a 
clinically manifest tumour is the only method to absolutely proof that a biopsy is false-
negative. Therefore follow-up data is crucial in accurately defining the extra diagnostic 
yield of immunohistochemistry of biopsy specimens. 
Immunohistochemical staining results are dependent on tissue fixation and 
standardization of the protocols. Bouin’s fixative is known to provide excellent nuclear 
morphology, which is achieved by the addition of picric acid to formalin, but this fixation 
results in prevention of DNA denaturation34. We speculate that this could affect the 
immunoreactivity of the OCT3/4 nuclear antigen and cause sub-optimal 
immunohistochemical staining. Guidelines concerning fixatives of testicular biopsies are 
contradicting on the use of Bouin’s fixative or formalin4,35. Winstanley et al 35 suggested to 
use formalin fixation in case of CIS diagnostics and Bouin’s fixative in assessing 
spermatogenesis. In addition, the use of Bouin’s fixative makes DNA and RNA retrieval 
for molecular analysis troublesome, which may hamper additional molecular studies. 
CIS was thought to be homogeneously distributed throughout the testis and therefore be 
diagnosed with only a single open surgical biopsy containing >30 tubules and at least 3 
mm in diameter1,23. However, various orchidectomy studies revealed that CIS is non-
randomly distributed throughout the testis and false negative biopsy results can occur16, 36. 
Dieckmann et al recently advised to perform a two-sided testicular biopsy, which in his 
hands increases the diagnostic yield with 18%37. In our cohort six testicular biopsies from 
four patients contained less than 30 tubules and, therefore, a reliable negative diagnosis 
cannot be made. In spite of the limited amount of material available, OCT3/4 
immunohistochemistry showed the presence of CIS in one biopsy. In conclusion, as 
recommended as standard, physicians should take responsibility to provide an adequate 
biopsy containing at least 30 seminiferous tubules, allowing a reliable diagnosis. In this 
study, no correlation between presence or absence of CIS in the biopsy and age of the 
patient was found.  
Recent studies have shown a prevalence of CIS in infertile men of approximately 1% to 
5%1,38. In this perspective it is striking that testicular biopsies of men undergoing a 
testicular biopsy for evaluation of spermatogenesis or sperm extraction (TESE) are not 
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routinely checked for CIS. Schulze et al found five patients with CIS (two bilateral) out of 
766 patients undergoing TESE (0.7%)39. Only two articles describe histological evaluation 
of TESE material and the presence of malignancy, based on morphological criteria 
alone39,40. Both studies underscore the need for histological evaluation for patients at risk 
for TGCT who have a TESE performed. Other risk factors include a history of 
undescended testis, ambiguous genitalia, contralateral TGCT or bilateral testicular 
microlithiasis, with an estimated prevalence of 3, 6-25, 5 and 20%, respectively1,11. In 
these men testicular biopsies should be routinely checked on CIS besides scoring quality 
and quantity of spermatogenesis. It is the responsibility of the referring physician to 
accurately judge the risk for CIS and inform the pathologist of the risk factors in a 
particular patient.  
Diagnosis of CIS before development of an invasive tumour protects patients from 
disseminated disease. Metastatic disease often needs treatment regimes containing 
radiation or chemotherapy, which may lead to severe long-term sequelae. Moreover, 
there is no quarantee that CIS present in the contralateral testis will be eradicated by 
chemotherapy. Therefore, a secondary germ cell tumour can still develop41. In contrast to 
invasive tumours, CIS is curable in almost 100%, although Dieckmann et al reported on 
two cases of testicular cancer despite previous radiotherapy (20 Gy) to the testis42. 
Testicular irradiation eradicates all germ- and CIS cells, but may effect Leydig cell 
function and induce hypogonadism in only a limited number of cases43. However, this 
stands in no contrast to the potential side-effects of chemotherapy, such as vascular 
toxicity, peripheral neuropathy and the potential formation of secondary tumours41,44. In 
our study four patients with a history of TGCT developed a contralateral tumour after a 
false-negative biopsy. In all cases review of the initial biopsy showed the presence of CIS. 
Treatment of CIS in these three patients with local radiation would have prevented the 
second orchidectomy and life-long treatment with androgens. At least one of these three 
patients was initially treated with chemotherapy, confirming that receiving 
chemotherapy (bleomycin/etoposide/cisplatin) does not rule out development of a 
contralateral cancer. Christensen et al found CIS in the contralateral testis after 
chemotherapy in six out 33 patients and estimated a cumulative risk at 10 years of 42%45. 
It is suggested that patients with contralateral CIS should be treated with localized 
radiotherapy or Carboplatin based chemotherapy45,46. 
We are aware of the limitations of our retrospective study. No data are available on 
treatment modality, survival and quality of life. Therefore, we cannot make a definite 
calculation regarding the profit of making a diagnosis of CIS in the first biopsy. However, 
we can conclude that these patients at least were spared an orchidectomy if they would 
have been treated with irradiation alone and life-long androgen supplementation would 
have been prevented in a selection of them.  
A number of conclusions can be drawn from this study: 1) immunohistochemistry is 
needed for the diagnosis of CIS on testicular biopsies, even for expert pathologists; 2) 
OCT3/4 is recommended on formalin-fixed tissue, and c-KIT or PLAP on Bouin-fixed 
tissue (depending on fixation duration); 3) physicians must be aware of the risk factors for 
type II TGCTs, and provide these as relevant clinical information in the pathology request 
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form; 4) testicular biopsies containing at least 30 seminiferous tubules are needed for 
accurate diagnosis of CIS. 
Our study shows that immunohistochemistry is mandatory in evaluating testicular 
biopsies for the presence of CIS. 
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ABSTRACT 
 
Germ cell tumors show many similarities to normal embryogenesis. This is, for example, 
illustrated by the expression of the marker of pluripotency, OCT3/4, known to play a 
pivotal role in the early stages of normal development. Interestingly, it is found to be the 
most informative diagnostic marker for the early developmental stages of malignant germ 
cell tumors. Expression regulation of OCT3/4 has been extensively studied in murine and 
human cell lines, including embryonic stem cell lines and tumor derived cell lines. We 
investigated for the first time the methylation status of the upstream region of the OCT3/4 
gene in normal and neoplastic testicular primary tissues using bisulfite genomic 
sequencing. The cell line JKT-1, supposedly seminoma-derived, was included in the 
survey. Normal testis parenchyma, peripheral blood lymphocytes, spermatocytic 
seminoma, yolk sac tumor and teratoma, and JKT-1 showed a consistent 
hypermethylation. In contrast, seminoma and embryonal carcinoma were 
hypomethylated, confirmed by analyses after tumor micro-dissection. Testicular 
lymphomas showed the most heterogeneous pattern, although specific regions were 
consistently hypermethylated. 
In conclusion, the results obtained from this set of adult normal and neoplastic in vivo 
derived samples is in accordance to the in vitro data that expression of OCT3/4 is 
associated with specific changes in methylation. Moreover, the findings argue against 
OCT3/4 being a driving oncogenic factor in the pathogenesis of human germ cell tumors. 
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INTRODUCTION 
 
Gene expression during normal development is tightly regulated by epigenetic 
modifications, including cytosine (CpG) methylation and histone acetylation (1). During 
the process of tumorigenesis, the physiological (normal) epigenetic patterns may become 
disturbed and as a result, genes under control of these epigenetic modifications, may 
become silenced by promoter hypermethylation (2). Testicular germ cell tumors of 
adolescents and young adults (TGCTs), i.e., the seminomas and non-seminomas, have a 
heterogeneous epigenetic phenotype (3). Overall, gene promoters in seminomas are highly 
demethylated, whereas the non-seminomas show methylation of the majority of 
promoters, as reported for other solid tumors (4,5). The methylation status of seminomas 
is consistent with the cell of origin of TGCTs, the primordial germ cell (PGC) (reviewed in 
ref. 3). During early embryogenesis, PGCs migrate from the yolk sac to the genital ridge, 
from which the gonad develops. During this migration the epigenetic marks of the PGCs 
are largely erased and only become re-established as the PGCs mature during 
gametogenesis eventually leading to either oocytes or spermatozoa (6). Another hallmark 
that PGCs share with some histological elements of TGCTs is the expression of OCT3/4 
(POU5F1), a member of the POU family of transcription factors. OCT3/4 is regarded as 
one of the key regulators of pluripotency and is only expressed in pluripotent stem and 
germ cells (7-10). In the human embryo, OCT3/4 expression starts at the morula stage and 
becomes restricted at first to the inner cell mass during blastocyst formation, subsequently 
to the epiblast during gastrulation and finally to the PGCs. In TGCTs mRNA and protein 
encoded by OCT3/4 is present in carcinoma in situ (CIS), the precursor of all TGCTs (11), 
as well as in all seminomas and the undifferentiated component of non-seminoma, i.e., 
embryonal carcinoma (EC) (12,13). Yet, when EC cells differentiate, either into teratoma, 
yolk sac tumor or choriocarcinoma, expression of OCT3/4 is consistently turned off (12). 
In murine and human EC-derived cell lines the same pattern of down-regulation is found 
upon induction of differentiation by retinoic acid (14,15). However, it must be 
emphasized that murine and human EC cells are not interspecies equivalents and have a 
different pathogenesis (3). 
Methylation of the OCT3/4 upstream region has been studied in several human and 
murine tumor-derived and embryonic stem cell (ESC) derived cell lines. In mouse ESCs, 
Hattori et al showed the hypomethylation of this region and compared it to trophoblast 
stem cells (TSCs) and mouse liver cells which were hypermethylated (16). In addition, 
they showed that in vitro methylation suppressed OCT3/4 enhancer/promoter activity in 
a reporter assay, and the demethylating agent 5-aza-2'-deoxycytidine induced aberrant 
OCT3/4 expression in TSCs. In cloned mouse embryos the OCT3/4 promoter underwent 
gradual demethylation during pre-implantation development and inefficient 
demethylation of the OCT3/4 promoter was associated with developmental retardation at 
early cleavage stages (17). In the malignant equivalent of ESCs, the EC cells, it was 
demonstrated in 1993 that inhibition of OCT3/4 expression in retinoic acid (RA)-induced 
differentiated murine EC cells is achieved through changes in methylation status, 
chromatin structure and transcriptional activity of the OCT3/4 upstream regulatory 
region (18). These results were confirmed by independent studies (19,20). Loss of OCT3/4 
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expression during differentiation of a human EC-derived cell line (NTera2) was found to 
be correlated with increased methylation in the OCT3/4 upstream region (15). Recently, 
this correlation was also found in human ESCs (21). 
To augment the current knowledge, we analyzed the methylation status of the 2.3-kb 
upstream region of the human OCT3/4 gene in different types of primary TGCTs and 
nongerm cell tumors of the testis. Analysis was performed by PCR and sequencing of 
bisulfite-treated DNA from seminoma, histological variants of non-seminoma, 
spermatocytic seminoma, testicular lymphoma, normal testicular parenchyma and 
peripheral blood lymphocytes. In addition, micro-dissected seminoma and EC as well as 
the cell line JKT-1, supposedly derived from a seminoma (22), were included. We 
demonstrate a tissue-specific differential methylation of the upstream region of the 
OCT3/4 gene correlating with gene expression, with a profound general hypomethylation 
in microdissected seminoma and EC and a heterogeneous hypermethylation in samples of 
differentiated histology. Some regions were identified that could be related to activity of 
the promoter. 
 
 
MATERIALS AND METHODS 
 
Tissue samples 
 Use of tissues for scientific reasons has been approved by an institutional review board 
(MEC 02.981). The samples are used according to the ‘Code for Proper Secundary Use of 
Human Tissue in the Netherlands’, as developed by the Dutch Federation of Medical 
Scientific Societies (FMWV) (version 2002). 
 
Immunohistochemistry 
Frozen sections were stained using immunohistochemistry with a monoclonal antibody 
for OCT3/4 (sc-5279; Santa Cruz Biotechnology) as described previously (23). The 
secondary antibody was a biotinylated rabbit anti-mouse antibody (E0413; Dako). Final 
visualization was made with diaminobenzidine (DAB, FLUKA), after which the slides 
were counterstained with haematoxylin. 
 
DNA-isolation and PCR 
Genomic DNA was isolated from peripheral blood lymphocytes, normal testis 
parenchyma, spermatocytic seminoma, testicular lymphoma, embryonal carcinoma, yolk 
sac tumor, teratoma and seminoma by standard phenol extraction. Of each type of 
material three independent DNA samples were used, except for yolk sac tumor of which 
only two samples were included. In addition, genomic DNA from the JKT-1 cell line was 
isolated. DNA was treated with bisulfite (EZ DNA methylation kit, Zymo Research) to 
convert unmethylated cytosines into uracil. On this converted DNA PCR was performed 
with seven primer pairs used in previous experiments (15). For the PCR reactions two 
different Taq polymerases were used. For primer pair 3 and 4 Taq polymerase (Qiagen) 
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was used with the following program on a MJ Research Cycler (Waltham): 95°C for 3 min, 
35 cycles of 94°C for 30 sec (denaturation), 58°C for 45 sec (annealing), 72°C for 1 min 
(extension), and finally an extension at 72°C for 8 min. For primer sets 5-9 a High Fidelity 
Taq polymerase (Invitrogen) was used with this program: 95°C for 3 min, 35 cycles of 94°C 
for 30 sec, 58°C for 45 sec, 68°C for 45 sec, and an extension at 68°C for 8 min. The 
obtained PCR products were purified (Qiagen PCR-28106 purification kit). 
 
Sequencing 
Forward primers were labelled with [γ32P]ATP. PCR products were sequenced using a 
cycle reader DNA sequencing kit (K1711 Fermentas). The sequencing program was 95°C 
for 3 min, 25 cycles of 94°C for 30 sec, 58°C for 45 sec, 72°C for 1 min and 4°C for 30 min. 
Gels (6 and 8%) ran from 1-4 h, depending on the size of the sequenced fragment. 
 
Micro-dissected samples 
Micro-dissection was performed with a PALM-microlaser system (Zeiss) on frozen slides 
guided by Alkaline Phosphatase staining found to be informative to distinguish seminoma 
and EC cells from other cell types (24,25). DNA from three micro-dissected ECs and 
seminomas was processed as described above by bisulfite treatment, PCR and sequencing. 
 
 
RESULTS 
 
We examined the methylation status of 32 CpG sites between the transcription start site 
and position -2351 upstream of the human OCT3/4 gene of in vivo derived human 
samples. In addition, matched micro-dissected samples were included to exclude 
misinterpretation of the data due to the presence of host tissue (Fig. 1). Based on sequence 
analysis each position was scored as complete methylation, partially methylated and 
unmethylated (Fig. 2). Because direct sequencing was applied to the tumor samples, we 
checked if this method was comparable to sequencing of cloned PCR products. Therefore, 
part of the upstream sequence (primer pair 9) was analyzed by both methods in 
undifferentiated and retinoic acid differentiated NTera2 cells. Results were similar [data 
not shown, in accordance to previous findings (26)] and confirmed the results obtained by 
Deb-Rinker et al (15). Therefore, we only investigated the direct sequencing derived data 
in this study. Results from the human tissue samples are schematically represented in Fig. 
3. 
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FIGURE 1. Embryonal carcinoma 
(black arrows) before (A) and after 
(B) micro-dissection. Enzymatic 
alkaline phosphatase stains 
embryonal carcinoma as well as the 
carcinoma in situ cells (white 
arrows). 
(Figure 1 colour image on page 181) 
 
 
Some of the positions could not be reliably scored due to sequencing limitations and these 
are omitted from further analysis as indicated (Fig. 3). The CpG sites at position -1891 and 
-2351 could not be conclusively analyzed in any sample. Deviating from the sequence of 
the upstream region of the human OCT3/4 gene in the article by Nordhoff et al (27) we 
found two extra CpG sites at positions -1692 and -1755 generated by single nucleotide 
polymorphisms. For position -1692 the polymorphism was CG/CA and for position -1755 
it was CG/CT. In addition, position -1772 was also a polymorph and consisted of a CG/CC 
polymorphism. Frequency and functionality of these specific polymorphisms in normal or 
patient populations were not investigated in this study, and remain to be elucidated. 
To compare the methylation status of the different samples, the number of complete 
methylated CpG sites was divided by the total number of CpG sites analyzed. This 
resulted in the percentage of completely methylated CpG sites per sample (Fig. 3). 
Peripheral blood lymphocytes, spermatocytic seminoma and differentiated components of 
non-seminoma, i.e., yolk sac tumor and teratoma had a hypermethylated upstream region 
of the OCT3/4 gene, ranging from 56 to 89%. The testicular lymphomas were 
heterogeneous with methylation percentages of 31 to 94%, while they were all 
immunohistochemically negative for OCT3/4. The JKT-1 cell line was hypermethylated, 
and also lacked expression of OCT3/4. 
In contrast to the differentiated TGCT components, the seminomas and embryonal 
carcinomas had a relatively low level of CpG methylation, ranging from 9 to 42%. 
Matched micro-dissected samples of these two histologies, lacking (hypermethylated) host 
cells, such as lymphocytes and normal testis parenchyma, were all unmethylated (Fig. 3). 
 
 
 
FIGURE 2. Sequencing analysis of bisulfite treated DNA. Position-1755 (arrow) in representative samples. 
Unmethylated CpG site shows only a band at the T position (left panel), partially methylated site has a band 
at both the T and C position (middle panel), and complete methylated site has only a band at the C position 
(right panel).  
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FIGURE 3. Methylation status of the upstream region of the OCT3/4 gene. At the top conserved regions 
(CR) between human, murine and bovine sequences are represented as grey boxes and accompanied by their 
relative position to the transcription start site (TSS). Directly below the examined CpG sites and their 
position relative to TSS are indicated. On the left side are the histological groups, each group consisting of 
three independent DNA samples, except for the group of yolk sac tumors that contains two samples. In 
addition, OCT3/4 immuno-histochemistry (IHC) results are indicated as positive (+) or negative (-). Each 
horizontal row of circles represents one sample. A black circle signifies a complete methylated CpG site, a 
grey circle partial methylation and a white circle no methylation. In addition, gritted circles signify an 
inability to analyse and polymorphic sites (indicated by p) not constituting a CpG are omitted. Letters a to e 
at the right end of (micro-dissected) seminoma and embryonal carcinoma samples indicate which samples 
were derived from the same tumor. The primer pairs that cover the CpG sites are represented at the bottom. 
At the right of each row is the fraction of complete methylated CpG sites and total CpG sites analysed. This 
fraction is represented as a percentage in the vertical histogram. Differentiated samples of peripheral blood 
lymphocytes, normal testis parenchyma, spermatocytic seminoma, yolk sac tumor and teratoma have a high 
level of methylation. Seminoma and embryonal carcinoma were hypomethylated, which was confirmed in 
the micro-dissected samples where no contaminating normal cells were present. In contrast, methylation in 
the group of testicular lymphomas was heterogeneous. 
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DISCUSSION 
 
The methylation status of the upstream region of the OCT3/4 gene has been studied in 
various murine and human cell lines, both benign and malignant. Here we showed the 
differential methylation of this region in a range of primary human testicular tumors and 
normal tissue, an unexplored field so far. This differential methylation is in accordance 
with previous data obtained from in vitro grown cells. In fact, undifferentiated, OCT3/4 
expressing cells, have overall a hypomethylated upstream region, whereas differentiated 
cells, lacking OCT3/4 expression, are hypermethylated. 
In our study, seminoma and the undifferentiated nonseminomatous EC, both 
characterized by OCT3/4 expression, are hypomethylated. However, tumor tissue can be 
quite heterogeneous and especially seminoma cells are intermingled with lymphocytic 
infiltrations that can drastically decrease the percentage of tumor cells to below 50%. 
Also, EC often constitutes a low percentage of cells in the tissue, because of growing in 
nests and their capacity to differentiate into extra-embryonic and embryonic tissues. Of 
course, this contamination distorts the results of the analyses, especially if total samples 
are investigated. Therefore, in this study, also micro-dissected seminoma and EC samples 
were investigated, and these samples showed almost no methylation of the region 
analyzed. In contrast to seminoma and EC, differentiated non-seminomatous components, 
teratoma and yolk sac tumor, which do not express OCT3/4, were indeed found to be 
hypermethylated. Spermatocytic seminoma, normal testis parenchyma and peripheral 
blood lymphocytes, all consisting of differentiated cells, are hypermethylated. These 
findings support the different cell of origin and pathogenesis of seminoma and 
spermatocytic seminoma (28). The cell line JKT-1, supposed to be derived from a 
seminoma (22), was hypermethylated (78%), adding to the accumulating evidence that it 
is not of seminomatous origin (unpublished data). The testicular lymphomas are the only 
tumors that show a heterogeneous pattern in this limited set of samples. While all were 
negative for OCT3/4, two (both of T-cell origin) showed a low level of methylation, while 
one B-cell lymphoma showed a high level of methylation. This might be of interest, 
although it needs further investigation (29). 
In the human EC-derived cell line NTera2 Deb-Rinker et al showed that a relatively small 
increase in methylation of specific CpG sites in the upstream OCT3/4 region is sufficient 
to shut-down expression of the gene (15). These specific CpG sites correspond to positions 
-1001, -231, -50, +5 and +35 (Fig. 3). The sites upstream of the transcription start site were 
also differentially methylated in our analysis; the latter two were not represented in our 
search. In addition, the previous report identified CpG sites that were already methylated 
in the undifferentiated EC cells. This block of constitutive methylation (CpG sites -519 to 
-881) was not present in the microdissected EC samples and is possibly related to the 
clonal origin of the NTera2 cells and/or their in vitro propagation. It is indeed known that 
upon in vitro growth hypermethylation might occur compared to the original in vivo 
obtained cells (30). 
Expression of the OCT3/4 gene is, besides methylation, regulated by other factors, such as 
binding of transcription factors to specific regions in the upstream sequence. These 
regions are conserved between different species and designated CR1 to CR4 by Nordhoff 
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et al (27). OCT3/4 expression is regulated by a minimal TATA-less promoter (31) present 
in CR1. In addition, there are two enhancer sites more upstream: a proximal enhancer 
(PE) mainly coinciding with CR2 that activates OCT3/4 in the epiblast (32), and a distal 
enhancer (DE) in CR4 driving gene expression in the morula, inner cell mass and PGCs 
(32). Next to the DE the CR4 also contains the OCT3/4-SOX2 binding site (33). These 
promoter and enhancers are the key regulatory sequences for OCT3/4 gene expression and 
therefore methylation status of their associated CpG sites can be expected to be of more 
importance than the sites of non-regulatory upstream sequences. However, thus far this 
was not experimentally tested. The minimal OCT3/4 promoter in CR1 has no CpG island, 
but harbors 4 of the investigated CpG sites (position -14, -24, -50 and -114 relative to the 
transcription start site). Unfortunately, the DE in CR4 lies outside the examined upstream 
region and CR2 containing the PE has no CpG sites (Fig. 3). Because of the limited 
number of CpG sites in the regulatory regions, no clear relation between methylation of 
these regions and gene expression could be made. However, some general patterns can be 
observed. Overall, CpG sites -14 to -1659 and -2193 to -2317 show differential 
methylation between differentiated and undifferentiated tissue, whereas this relation is 
not present in CpG -1672 to -2162 lying in between (Fig. 3). The same pattern was 
observed in NTera2 cells (15). Most of these differentially methylated CpG sites had no 
association with known transcription factor binding sequences, except for position -114 
where Sp1 and Sp3 can bind. 
Genomic methylation patterns in solid tumors might be disturbed compared to their 
normal counterpart, causing for example gene silencing by aberrant promoter methylation 
(34). If this is the case, these epigenetic alterations, together with mutations, can 
contribute to the process of tumorigenesis (reviewed in ref. 34). Thus far, no mutations or 
aberrant epigenetic patterns for OCT3/4 have been described and OCT3/4 is only 
expressed in the malignant counterpart of cells normally expressing the gene, i.e., 
CIS/seminoma and EC, respectively representing neoplastic PGCs and ESCs (35). This 
observation, together with our results presented here on the methylation status in human 
TGCTs supports the view that OCT3/4 is not one of the driving oncogenic forces in these 
tumors. However, the data support the model that TGCTs can be used to study 
mechanisms involved in normal embryogenesis, as we previously reported for X-
inactivation (36). 
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ABSTRACT 
 
The JKT-1 cell line has been used in multiple independent studies as a representative 
model of human testicular seminoma. However, no cell line for this specific tumour type 
has been independently confirmed previously; and therefore, the seminomatous origin of 
JKT-1 must be proven. The genetic constitution of the JKT-1 cells was determined using 
flow cytometry and spectral karyotyping, as well as array comparative genomic 
hybridization and fluorescent in situ hybridization. Marker profiling, predominantly 
based on differentially expressed proteins during normal germ cell development, was 
performed by immunohistochemistry and Western blot analyses. Moreover, genome wide 
affymetrix mRNA expression and profiling of 157 microRNAs was performed, and the 
status of genomic imprinting was determined. A germ cell origin of the JKT-1 cells was in 
line with genomic imprinting status and marker profile (including positive staining for 
several cancer-testis antigens). However, the supposed primary tumour, from which the 
cell line was derived, being indeed a classical seminoma, was molecularly proven not to be 
the origin of the cell line. The characteristic chromosomal anomalies of seminoma, e.g. 
gain of the short arm of chromosome 12, as well as the informative marker profile 
(positive staining for OCT3⁄ 4, NANOG, among others) were absent in the various JKT-1 
cell lines investigated, irrespective of where the cells were cultured. All results indicate 
that the JKT-1 cell line is not representative of human seminoma. Although it can 
originate from an early germ cell, a non-germ cell derivation cannot be excluded. 
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INTRODUCTION 
 
Generation of cell lines derived from cancer cells of different organisms has been 
successful for more than half a century. Availability of these cell lines has been proven 
informative in various studies, although their impact on understanding the actual in vivo 
situation remains a matter of debate. Moreover, and at least equally important, the origin 
and purity of the cell lines currently used have been questioned, for relevant and obvious 
reasons. Proper molecular characterization and classification of cell lines will prevent 
scientific misinterpretation (Masters et al., 2001; Drexler et al., 2003). Besides verifying 
the origin and excluding contamination, it must be kept in mind that cells may undergo 
changes in their genome, epigenome and phenotype upon extensive and continuous in 
vitro culture because 
of the non-physiological environment (Looijenga et al., 1997). This may hamper 
interpretation of the data obtained in various laboratories depending on specific culture 
conditions, even when cell lines of the same origin are analyzed. 
Human germ cell tumours (GCTs) are a defined group of solid tumours, which can be 
classified based on various parameters, including histology and, to a certain level, 
chromosomal constitution (Oosterhuis & Looijenga, 2005). From a developmental point of 
view, the seminomas (SE) and non-SE, the so-called type II GCTs are of great interest. In 
the testis, these tumours (then called TGCTs) originate from a transformed embryonic 
germ cell, either a primordial germ cell (PGC) or gonocyte. This precursor lesion is 
referred to as carcinoma in situ (CIS) or intratubular germ cell neoplasia unclassified (Elbe 
et al., 2004; Skakkebaek, 1972). The invasive tumours are subdivided into seminomatous 
(SE) and non-seminomatous (NS) tumours. Subsequently, the NS can be subdivided into 
various subtypes: embryonal carcinoma (EC), teratoma, yolk sac tumour and 
choriocarcinoma, representing both undifferentiated and differentiated embryonic and 
extra-embryonic elements. In 1975, the first type II-GCTderived cell line was established 
by culturing EC (Fogh & Trempe, 1975). Since then, a series of NS-derived cell lines were 
successfully generated, used in various studies (Fogh, 1978). These have been very 
informative, although differences between various sub-lines, cultured in different 
laboratories, have been reported, for example regarding their pattern of X-inactivation 
(Looijenga et al., 1997). In contrast to the wealth of independently generated NS-derived 
cell lines, only single reports on cell lines representative for either CIS or seminoma are 
available. This is most likely because of the exceptional sensitivity of seminoma cells to 
undergo programmed cell death (apoptosis) upon disruption of their microenvironment, 
also known as anoikis (Berends et al., 1991; Olie et al., 1996). These observations might be 
related to the notion that PGCs rapidly go into apoptosis when they are situated at 
extragonadal locations during normal embryonic development (Stallock et al., 2003). 
Besides the type II TGCTs, a different type of GCT can occur in the testis. This so-called 
spermatocytic seminoma (type III) is rare, and can be distinguished from seminoma based 
on clinical behaviour, marker expression profile and chromosomal constitution (Eble, 
1994; Rajpert-De Meyts et al., 2003b; Looijenga et al., 2006). No representative cell line 
for spermatocytic seminoma has been reported so far. Most recently, SE and spermatocytic 
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SE could also be distinguished from each other using microRNA (miRNA) expression 
profiling (Voorhoeve et al., 2006, and unpublished observations). 
Interestingly, in 1993 Mizuno et al. reported on the establishment of a seminoma cell line, 
named TCam-2 (Mizuno et al., 1993). Up-to-date, the seminomatous origin of this cell line 
and retention of the characteristics have not been independently confirmed. A few years 
later, the establishment of the JKT-1 cell line was described (Kinugawa et al., 1998). It was 
derived from a testicular seminoma of a 40-year-old Japanese male. By 
(immuno)histopathological criteria, the primary tumour was a pure seminoma, positive 
for placental-like alkaline phosphatase (PLAP) and negative for alpha fetoprotein (AFP) 
and beta human choronic gonadotropin (β-hCG). These last two are markers for yolk sac 
and trophoblastic differentiation, respectively. The cell line was generated using the 
traditional explant culture method and the tumour cells were successfully transplanted 
into nude mice. Subsequently, a highly metastatic sub-cell line, named JKT-HM, was 
derived (Jo et al., 1999). A worrying finding is that the chromosomal analysis of both the 
original and the metastatic variant of JKT-1 lacked the characteristic chromosomal 
anomalies for seminoma, including gain of the short arm of chromosome 12, a genomic 
hallmark for invasive type II GCTs (Looijenga et al., 2003c). In fact, overrepresentation of 
12p sequences is present in all invasive SE and NS, independent of histological 
composition of the latter, in up to 80% because of the presence of one or more 
isochromosomes 12p [i(12p10)] (Atkin & Baker, 1982; Looijenga et al., 2003c). This has 
been successfully used for diagnostic purposes (Bosl et al., 1994). 
So far, the JKT-1 cell line has been used for various investigations, consistently described 
as representative of seminoma (Fujii et al., 2002; Hatakeyama et al., 2004; Kobayashi et al., 
2004; Roger et al., 2004, 2005; Shiraishi et al., 2005) and the data obtained from the 
different studies were subsequently interpreted as such. Because of the uniqueness of a 
cell line representative of seminoma and the impact of its existence, both clinically and 
(patho-)biologically, we undertook an extensive characterization of the JKT-1 cell line, 
from genomic constitution to immunohistochemical marker profile. JKT-1 cell lines 
maintained in independent laboratories were included in the survey, as well as the 
(supposed) tumour of origin (Kinugawa et al., 1998). 
 
 
MATERIALS AND METHODS 
 
Cell lines and primary tumour 
JKT-1 cells were obtained twice independently from Michiko Fukuda (The Burnham 
Institute, La Jolla, CA, USA), designated JKT-1 I and II, and Chris Lau (VA Medical 
Center, University of California, San Francisco, CA, USA), named JKT-1 III. The cells 
were cultured in a-modified Eagle medium + GlutaMAX (32564-029, Invitrogen, Breda, 
The Netherlands) supplemented with 10% fetal calf serum and penicillin ⁄ streptomycin in 
a 5% CO2 humidified incubator and passaged when 80% confluency was reached. Cells 
were washed twice with PBS and then incubated with Trypsin-EDTA (25300-054, 
Invitrogen) and harvested for the different experiments. Cytospins were prepared and 
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DNA, RNA and protein were isolated (see below). All sub cell lines were analysed by 
immunohistochemistry. Only JKT-1 I was used for expression profiling, determining of 
imprinting status, as well as mutation- and chromosomal analyses. 
Paraffin-embedded specimens of the primary tumour were provided by Shingo 
Hatakeyama. 
 
Immunohistochemistry 
Immunohistochemical staining was performed on cytospin preparations of the JKT-1 cells 
I-III and on 3 μm thick tissue sections of the paraffin-embedded primary tumour. General 
markers as vimentin and cytokeratin 8 (CAM5.2), and specific markers for various 
maturation stages of germ cell development were applied. Published data on the 
expression of the markers PLAP, OCT3⁄ 4, NANOG, c-KIT, TSPY, DAZ, DAZL, VASA, 
MAGE-A4, DMRT1, SSX2-4, XPA, SYCP1 and SYCP3 in spermatogenesis and germ cell 
tumours is collected in Table 1  (Lammers et al., 1994; Lau et al., 2000; Reijo et al., 2000; 
Stoop et al., 2001;  Lifschitz- Mercer et al., 2002; Zeeman et al., 2002; Looijenga et al., 
2003b, 2006; Rajpert-De Meyts et al., 2003a; Hoei-Hansen et al., 2005). 
 
 
TABLE 1. Immunohistochemical profile of consecutive maturation stages of male germ cells 
 Spermatogenesis Germ cell tumours JKT-1 
 
Markers  
PGC/ 
gonocyte 
Prespermato-
gonium 
Spermato- 
gonium 
 
Spermatocyte 
 
Spermatid 
 
Seminoma 
Spermatocytic 
seminoma 
Primary 
tumour 
 
I 
 
II 
 
III 
Positive in spermatogenesis          
PLAP + +/- - - - + - + - - - 
OCT3/4 + +/- - - - + - + -c -c -c 
NANOG + - - - - + - + -c -c -c 
c-KIT + + - - - + - + -e -e -e 
TSPY +/- + + +/- - +/-a +a - -d -d -d 
DAZ + + + +/- +/- +/- + - -d -d -d 
DAZL + + + + + +/-a +/-a - +/- +/- +/- 
VASA +/- +/- +/- + + +/-a + - +/- +/- +/- 
MAGE-A4 - + + +/- - +/-a +a - - - - 
DMRT1 nd -b +b +b -b +/- + - + + + 
SSX2-4 nd nd +/- +/- - +/- + - - - - 
XPA - - - + - +/- + - +c +c +c 
SYCP1 nd - - + - - + nd +c +c +c 
SYCP3 nd - - + - +b +b nd +c +c +c 
Negative in spermatogenesis 
      
CAM5.2        - + + + 
Vimentin        +/- + + + 
AFP        - - - - 
hCG        - - - - 
Spermatogenic cells (left panel: from left to right); germ cell tumours: seminoma and spermatocytic 
seminoma (middle panel); and cell line JKT-1 as well as (supposed) matched primary tumour (right panel). 
Positive staining in >90% of cells (+), weak or heterogeneous staining (±), negative (-) staining in >95% of 
cells; not determined (nd). PLAP, placental-like alkaline phosphatase; CAM5.2, cytokeratin; AFP, alpha 
fetoprotein; hCG, human chorionic gonadotropin. aUnpublished results from tissue microarrays (TMA) 
including 50 primary seminomas and 23 spermatocytic seminomas (Looijenga et al., 2006) are indicated; 
bown observations: protein expression of DMRT1 in spermatogenesis; cconfirmed by Western blotting; 
dconfirmed by PCR; econfirmed by immunoprecipitation and Western blotting. 
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In addition, the samples were stained for CD34 and CD45 to identify haematopoietic cells 
and inhibin-a for sertoli cells. The primary antibodies, dilutions and incubation conditions 
are listed in Table 2. For cytospin preparations, the same dilutions were used as described 
for the tissue sections with a standard 1-h incubation at room temperature (RT). On 
paraffin sections heatinduced antigen retrieval (HIAR) was performed by high pressure-
cooking using 0.01 M sodium citrate (pH 6.0) for most antibodies. The antibodies directed 
against AFP and β-hCG required no antigen retrieval; for CAM5.2 staining, slides were 
treated for 15 min with protease (P5147; Sigma, Steinheim, Germany) 0.01% in PBS at 
37°C, and HIAR for DMRT1 was performed in 1.0 M Tris–EGTA (pH 8.0). Secondary 
biotinylated antibodies SWine-Anti-Rabbit, rabbit-anti-mouse (DAKO, Glostrup, 
Denmark) and Horse-Anti-Goat (HAG) (Vector Laboratories, Burlingame, CA, USA) were 
used in a 1:200 dilution and incubated for 30 min at RT. Antibody complex was visualized 
by avidin-biotin conjugated with horseradish peroxidase or alkaline phosphatase, 
respectively using 3,3-diaminobenzidine and New Fuchsin (72200; Fluka, Buchs SG, 
Switzerland) as chromogens, resulting in a brown and a red signal. All slides were 
counterstained with haematoxylin. In addition, double staining was performed for DAZL 
and VASA, respectively, with 3-amino-9-ethyl-carbazole (A5754; Sigma) ⁄H2O2 for a red 
staining and Fast Blue ⁄ Naphthol AS-MX phosphate (F3378 and N500; Sigma) for a blue 
staining. 
 
TABLE 2. Origin and conditions used for primary antibodies 
 
 Origin Dilution Incubation for paraffin 
AFP A0008, DAKO, Glostrup, Denmark 1:600 Overnight, 4°C 
AR (Zegers et al., 1991) 1:50 ½h, RT 
CAM5.2 345779, BD Biosciences, San Jose, CA, USA 1:20 2h, RT 
c-KIT A4502, DAKO 1:100 Overnight, 4°C 
CD30 M751, DAKO 1:100 Overnight, 4°C 
CD34 MS-363-P, Neomarkers, Fremont, CA, USA 1:30 ½h, RT 
CD45 M701, DAKO 1:200 ½h, RT 
DAZ Provided by F. Moore and R. Reijo Pera (Reijo et al., 2000) 1:400 2h, RT 
DAZL Ab17224, Abcam, Cambridge, UK 1:750 2h, RT 
DMRT1 Provided by D. Zarkower and V. Bardwell (Raymond et al., 2000) 1:400 2h, RT 
HCG A231, DAKO 1:10000 Overnight, 4°C 
Inhibin α MCA951S, Serotec, Oxford, UK 1:50 Overnight, 4°C 
LHR Provided by A. Themmen; (Funaro et al., 2003) 1:6400 Overnight, 4°C 
MAGE-A4 Provided by H. Jacobs; (Kocher et al., 1995) 1:100 2h, RT 
NANOG AF1997, R&D Systems, Abingdon, UK 1:800 2h, RT 
OCT3/4 sc-5279, Santa Cruz Biotechnology CA, USA 1:1000 2h, RT 
P53 M7001, DAKO 1:50 2h, RT 
PLAP 203, Cell Marque Corp, Hot Springs, AR, USA 1:200 Overnight, 4°C 
SYCP1 Provided by C. Heyting (Meuwissen et al., 1992) 1:500 2h, RT 
SYCP3 Provided by C. Heyting  (Lammers et al., 1994) 1:500 2h, RT 
SSX2-4 Provided by A. Geurts van Kessel (dos Santos et al., 2000) 1:100 2h, RT 
TSPY Provided by Y.-F. C. Lau (Lau et al., 2000) 1:4000 Overnight, 4°C 
VASA Provided by D. Castrillon (Castrillon et al., 2000) 1:1000 Overnight, 4°C 
Vimentin M725, DAKO 1:80 2h, RT 
XPA MS-650-P, Neomarkers 1:50 1h, RT 
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Protein isolation and Western blotting 
Isolation of protein and Western blotting were performed as described previously (de Jong 
et al., 2005). 
 
Genotyping 
Allelotyping was performed by radioactive polymerase chain reaction (PCR)-
amplification of five highly polymorphic microsatellite markers: D9S156, D9S157, 
D17S786, D8S133 and D8S136 using standard methods. 
 
Flow cytometry 
Cellular DNA content and cell cycle characteristics were determined using a FACS scan 
flow cytometer (FACSCalibur; Becton-Dickinson, Franklin Lakes, NJ, USA). In total 10 
000 events were analyzed. Briefly, JKT-1 cells were collected and fixed with cold 70% 
ethanol. Cells were resuspended in 1 ml of PBS containing propidiumiodide (50 lg ⁄ ml), 
glucose (1 mg ⁄ ml) and RNase A (0.1 mg ⁄ ml). The suspensions were incubated at RT for 
30 min. The ploidy determination of nuclei was estimated by flow cytometry of DNA 
content in relation to an independent proven control with a diploid DNA content. 
 
Spectral karyotyping 
Standard cytogenetical preparations were pre-treated with RNase for 30 min at 37°C and 
digested in 0.012% pepsin for 5 min. After washing, cells were fixed in 1% formaldehyde ⁄ 
50-mM MgCl2 in PBS for 10 min, washed, and dehydrated. Hybridization and detection 
for Spectral karyotyping (SKY) analysis was performed according to the manufacturer’s 
protocol with minor adjustments (Applied Spectral Imaging, Migdal Ha’Emek, Israel). 
Briefly, after 2 days of hybridization, slides were washed in 4xSSC (pH 7.0) for 15 sec at 
72°C followed by 2xSSC at RT. Cells were counterstained with DAPI and mounted in 
antifade solution (Dabco-Vectashield 1:1; Vector Laboratories, Burlingame, CA, USA). 
Using the SD300-C SpectraCube and Skyview analysis software (Applied Spectral 
Imaging), nine metaphase cells were examined (Naus et al., 2001). 
 
DNA isolation 
Genomic DNA from the primary tumour and the cultured cells was extracted as described 
before (Kersemaekers et al., 2002). Briefly, each sample was treated with proteinase K 
followed by phenol ⁄ chloroform extraction and DNA was dissolved in TE buffer (10 mM 
Tris–HCl, 1 mM EDTA, pH 8.0). 
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Array-comparative genomic hybridization 
A human BAC⁄PAC array containing 3600 clones covering the full genome at an average 
of 1 Mb-spacing, was used (Cardoso et al., 2004). Labelling and hybridization were 
performed as described before (Cardoso et al., 2004). Scanning was performed on a 
ScanArray Express HT Microarray Scanner (Perkin-Elmer, Fremont, CA, USA) and the 
resulting images were analyzed with the GenePix Pro 5.0 software (Molecular Devices 
Corp., Sunnyvale, CA, USA). Breakpoint flanking clone positions were verified with 
Ensemble (v36, December 2005; http://www.ensemble.org). The baseline DNA copy 
number (log2=0) in the JKT-1 cell line referred to triploidy. 
 
Fluorescent in situ hybridization 
FISH was performed on cytospins of JKT-1 cells and sections of the primary tumour as 
described before (Zafarana et al., 2002). The following probes were used: RP11-344A7 
(9p21.3), RP11-621O18 (9p22.3), RP11-117 J28 (9p23), RP11-28O4 (9q32.33), RP11-
417B4 (9q33), RP11-83 N9 (9q34.13), RP11-277 J24 (12p13.1 containing NANOG), RP11-
449P1 (12p12.1) and RP11-268P4 (12p12.1) [the latter two clones containing EKI1, a gene 
located at the telomeric region of the shortest region of overlap of amplification in SE: 
p11.2-p12.1 (Zafarana et al., 2002)], TSPY plasmid of 12.5 kb (Zhang et al., 1992) and 
centromere-specific probes D9Z1 (Moyzis et al., 1987), Pα12H8 (Looijenga et al., 1990), 
DXZ1 (Willard et al., 1983) and DYZ3 (Cooke et al., 1982), respectively for chromosome 
9, 12, X and Y. Centromere specific probes were labelled with biotin-16-dUTP (Roche, 
Mannheim, Germany) and detected using streptavidin-Cy3 (Jackson Immuno Research 
Laboratories, Cambridgeshire, UK), the other probes were labelled with digoxigenin-11-
dUTP (Roche) and visualized with FITC-conjugated sheep anti-digoxigenin (Roche). 
 
Multiplex PCR AZF regions 
Screening for micro-deletions of the Y chromosome was performed by a standardized 
multiplex PCR as described in Simoni et al. (2004). The STS primers used were sY84 
(DYS273) and sY86 (DYS148) for the AZFa region, sY127 (DYS218) and sY134 (DYS224) 
for AZFb and sY254 (G38349) and sY255 (G65827) for AZFc, both primers were located 
in the DAZ gene. As controls, the SRY gene on Yp, normal male and female DNA were 
taken, and the ZFX ⁄ ZFY gene served as an internal control. This primerset enables the 
detection of almost all the clinically relevant deletions (resulting in azoospermia or 
oligospermia) and over 95% of the deletions reported in the literature in the three AZF 
regions (Simoni et al., 2004). 
 
Imprinting status of IGF2 ⁄ H19 imprinting control region 
To determine whether imprinted genes are either monoallelically or bi-allelically 
expressed in the JKT-1 cells, the ApaI and RsaI polymorphisms within the IGF2 ⁄ H19 
imprinting control region (ICR) were investigated. Therefore, DNA of cultured cells was 
amplified at both loci by PCR, followed by restriction enzyme digestion. In case 
heterozygosity was determined, a similar analysis was performed on cDNA (van Gurp et 
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al., 1994). The following primers were used: 5’-CTTGGACTTTGAGTCAAATTGG-3’ and 
5’-GGGTCGTGCCAATTA-CATTTCAT-3’ (IGF2 locus); 5’-TGACTGAGGAATCGGCT-
CTGGAAG-3’ and 5’-CGGTCG-GAGCTTCCAGACTAG-3’ (H19 locus). 
 
Methylation status 
IGF2 ⁄ H19 ICR 
The methylation status of the IGF2 ⁄ H19 ICR was determined by methylation-sensitive 
single nucleotide primer extension (MS-SNuPE), PCR and sequencing of the CTCF core 
binding domain as described by Sievers et al. (2005). The SNuPE primer sequence for the 
first cytosine in the CTCF binding domain was C10-GTTGTGGAAT(C ⁄ T)GGAAGTGGT 
(primer A) and for the first cytosine before the CTCF core domain was C12-
GAATTGGTTGTAGTTGTGGAAT (primer B). Primers for amplifying the CTCF core 
domain were 5’-TGTATAGTATATGGGTATTTTTGGAGGTTT-3’ and 3’-GGGAAT-
AGGATATTTA-TAGGA-5’. Sperm DNA was used as a control. 
 
OCT3 ⁄ 4 promoter 
Bisulfite treatment was carried out on isolated DNA (see above), using the EZ DNA 
Methylation Kit (Zymo Research, Orange, CA, USA) as described before (de Jong et al., 
2007). Amplification was performed by means of PCR using the primer pairs OCT4-3 to 
OCT4-9 as described by Deb-Rinker et al. (2005). PCR products were sequenced using 
radioactive labelling. 
 
Expression analysis 
Microarray expression profiling 
Expression profile of the JKT-1 cell line was determined using Affymetrix GeneChip 
Human Genome U133 plus 2.0 array as described before (Looijenga et al., 2006). 
Previously published expression data of patient derived GCT samples were used for 
clustering (Looijenga et al., 2006). 
 
MicroRNA expression profiling 
RNA highly enriched for low molecular weight (LMW) RNA species (LMW) was isolated 
using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) according to the 
manufacturer’s protocol. RNA quantity and quality were determined using a high-
resolution electrophoresis bioanalyser 2100 (Agilent, Amstelveen, NL) and by UV 
absorbance. 
Expression of 157 mature miRNAs was analyzed by using TaqMan miRNA Assays Human 
Panel (Applied Biosystems, Foster City, CA, USA) following the manufacturer’s protocol. 
Briefly, single-stranded cDNA was synthesized from 10 ng of LMW RNA, using the so-
called hair-pin RTprimer, in 15 μl reaction volume by using the TaqMan miRNA Reverse 
Transcription Kit. The reactions were incubated first at 16°C for 30 min and then at 42°C 
for 30 min. The reactions were inactivated by incubation at 85°C. Each cDNA generated 
was amplified by Quantitative PCR (Q-PCR) using sequence-specific primers ⁄ probes on a 
fully automated Applied Biosystems 7900HT Real-Time PCR system. The 10 μl PCR 
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included 5 μl Universal PCR Master Mix (Applied Biosystems; No AmpErase UNG), 1 μl of 
sequence-specific primers ⁄ probes and 1.5 μl of RT-product. The reactions were incubated 
in duplicate at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 
min. Mir-16 and let-7 were used as internal controls. The median threshold value of the 
controls was determined and the difference with the target threshold was determined as 
delta CT. This was used to investigate the different samples for expression of the targets 
along all samples included in the survey. Using the Omniviz tools, biostatistical analyses 
were performed on the total data set as described before (Looijenga et al., 2006). 
In addition, the presence of miRNA-372 and 373 in SE, was determined as described 
recently by Voorhoeve et al. (2006). 
 
Mutation analysis of P53, KRAS2 and BRAF 
To investigate the presence of P53 mutations, in this case in exon 5–8, the single-strand 
conformation polymorphism approach as described before (Kersemaekers et al., 2002) was 
applied. If aberrant bands after gel electrophoreses were identified, these were sequenced. 
KRAS2 and BRAF mutation analysis was performed by locked nucleic acid-mediated PCR 
clamping and melting curve analysis followed by sequencing. For KRAS2 primers, 
oligomer and probe were used from Chen et al. (Chen et al., 2004). Oligonucleotides used 
for BRAF mutation analysis were the following: CATCTCAGGGCCAAAAAT (BRAF-F), 
TCCTTTACTTACTACACCTCAG (BRAF-R), GAGATTTCACTGTAGCTAGACCAA-Flu 
(sensor), LC Red 640-TCACCTATTTTTACTGTGAGGTCTTCATGAAGAAA-Ph (anchor), 
GAGATTT-CTCTGTAGCTA-Ph (LNA). 
 
 
RESULTS 
 
Morphology and immunohistochemistry of the primary tumour and JKT-1 cells 
The primary tumour from which the JKT-1 cell line was reported to derive consists of 
sheets of uniform cells with clear cytoplasm and large nuclei mingled with lymphocytic 
infiltrations. Immunohistochemistry of the tumour cells confirmed the morphological 
diagnosis of a seminoma, with a consistent strong nuclear positive staining for both OCT3⁄ 
4 (Fig. 1A) and NANOG, a predominantly membranous staining for PLAP and c-KIT 
(Oosterhuis & Looijenga, 2005; Table 1). All markers included in this study (Tables 1 and 
2) specific for later stages of spermatogenesis, which are positive in spermatocytic 
seminoma, like DMRT1, SSX2-4 and XPA were negative in the primary tumour (Table 1), 
consistent with the seminoma histology. Markers reported previously to be 
heterogeneously expressed in SE, like MAGE-A4, DAZL and TSPY (Table 1), were 
negative in the primary tumour. Based on the immunohistochemical data and 
morphology, the primary tumour is a classical seminoma. 
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FIGURE 1. 
 (A) Immunohistochemistry 
of the primary tumour for 
OCT3 ⁄ 4;........ immunohisto-
chemistry of JKT-1 cells: (B) 
double staining for VASA 
(red color) and DAZL (blue 
color). Note the more 
intensive DAZL staining in 
the cells positive for VASA; 
(C) XPA; (D) SYCP3; (E) 
Western blot analysis of a 
seminoma, the EC-derived 
cell line NT2, and the three 
subclones of the JKT-1 cell 
lines (I, II, and III), for 
SYCP3, SYCP1, XPA, OCT3 ⁄ 
4, NANOG and VASA, ß-
actin was used as a loading 
control; (F) clonality analysis 
of the supposed primary 
tumour and the three JKT-1 
cell lines, designated I, II and 
III. The following markers 
were applied: D9S156, 
D9S157, D17S786, D8S133, 
and D8S136. Note that the 
different sub-lines show the 
same pattern, meaning a 
monoclonal origin, but these 
were clonally unrelated to 
the primary tumour. The 
limited number of bands per 
marker indicate that both 
cell lines and primary 
tumour have no micro-
satellite instability. (Figure 1 
colour image on page 182) 
 
 
JKT-1 cells grown in vitro formed colonies of polygonal cells, with polynuclear cells in up 
to 5%. Up to 60% of the cells were positive for VASA, both with immunohistochemistry 
and Western blotting (Fig. 1B and 1E). In addition to VASA, these cells were positive for 
DAZL (Fig. 1B). In contrast to the primary tumour, the JKT-1 cells were positive for a 
series of markers found to be specific for later stages of normal germ cell development, 
including DMRT1, XPA (Fig. 1C and E) and meiosis markers SYCP1 and SYCP3 (Fig. 1D 
and 1E), both by immunohistochemistry and Western blotting. The cells were 
consistently negative for OCT3⁄ 4 (Fig. 1E), NANOG (Fig. 1E), enzymatic alkaline 
phosphatase, PLAP (<1% positive), and c-KIT (Table 1). The JKT-1 cells were also positive 
for vimentin and CAM5.2, while others, like CD30 and CD45 were negative. No 
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difference in staining pattern was identified for the three sub-lines (I, II and III) included 
in this survey (Table 1). Therefore, they will not be referred separately in this report, 
except when relevant. 
 
Primary tumour and JKT-1 cell line are not related 
Because of the striking differences between the characteristics of the primary tumour and 
the supposedly derived cell lines, we investigated their clonality using multiple 
informative molecular markers. These markers are used in daily clinical practice to 
identify possible monoclonal origin of multiple tumours in a single patient, and mix-up of 
patient samples. The results clearly demonstrate that the three sub-lines of JKT-1 obtained 
from the different laboratories are monoclonal and of human origin (Fig. 1F), in line with 
their similar marker expression (Table 1). Moreover, it indicated that the marker profile of 
the cell line grown in vitro is rather stable and has no micro-satellite instability. In 
contrast, the primary tumour is unrelated to the cells grown in culture (Fig. 1F). All 
markers applied showed discordance between the cell lines and primary tumour, 
revealing that the JKT-1 cell line is not derived from this tumour. Despite multiple 
attempts, the cell line could not be traced back to its origin. Therefore, the seminomatous 
histology of the supposed primary tumour cannot be used as supportive evidence that the 
cell line is representative for seminoma. Based on these findings, the primary tumour was 
not included for further investigation in this study. 
 
Genomic constitution of the JKT-1 cells 
The ploidy and growth characteristics of the JKT-1 cells were determined by flow 
cytometry. In accordance with the original description of the cell line, the cells show a 
triploid DNA content (index of 1.4), with a distribution in G1 and G2-M-phase 
respectively of 43 and 33% (data not shown). The near triploid status was confirmed by 
SKY, showing that metaphase spreads with the number of chromosomes ranging from 61 
to 68. The most prominent genomic aberrations were loss of chromosomes 4, 13, 22 and Y, 
and gain of 5p (present as an isochromosome) and X. A representative metaphase analysed 
by SKY is shown in Fig. 2A (of which the consensus constitution is indicated in the 
legend). Array CGH (Fig. 2B) showed loss of fragments of 2q, the centromeric region of 
chromosome 3, the telomeric region of 6q, 10p, centromeric region of 13 and 
chromosomes 4, 18, 22 and Y. Gain was found for 5p, 9q and chromosome X. In contrast, 
no gain of 12p was identified in either of the metaphase spreads investigated and 
confirmed by FISH with region-specific probes. The findings in SKY and array-CGH are 
overall consistent with each other. For example, chromosome 4, 13 and 22 are found in 
two copies, and show loss in the array CGH approach. Accordingly, chromosomes 7, 8, 12, 
14, 15, 17 and 21 are present in three copies and balanced in the array CGH profile. 
Chromosome 9 was investigated in more detail because of the recurrent gains in 
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FIGURE 2 
(A) Representative metaphase of 
spectral karyotyping analysis of 
JKT-1. Characteristic aberrations 
are loss of chromo-somes 4, 13, 
18, 22 and Y; gain of X; and 
isochromosome 5p. The clonal 
chromosomal constitution based 
on nine metaphases is: 61-
68,XX,+der(X)t(X;3)(q22;?) [7] -
Y,der(1) t(1;9)(q21;q?)[8],der(1;3) 
(q10;p10)[8], der(2)t(2;3)(q21;q2) 
[2],der(2)t(2;5)(q21;?),der(3)del(3)
(p?) del(3) (q?) [2], der(3;5), (p10; 
q10)[8],-4,+i(5)(p10), der(6) t(3;6) 
(?;q22)[7],del(7)(p21)[3],-9,add(9) 
(p11) [4], -10[3], del(10)(p1) [2], 
der(10)t(3;10)(?;p1?2)[6], der(11) 
dup(11) (p?p?) t(3;11) (?;p14) 
dup(11) (q?q?) t(3;11) (?;q24)[3], 
der(11)dup(11)(p?p?)t(9;11)(?;p14) 
dup(11)(q?q?)t(9;11)(?;q24)[6],-13, 
+der(16) t(15;16) (?;q23), -18[7], 
der(18) -del(18) (p1) del(18) 
(q?1)[2], der(19) (19::11::13) [8], 
der(19)t(19;20)(?;?)[2],der(20)t(18;
20)(?;?)[5],-22, +der(?) (5::9::X) 
[8], +der(?)(5::9::X)[2], +der(?) 
(?;3)[2] [cp9]. (B) Results of the 
3.6 K BAC ⁄ PAC array CGH 
analysis of the JKT-1 cells. See 
Table 3 for detailed description; 
(C) methyl-ation-sensitive single 
nucleotide primer extension (MS-
SNuPE) of the IGF2 ⁄ H19 
imprinting control region of JKT-
1 shows a very low methylation 
level by two independent primers 
(7% for primer A and 0% for 
primer B). In contrast, the sperm 
DNA control has a 30% 
methylation level; (D) Sequencing of the CTCF core binding domain on bisulfite treated DNA of JKT-1 
confirms the MS-SNuPE data. All cytosines (initial sequence on top) have been converted to thymine 
because they were unmethylated (bisulfate treated DNA sequence below); (E). Results of Affymetrix 
expression profiling. Unsupervised clustering of JKT-1, 5 spermatocytic seminomas (SS), 4 seminomas (SE) 
and 3 dysgerminomas (DG) using Omniviz. The SE and DG could not be separated, in contrast to the SE ⁄ DG 
and SS. JKT-1 does not cluster with any of the tumour samples. (Figure 2 colour image on page 183) 
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spermatocytic SE (Looijenga et al., 2006), and the multiple breakpoints affecting 
chromosome 9 in the JKT-1 cells (SKY results). This is of specific interest because of the 
positive staining of the JKT-1 cells for DMRT1 (which maps to 9p21) that was identified 
recently as a candidate gene in the genesis of spermatocytic seminomas (SS) (Looijenga et 
al., 2006). In fact, chromosome 9 sequences were found in association with chromosome 1 
and 11 in the SKY analysis. However, array CGH did not indicate that (part of) 
chromosome 9 was gained, with the exception of 9q33-9qtel, as confirmed by FISH (data 
not shown). The absence of the complete Y-chromosome detected in array-CGH and SKY 
analysis was supported by FISH and multiplex PCR for the AZF regions (data not shown). 
The results on array-CGH, SKY and FISH in comparision with previously obtained results 
(Jo et al., 1999) are summarized in Table 3. 
 
TABLE 3. Comparison of genomic aberrations of JKT-1 as found by array CGH, SKY, FISH and CGH. 
Array CGH   
  
 
 
 
 
Chromosome 
 
Gain/ 
Loss 
 
Chromosome 
band 
 
 
Flanking clones 
 
Size 
(Mb) 
 
 
SKY 
 
 
FISH 
CGH 
(Jo et al., 
1999) 
1 gain p13.3-q25.3 RP11-28P8 - RP11-293B7 72   +1q 
2 loss q12.3-qter RP11-443K8 - RP11-556H17 133    
3 loss p14.2-q12.1 RP11-154D3 - RP11-569H14 37    
4 loss chr. 4  191 -4   
5 gain p12-pter RP11-28I9-b - CTD-2265D9 42 i(5p)   
6 loss q22.1-qter CTB-57H24 - RP1-94G16 52    
7 loss p11.2-q11.22 RP4-725G10 - RP11-409J21 14    
8 gain q24.11-qter RP11-67N21 -  CTC-489D14 27    
9 gain q33.1-qter RP11-574M5 - GS1-135I17 18  3c,5qa  
10 loss p11.21-pter CTB-164I22 - CTC-306F7 37    
11 gain pter-q22.2 CTC-908H22 - RP11-21G19 100   +11 
 loss q22.2-qter RP11-305O6 - RP11469N6 32    
12 gain q12-q13.3 RP11-283I17 - RP11-181L23 12  3p, 3c  
13 loss q12.11-q14.3 RP11-76K19 - RP11-200F15 34 -13   
15 gain q26.1-qter RP11-405A15 - CTB-154P1 106    
17       +17q 
18 loss chr. 18  77 -18  -18p 
20 loss cen-pter RP11-348I14 - CTB-106I1 29    
22 loss cen-q12.3 XX-p8708 - CTA-221H1 17 -22   
X gain chr. X  154 XX 3X +X 
Y loss chr. Y  57 -Y -Y -Yq 
To simplify the overall picture, only distinctive aberrations for SKY were included. CGH data were derived 
from published data (Jo et al., 1999). FISH column: number of copies centromere (c), p-arm (p) and q-arm 
(q). aWith q probes in q33.1-qter. 
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Imprinting and methylation 
The pattern of genomic imprinting established during normal germ cell development 
(Surani, 1998), has been used to characterize the origin of the seminomatous and NS GCTs 
as well as SS (van Gurp et al., 1994). Because of non-informativity of the reported 
polymorphisms within the IGF2 ⁄ H19 locus, no data on bi- or mono-allelic expression of 
these genes could be obtained. However, the methylation status of the CTCF binding 
domain within this locus could be studied, which is also informative for imprinting status 
(Sievers et al., 2005). Overall, a low level of methylation was found (7% for primer A and 
0% for primer B) (Fig. 2C). This was also found for the CTCF core-binding domain 
regarding all four CpG sites investigated (Fig. 2D). The data are consistent with an 
immature germ cell (Kawakami et al., 2006). 
An inverse relationship has been found between expression of OCT3 ⁄ 4 and methylation 
of its promoter in Ecderived cell lines (Deb-Rinker et al., 2005). We confirmed this 
pattern in primary tumour samples and showed that the JKT-1 cells, which lack 
expression of OCT3⁄ 4, contain a high level of methylation (de Jong et al., 2007). A similar 
level of expression is found in SS, amongst other tumour types of non-germ cell origin, 
while SE show an almost unmethylated pattern (de Jong et al., 2007). 
 
Expression pattern 
Affymetrix expression array analysis showed that the JKT-1 cell line did not cluster in 
either the seminoma or spermatocytic seminoma group (Fig. 2E). In fact, it is not more 
closely related to either of these histological subtypes. The data have to be interpreted 
with caution because of the comparison between primary tumours (seminoma and 
spermatocytic seminoma) and a cell line. In addition, JKT-1 clustered separately when 
compared with a published data set of 175 carcinomas of various histologies and organ of 
origin (Su et al., 2001) (data not shown). The mRNA expression data of JKT-1 and the 
GCT samples used for clustering are available as supplemental data (see Supplementary 
material; Tables S1–S3). 
We previously showed that SE and SS have different patterns of gene expression, both by 
RT-PCR profiling and by comparative expressed sequence hybridization (CESH) 
(Looijenga et al., 2006). Most recently, we demonstrated that the majority of SE, in 
contrast with SS, expresses specific miRNAs, i.e. miRNA 372-373, that are members of the 
hsa-miRNA 371-373 cluster on chromosome 19 (Voorhoeve et al., 2006). This is most 
likely related to the presence of wild type of P53 in these tumours. The JKT1 cells were 
negative for this set of miRNAs, just like all SS investigated, while a selection of cell lines 
derived from EC were positive (data not shown). Based on these findings, a general profile 
based on a panel of 157 miRNAs was determined by Q-PCR in the JKT-1 cell line. The 
different miRNAs included in the study were grouped into three classes based on their 
relative expression level compared with the normalized control: high expression (>2 SD), 
intermediate (–2 SD to 2 SD) and low (under )2 SD) (Table 4). Within the group of highly 
expressed miRNAs, no direct correlation with DNA copy numbers could be identified 
(data not shown). 
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TABLE 4. MicroRNA expression profile of JKT-1 
 
High 
 let-7d, 16, 17-5p, 19a, 20, 21, 23a, 27a, 29a, 30b, 30c, 92, 99a,100,106a  
Intermediate 
 let-7a, let-7g, let-7i, 15b, 23b, 27b, 29b, 29c, 30a-3p, 31, 98, 103, 186, 221, 301, 320 
Low 
 lin-4, let-7e, 9, 9*, 10a, 15a, 17-3p, 26a, 26b, 28, 30e, 34a, 34b, 34c, 95, 96, 104, 105, 107, 122a, 124a, 
124b, 125a, 125b, 126, 127, 128a, 128b, 129, 130a, 130b, 132, 133a, 133b, 134, 135a, 135b, 137, 138, 139, 
140, 141, 142-3p, 142-5p, 144, 145, 146, 147, 148a, 149, 150, 151, 152, 154, 154*, 155, 159a, 181a, 181b, 
181c, 182, 182*, 183, 184, 185, 187, 189, 190, 191, 193, 194, 195, 197, 198, 199a, 199a*, 199b, 199-s, 200a, 
200b, 200c, 203, 204, 205, 210, 211, 213, 214, 215, 216, 218, 219, 220, 222, 223, 224, 296, 299, 302, 302b, 
302b*, 302c, 302c*, 302d, 308, 323, 324-5p, 325, 326b, 328, 330, 331, 335, 337, 338, 339, 340, 342, 367, 
368, 370, 371, 372, 373, 373*, 374  
Panel of 157 human miRNAs were divided in groups of high (more than 2SD), intermediate (-2SD to 2SD) 
and low (under –2SD) expression level. Members of known clusters are indicated in bold (Voorhoeve et al., 
2006), underlined (Suh et al., 2004) and italic (O'Donnell et al., 2005). 
 
Mutation screening 
Overall, SE have a very low-mutation rate in the genes encoding receptor kinases (Bignell 
et al., 2006). In contrast, mutations can be found in the stem cell factor receptor c-KIT 
(Kemmer et al., 2004), in particular in bilateral tumours (Looijenga et al., 2003a). 
Moreover, some mutations have been identified in the proto-oncogenes KRAS2, BRAF, 
and very seldom in P53 (Kersemaekers et al., 2002; McIntyre et al., 2005; Sommerer et al., 
2005). No mutations in c-KIT, KRAS2, BRAF and P53 were found in the JKT-1 cell line 
(data not shown). 
 
 
DISCUSSION 
 
After the first report on the human cell line JKT-1 as a representative model of testicular 
seminoma, this cell line has been used in multiple studies. These relate to the functional 
role of trophinin (Hatakeyama et al., 2004), connexin 43 (Roger et al., 2004) and estrogen 
(Roger et al., 2005) in the pathogenesis of TGCTs. In addition, it has been used in the 
identification of the mechanisms related to cisplatin sensitivity and especially resistance 
(Kobayashi et al., 2004). It is known that overall TGCTs, both seminomatous and NS 
tumours, with the exception of teratoma, are highly sensitive to cisplatin-based 
chemotherapy. An observation of interest, while treatment of other types of solid cancers 
might benefit of elucidation of the mechanisms involved (Masters & Koberle, 2003). 
Moreover, the cell line has been investigated regarding its response at the so-called 
hGABP⁄ E4TF1 site of the retinoblastoma gene (RB) promoter (Shiraishi et al., 2005). The 
data obtained, although of interest, were interpreted with the assumption that the JKT-1 
cells are derived from a testicular seminoma, and could serve as model for this tumour 
type. 
Initially, based on the absence of gain of 12psequences, which is a characteristic 
chromosomal anomaly of all SE, in combination with the absence of representative cell 
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lines for this tumour type, we questioned the origin of the JKT-1 cell line, and initiated 
the study of which the results are reported here. 
As demonstrated in this comprehensive study, the JKT-1 cells obtained from different 
laboratories are clonal in origin, and stable regarding the analysed protein expression. 
However, the cell line was not derived from the supposed primary tumour as proven by 
genotyping and immunohistochemistry. This conclusion was further strengthened by the 
chromosomal constitution of the cell lines, lacking the characteristic overrepresentation 
of 12p of invasive TGCTs (Atkin & Baker, 1982; Looijenga et al., 2003c), in accordance 
with the original report (Jo et al., 1999). This indicates that the lack of gain of 12p-
sequences is not the result of extensive in vitro culturing. 
The obvious and relevant question is what the cell of origin of the cell line JKT-1 is. The 
immunohistochemical profile of JKT-1 corresponds largely to a more mature germ cell, 
like a spermatogonium or spermatocyte (Table 1). The presence of SYCP1 and SYCP3 
strongly supports the origin of a cell undergoing (partial) meiosis (see below). We have 
made a similar observation in SS (Looijenga et al., 2006). In addition, the co-expression for 
DAZL and VASA in 60% of the cells relates to the stabilizing function of DAZL on 
translation of VASA (Reynolds et al., 2005) as seen in pre-meiotic germ cells. Our 
immunohistochemical results deviate remarkably from those of the original article, in 
which JKT-1 was described. The initial paper reported that the cell line is positive for 
PLAP, whereas our stainings show the exact opposite: <1% of JKT-1 cells are positive for 
this marker. Based on the finding that the cells are also negative for the enzymatic activity 
of this enzyme, it can be excluded that this negative result is because of the use of, for 
example, different antibodies. The three sub-lines investigated showed the same pattern 
marker expression. This makes it unlikely that the different pattern of marker profile is 
because of specific culture conditions, because the cell lines from the other institutes were 
cultured only in our facility for a very limited time. We hypothesized that the JKT-1 cell 
lines originate from a spermatocytic seminoma. This tumour is less frequent than 
seminoma, and can be misdiagnosed as a classical seminoma (Stoop et al., 2001). The SS 
have a specific pattern of marker expression, different from classical seminoma (Rajpert-
De Meyts et al., 2003b). They are positive for cancer-testis antigens XPA, SSX2-4 and 
SYCP1, amongst others and more recently, others were added, like DMRT1 (Looijenga et 
al., 2006). Interestingly, most of these markers were indeed found to be consistently 
positive in the JKT-1 cells. These observations support the model that the JKT-1 cells do 
indeed originate from a spermatocytic seminoma. However, the chromosomal 
constitution of the cells is not in accordance with the expected pattern, although so far 
only a limited number of this type of tumours have been investigated. We and others 
showed that the SS contain different populations of tumour cells, showing a diploid, a 
tetraploid and a hypertetraploid DNA content (Looijenga et al., 1994; Verdorfer et al., 
2004). This is in contrast to the triploid DNA content of the JKT-1 cells. Moreover, all SS 
investigated so far, using karyotyping, SKY, array CGH, and FISH showed specific 
overrepresentation of chromosome 9, and a specific amplification of the 9p21-p24 region 
in a single case. The DMRT1 gene has been found by us to be the most likely candidate 
within this region, being overexpressed in all SS investigated so far (Looijenga et al., 
2006). Although DMRT1 is indeed expressed in the JKT-1 cells, no gain of this 
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chromosomal region could be identified, not even using FISH with region-specific probes. 
In this context, the specific methylation pattern within the IGF2 ⁄ H19 ICR should be 
noted. Compared with all other biological subtypes of GCTs, SS show the highest degree 
of methylation at this site, indicating a gain of methylation related to germ cell 
maturation, while the methylation imprint is at least partially erased in the other tumours 
(Sievers et al., 2005). As we detected a low methylation level in JKT-1, this finding also 
argues against the origin from a spermatocytic seminoma. 
Otherwise, the significant structural chromosomal changes detected by us stand in sharp 
contrast to the minimal changes found previously by Jo et al. (1999), who characterized 
JKT-1 and JKT-HM >5 years ago with karyotyping and conventional CGH. These 
differences might be because of the extended in vitro growth of these cells, possibly 
related to the selection or induced changes. 
Based on these results, as well as the mRNA and miRNA expression profiling, it can be 
definitely concluded that the JKT-1 cells are not representative for (testicular) seminoma. 
Therefore, the reported data on the role of trophinin, connexin 43, estrogen, mechanisms 
of cisplatin-sensitivity and RB-related cell cycle control must be re-interpreted in the 
context of the pathogenesis of TGCTs. It remains to be established whether the JKT-1 cell 
line is derived from a spermatocytic seminoma, or a normal spermatocyte. Alternatively, 
it might originate from another source. In this context, the high expression of a number of 
miRNAs in JKT-1, i.e. miR-17-5p, 20 (both part of one genomic cluster), 21, 106a, is 
interesting as these are reported as part of a miRNA signature for solid epithelial cancers 
(Volinia et al., 2006). 
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ABSTRACT 
 
Testicular germ cell tumors of adolescents and adults (TGCTs) can be classified into 
seminomatous and nonseminomatous tumors. Various nonseminomatous cell lines, 
predominantly embryonal carcinoma (EC), have been established and proven to be 
valuable for patho-biological and clinical studies. So far, no cell lines have been derived 
from seminoma which constitute more than 50% of invasive TGCTs. Such a cell line is 
essential for experimental investigation of biological characteristics of the cell of origin of 
TGCTs, i.e. carcinoma in situ of the testis (CIS), which shows characteristics of a 
seminoma cell. 
Before a cell line can be used as model, it must be verified regarding its origin and 
characteristics. Therefore, a multidisciplinary approach was undertaken on TCam-2 cells, 
supposedly the first seminoma cell line. Fluorescent in situ hybridization, array 
comparative genomic hybridization and spectral karyotyping demonstrated an aneuploid 
DNA content, with gain of 12p, characteristic for TGCTs. Genome wide (Affymetrix) 
mRNA and (Applied Biosystems) microRNA expression profiling supported the seminoma 
origin, in line with the biallelic expression of imprinted genes IGF2/H19 and associated 
demethylation of the imprinting control region. Moreover, the presence of specific 
markers, demonstrated by immunohistochemistry, including (wild type) c-KIT, stem cell 
factor (SCF), placental alkaline phosphatase (PLAP), OCT3/4 and NANOG, and the 
absence of CD30, SSX2-4, and SOX2, confirms that TCam-2 is a seminoma cell line. 
Although mutations in oncogenes and tumor suppressor genes are rather rare in TGCTs, 
TCam-2 had a mutated BRAF gene (V600E), which likely explains the fact that these cells 
could be propagated in vitro. 
In conclusion, TCam-2 is the first well characterized seminoma-derived cell line, with an 
exceptional mutation, rarely found in TGCTs. 
 
 
 
submitted for publication
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INTRODUCTION 
 
Human testicular germ cell tumors of adolescents and adults (TGCTs) - the so called type 
II germ cell tumors (Oosterhuis and Looijenga 2005, for review) - originate from a 
transformed embryonic germ cell, either a primordial germ cell (PGC) or gonocyte. The 
precursor lesion is referred to as carcinoma in situ (CIS) or intratubular germ cell 
neoplasia unclassified (ITGCNU) (Eble, et al. 2004; Skakkebaek 1972). The invasive 
tumors are subdivided clinically and histologically into seminomatous and 
nonseminomatous (NS) tumors. The NS can be subclassified into embryonal carcinoma 
(EC), teratoma (TE), yolk sac tumor (YST) and choriocarcinoma (CHC), representing both 
undifferentiated and differentiated embryonic and extra-embryonic lineages, respectively. 
Consistent with their cell of origin, the tumors show a unique combination of 
characteristics, like telomerase activity (Albanell, et al. 1999), expression of stem cell 
markers, including OCT3/4 and NANOG in seminoma and EC (Hoei-Hansen, et al. 2005; 
Looijenga, et al. 2003b), and in addition to these, SOX2 in EC (Korkola, et al. 2006), as 
well as an erased pattern of genomic imprinting (van Gurp, et al. 1994), and expression of 
the microRNA cluster hsa-miR 371-373, explaining the wildtype TP53 in these tumors 
(Voorhoeve, et al. 2006). All invasive TGCTs are chromosomally aneuploid and exhibit 
specific patterns of losses and gains of genomic regions, with overrepresentation of 12p as 
the only consistent finding (Looijenga, et al. 2003c; van Echten, et al. 1995). 
In 1975 the first type II TGCT-derived cell line was established by culturing EC cells 
(Fogh and Trempe 1975). Since then, multiple EC-derived cell lines have been generated, 
used in various studies (Andrews, et al. 2005). These have been very informative, although 
differences between various sub-lines, cultured in different laboratories, have been 
reported, for example regarding their pattern of X-inactivation (Looijenga, et al. 1997). In 
contrast to the relative wealth of independently generated EC-derived cell lines, only few 
reports on the establishment of cell lines representative for seminoma have been 
published (Kinugawa, et al. 1998; Mizuno, et al. 1993; von Keitz, et al. 1994). This is most 
likely due to the exceptional sensitivity of seminoma cells to undergo programmed cell 
death (apoptosis) upon disruption of their micro-environment (Berends, et al. 1991; Olie, 
et al. 1996), also known as anoikis (Frisch and Francis 1994). This might also explain why 
PGCs rapidly go into apoptosis when they stay extragonadal during normal embryonic 
development (Stallock, et al. 2003). So far, the seminomatous characteristics of the 
proposed seminoma cell lines have not been independently confirmed. In this context, we 
recently showed that the JKT-1 cell line, used in multiple studies as a model for 
seminoma, has none of the hallmarks of a classical seminoma (De Jong, et al. 2007), and is 
therefore not a seminoma cell line. 
Already in 1993, the establishment of the cell line TCam-2 was reported (Mizuno, et al. 
1993). This cell line originated from a primary testicular seminoma of a 35 year old patient 
and was generated by the traditional explant culture method, and succesfully transplanted 
into SCID mice. To proof it being representative for seminoma, we performed an 
extensive characterization of the TCam-2 cell line. The genomic constitution, imprinting 
status and immunohistochemical marker profile were determined, as well as genome wide 
(Affymetrix) mRNA and (Applied Biosystems) miRNA expression profiling. The results 
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show that TCam-2 cells contain all the typical features of seminoma. Furthermore, 
mutation analysis for several oncogenes and tumor-suppressor genes was done. In spite of 
a low mutation rate of these genes in TGCTs (McIntyre, et al. 2005; Sommerer, et al. 
2005), the BRAF gene was mutated in TCam-2. 
 
 
MATERIALS AND METHODS 
 
Cell lines and primary tumor 
TCam-2 cells were obtained from Sohei Kitazawa (Division of Molecular Pathology, Kobe 
University, Japan). The original formalin-fixed and paraffin-embedded tissues from the 
primary tumor could not be retrieved for investigation, and the patient data on clinical 
follow up were not available. The cells were cultured in RPMI 1640 (Invitrogen, Breda, 
The Netherlands) supplemented with 10% fetal calf serum (Hyclone, Thermo Fisher 
Scientific, Etten-Leur, The Netherlands) and penicillin/streptomycin (Invitrogen, Breda, 
The Netherlands) at 37°C in a humidified cell culture incubator with 5% carbon dioxide. 
EC cell lines Tera-1 (Fogh 1978), NTera-2 (Andrews, et al. 1984), 2102Ep (Wang, et al. 
1980) and NCCIT (Teshima, et al. 1988) were cultured as described before (Burger, et al. 
1999). Cells were trypsined and harvested for the different experiments. Cytospins were 
prepared and DNA, RNA and protein were isolated (see below).  
 
Fluorescent In Situ Hybridisation (FISH) 
FISH was performed on metaphase spreads of TCam-2 cells as described before (Zafarana, 
et al. 2002). The following probes on chromosome 12 were used: PAC 876C13 (12p11.23), 
BAC RP11-268P4 (12p12.1) (the latter clone containing EKI1, a gene located at the 
telomeric region of the shortest region of overlap of amplification in seminomas: p11.2-
p12.1 (Zafarana, et al. 2002)), and centromere specific probe Pα12H8 (Looijenga, et al. 
1990). The centromere specific probe was labelled with biotin-16-dUTP (Roche, 
Mannheim, Germany) and detected using streptavidin-Cy3 (Jackson ImmunoResearch 
Laboratories, Cambridgeshire, UK), the other probes were labelled with digoxigenin-11-
dUTP (Roche) and visualized with FITC-conjugated sheep anti-digoxigenin (Roche). 
 
Spectral karyotyping (SKY) 
Standard cytogenetic preparations were pretreated with RNase for 30 min at 37ºC and 
digested in 0.012% pepsin for 5 min. After washing, cells were fixed in 1% 
formaldehyde/50-mM MgCl2 in PBS for 10 min, washed, and dehydrated. Hybridization 
and detection for SKY analysis was performed according to the manufacturer’s protocol 
with minor adjustments (Applied Spectral Imaging, Migdal Ha’Emek, Israel). Briefly, after 
two days of hybridization, slides were washed in 0.4 x SSC (pH 7.0) for 15 sec at 72°C 
followed by 2 x SSC at RT. Cells were counterstained with DAPI and mounted in antifade 
solution (Dabco-Vectashield 1:1). Using the SD300-C SpectraCube and Skyview analysis 
software (ASI) 10 metaphase cells were examined. 
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DNA isolation and Array Comparative Genomic Hybridization (array CGH)  
Genomic DNA from the cultured cells was extracted as described before (Kersemaekers, et 
al. 2002). Briefly, each sample was treated with proteinase K followed by 
phenol/chloroform extraction and DNA was dissolved in TE buffer (10 mM Tris-HCl, 1 
mM EDTA, pH 8.0). 
TCam-2 cells and EC cell lines Tera-1, NTera-2, 2102Ep and NCCIT, were analysed on a 
human BAC/PAC array containing 3600 clones covering the full genome at on average a 1 
Mb-spacing (Cardoso, et al. 2004). Labeling and hybridization were performed as 
described before (Cardoso, et al. 2004). Scanning was done on a ScanArray Express HT 
Microarray Scanner (Perkin-Elmer) and resulting images were analyzed with the GenePix 
Pro 5.0 software (Axon Instruments).  
 
Mutation analysis of TP53, KRAS2, BRAF and c-KIT 
To investigate the presence of TP53 mutations, in this case in exon 5 to 8, the Single-
Strand Conformation Polymorphism approach as described before (Kersemaekers, et al. 
2002) was applied. If aberrant bands after gel electrophoresis were identified, these were 
sequenced.  
KRAS2, BRAF and c-KIT mutation analysis was done by Locked Nucleic Acid-mediated 
PCR Clamping and Melting Curve analysis followed by sequencing. For KRAS2 primers, 
oligomer and probe were used as reported previously (Chen, et al. 2004). Oligonucleotides 
used for BRAF mutation analysis are the following: 5’-catctcagggccaaaaat in intron 14 
(BRAF-F), 5’-tcctttacttactacacctcag in intron 15 (BRAF-R), 5’-gagatttcactgtagctagaccaa-Flu 
(sensor), 5’-LC Red 640-tcacctatttttactgtgaggtcttcatgaagaaa-Ph (anchor), 
gagatttctctgtagcta-Ph (LNA). For c-KIT the Lightcycler assay was adapted from Sotlar et 
al. (Sotlar, et al. 2003). The primers s (5’-cagccagaaatatcctccttact) and b (5’-
ttgcaggactgtcaagcagag) were used in combination with the sensor probe 5’-
agccagagtcatcaagaatgattcta-Flu and the anchor probe 5’-LC Red640-
atgtggttaaaggaaacgtgagtaccca-Ph. The LNA probe 5’-gccagagacatcaagaatg-Ph was used to 
suppress the WT allele (details of the method will be published elsewhere). In addition to 
the Lightcycler analysis, genomic DNA of TCam-2 was sequenced using forward (Intr16F 
5’-gcaacactatagtattaaaaagttag) and reverse (18R1pna 5’-gactgctaaaatgtgtgatatccc) primers 
encompassing exon 17 of c-KIT (details of the method will be published elsewhere). 
 
Expression of the imprinted genes IGF2/H19  
To determine whether imprinted genes are either mono-allelically or bi-allelically 
expressed in the TCam-2 cells, ApaI and RsaI polymorphisms within the IGF2 and H19 
genes were investigated. Therefore, DNA of cultured cells was amplified at both loci by 
PCR, followed by restriction enzyme digestion. In case heterozygosity was determined, a 
similar analysis was done on cDNA (van Gurp, et al. 1994). The following primers were 
used: 5’-cttggactttgagtcaaattgg-3’ and 5’-gggtcgtgccaattacatttcat-3’ (IGF2 locus); 5’-
tgactgaggaatcggctctggaag-3’ and 5’-cggtcggagcttccagactag-3’ (H19 locus).  
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Methylation status of IGF2/H19 imprinting control region 
The methylation status of the IGF2/H19 ICR was determined by methylation-sensitive 
single nucleotide primer extension (MS-SNuPE)-PCR and sequencing of the CTCF core 
binding domain as described before (Sievers, et al. 2005). Primers for amplifying the CTCF 
core domain were 5’-tgtatagtatatgggtatttttggaggttt-3’ and 3’-gggaataggatatttatagga-5’. The 
SNuPE primer sequence for the first cytosine in the CTCF binding domain was c0-
gttgtggaat(c/t)ggaagtggt (primer A) and for the first cytosine before the CTCF core domain 
was c12-gaattggttgtagttgtggaat (primer B). Automated  capillary electrophoresis and 
analysis were performed on an ABI PRISM 310 sequencer. MS-SnuPE profiles were 
confirmed by conventional bisulfite sequencing (Sievers, et al. 2005). 
 
Expression analysis 
Microarray expression profiling 
Expression profile of the TCam-2 cell line was determined using Affymetrix GeneChip 
Human Genome U133 plus 2.0 array and analyzed using Omniviz and SAM software as 
described before (Looijenga, et al. 2006). 
 
MicroRNA expression profiling 
RNA highly enriched for low molecular weight (LMW) RNA species was isolated using 
the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) according to the 
manufacturer’s protocol. RNA quantity and quality was determined by a high-resolution 
electrophoresis bioanalyzer 2100 (Agilent, Amstelveen, NL) and by UV absorbance. 
Expression of 300 mature miRNAs, including positive- and negative controls as well as 
normalization controls, was analyzed by TaqMan Multiplex MicroRNA Assays (Applied 
Biosystems, Foster City, CA, USA) following the manufacturer’s protocol. Briefly, single-
stranded cDNA was synthesized in 7 pools of miRNA-specific RT-primers (each pool 
contains approximately 48 primers) from 20 ng of  LMW RNA per pool in 20 μl reaction 
volume using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). 
The reactions were incubated first at 16°C for 30 min and then at 42°C for 30 min. The 
reactions were inactivated by incubation at 85°C. The Multiplex RT products were diluted 
10-fold by adding 180 μl H2O. Each cDNA generated was amplified by Q-PCR using 
sequence-specific primers/probes on a fully automated Applied Biosystems 7900HT Real-
Time PCR system. The 10 μl PCR included 5 μl Universal PCR Master Mix (No AmpErase 
UNG), 0.5 μl of sequence-specific primers/probes and 0.8 μl of diluted RT-product. The 
reactions were incubated in duplicate at 95°C for 10 min, followed by 40 cycles of 95°C 
for 15 s and 60°C for 1 min. Hsa-miR-16 /let-7, RNU-44 and RNU-48 were used as 
internal normalization controls. The median threshold value of the controls was 
determined and the difference with the target threshold was determined as delta Ct. This 
was used to investigate the different samples for expression of the targets along all samples 
included in the survey. Using the Omniviz tools, biostatistical analysis was performed on 
the total data set as described before (Looijenga, et al. 2006). 
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Immunohistochemistry 
Immunohistochemical staining was performed on cytospin preparations and TCam-2 cells 
grown in 50 mm hydrophob LUMOX-dish (96077305, Greiner, Frickenhausen, Germany). 
General markers as vimentin (1:80; M725, DAKO, Glostrup, Denmark) and CAM5.2 (1:20; 
345779, BD Biosciences, San Jose, CA, USA), and specific markers for various maturation 
stages of germ cell development like PLAP (1:200; 203, Cell Marque Corp, Hot Springs, 
AR, USA), OCT3/4 (1:1000; sc-5279, Santa Cruz Biotechnology, CA, USA), NANOG 
(1:800; AF1997, R&D Systems, Abingdon, UK), DAZL (1:750; Ab17224, Abcam, 
Cambridge, UK), VASA (1:1000; provided by D. Castrillon (Castrillon, et al. 2000)), TSPY 
(1:4000; provided by Y.-F. C. Lau (Lau, et al. 2000)) and SSX2-4 (1:100; provided by A. 
Geurts van Kessel (dos Santos, et al. 2000)) were applied. A standard 1-hour incubation at 
room temperature was used. Secondary biotinylated antibodies SWine-Anti-Rabbit 
(SWAR), Rabbit-Anti-Mouse (RAM) (both DAKO, Glostrup, Denmark) and Horse-Anti-
Goat (HAG) (Vector Laboratories, Burlingame, CA, USA) were used in a 1:200 dilution 
and incubated for 30 minutes at RT. Antibody complex was visualised by avidin-biotin 
conjugated with horseradish peroxidase or alkaline phosphatase, respectively using 3,3-
diaminobenzidine and New Fuchsin (72200, Fluka, Buchs SG, Switzerland) as 
chromogens, resulting in a brown and a red signal.  All slides were counterstained with 
haematoxylin. 
 
Protein isolation, Western Blotting and Immunoprecipitation 
Isolation of protein and Western blotting were performed as described before (de Jong, et 
al. 2005). Immunoprecipitation of c-KIT (using rabbit polyclonal antibody, A4502 from 
DAKO) in TCam-2 protein lysate was done overnight at 4°C. Protein lysate from the F36P 
cell line was used as a positive control for c-KIT expression. Detection on the Western 
blot was done with the same antibody. 
 
 
RESULTS 
 
Genomic constitution of the TCam-2 cell line 
To investigate the overall chromosomal constitution of the TCam-2 cell line array CGH 
and SKY analysis were performed. Array CGH of four well characterized EC cell lines was 
done for comparison. The hallmark of type II TGCTs, gain of the short arm of 
chromosome 12, was independently analyzed by FISH. 
SKY analysis showed about 90 chromosomes with a complicated pattern of 
rearrangements, confirming the tetraploid status as described in the original paper 
(Mizuno, et al. 1993). Because of the large number of marker chromosomes no consensus 
karyotype was determined. A metaphase analysed by SKY is shown in Figure 1A to 
illustrate the genomic complexity. 
The array CGH patterns of TCam-2 and for comparison the EC-cell lines Tera-2, NTera-2, 
2102Ep and NCCIT were analysed. Several chromosomes of TCam-2 had array CGH 
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FIGURE 1. Genomic constitution of TCam-2 cells was determined by SKY analysis, array CGH and FISH. In 
addition, the EC-cell lines Tera-1, NTera-2, 2102Ep and NCCIT were analysed by array CGH. A) A 
representative metaphase of SKY analysis of TCam-2. The majority of chromosomes contains anomalies, and 
a large number of marker chromosomes is present; B) 3.6 K BAC/PAC array CGH analysis of TCam-2 cells 
and four EC-cell lines. Gain of 12p is present in all cell lines, while for example the Y chromosome is lost; C) 
FISH analysis confirmed the increased number of 12p copies (green signal) compared to the centromeric 
region of chromosome 12 (red signal) in TCam-2. (Figure 1 colour image on page 184) 
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profiles that were close to baseline (i.e. tetraploid): chromosome 3, 5, 6, 10, 14, 15, 16, 19 
and 21. For other chromosomes, whole chromosomes or complete chromosome arms were 
gained (7p, 8q, 12p, 20) or deleted (9q, 13, 17p, 22 and Y). The following chromosomes 
contained gains or losses of a restricted region: 1, 2, 4, 7, 11, 18 and X. The characteristic 
chromosomal aberration of all invasive germ cell tumors, gain of 12p, was clearly present 
in TCam-2 cells as well as in all EC cell lines (Figure 1B). No other consistent patterns 
present in all cell lines, or when TCam-2 was left out, specific for EC cell lines, could be 
extracted. The specific gain of 12p in TCam-2 was confirmed by FISH analysis (Figure 1C).  
 
Imprinting and methylation of the ICR 
The pattern of genomic imprinting established during normal germ cell development 
(Surani 1998), has been used to characterize the embryonic germ cell origin of the 
seminomatous and the nonseminomatous TGCTs (van Gurp, et al. 1994). The 
polymorphisms within the IGF2/H19 locus were used to study mono- or bi-allelic 
expression. In TCam-2 cells both H19 and IGF2 were biallelically expressed (Figure 2A) 
which implicates erasure of the genomic imprinting as is the situation in an immature 
germ cell (Szabo, et al. 2002; Szabo and Mann 1995). The imprinting status of the 
IGF2/H19 locus is regulated by an imprinting control region (ICR) and the methylation 
status of the ICR is also informative for the status of genomic imprinting (Sievers, et al. 
2005). In TCam-2 the ICR of the IGF2/H19 locus was completely unmethylated (Figure 
2B), as consistently found in seminomatous TGCTs (Sievers, et al. 2005).  
 
FIGURE 2. 
The status of genomic imprinting in 
the IGF2/H19 locus was determined 
by polymorphic restriction enzyme 
digestion and the methylation status 
of the imprinting control region 
(ICR) in this locus. A) In TCam-2 
both H19 and IGF2 genes were 
informative as shown by RsaI and 
ApaI digestion on DNA derived PCR 
products (DNA+). The same 
restriction enzyme digestions of PCR 
products from TCam-2 mRNA 
showed biallelic expression of both 
H19 and IGF2 (cDNA+), indicated by 
both the A and B allele; B) Bisulfite 
sequencing reveals that the ICR in 
the IGF2/H19 locus was completely 
unmethylated and all cytosines were 
converted to thymines (indicated in 
red compared to the original 
sequence as shown below). (Figure 2 
colour image on page 185) 
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Marker expression profile 
In addition to to gain of 12p and an erased pattern of genomic imprinting,  seminoma and 
EC express a number of early embryonic markers. The one that has been demonstrated to 
be most informative in TGCT diagnostics, as well as for those tumors outside the testis, 
over the past few years is OCT3/4 (de Jong, et al. 2005). The presence of OCT3/4 in TCam-
2 was demonstrated by immunohistochemistry, showing an intense nuclear staining of the 
cells grown in culture (Figure 3A left panel) and a specific 43 kD band in Western blotting 
analysis (data not shown). High expression of OCT3/4 in TCam-2 comparable to the 
expression found in tumor samples of seminoma and EC is shown in Figure 3C (left 
panel), as determined by (Affymetrix) expression profiling. NANOG, another marker of 
pluripotency, with virtually the same expression pattern as OCT3/4 is highly expressed in 
TCam-2 as is the case in seminoma, CIS and EC (Hart, et al. 2005), determined by 
expression profiling and immunohistochemistry (data not shown). The embryonic stem 
cell marker SOX2, also involved in regulation of differentiation, was absent in TCam-2 
cells and seminoma on protein and mRNA level, in contrast to the high expression found 
in EC (Figure 3B left upper panel and 3C middle panel). This is in line with its absence 
during normal germ cell development (unpublished observations). In addition, CD30 is a 
member of the tumor necrosis factor superfamily of cytokine receptors, which consistent 
expression in EC and EC-derived cell lines is related to inhibition of apoptosis (Herszfeld, 
et al. 2006). CD30 was also not expressed in TCam-2 cells on protein level (data not 
shown) nor on mRNA level demonstrated by (Affymetrix) profiling (Figure 3C right 
panel). Furthermore, TCam-2 cells showed expression of placental alkaline phosphatase 
(PLAP; Figure 3A middle panel), as well as direct alkaline phosphatase staining. 
Cytokeratin 8, as detected by CAM5.2 exhibited a dot-like staining pattern that can be 
observed in many seminoma cells (Figure 3A right panel). Finally, the stem cell factor 
receptor, c-KIT, and its ligand SCF were both expressed in the TCam-2 cells as determined 
by immunoprecipitation for c-KIT (Figure 3B left lower panel), Affymetrix expression 
profiling (data not shown), and immunohistochemistry (Figure 3B middle and right 
panel). Moreover, the markers specific for later stages of germ cell maturaton, i.e., SSX2-4 
and DAZL were negative (data not shown). In contrast, VASA and TP53 showed a 
positive staining, the latter in a heterogeneous pattern. No expression was found for TSPY, 
due to the loss of the Y chromosome. Unsupervised hierarchical clustering of mRNA 
(Affymetrix) expression of a panel consisting of TCam-2 and TGCT tumor samples, 
showed that TCam-2 clustered in the seminoma-branch, separated from the EC samples 
(Figure 4). 
In addition to the markers indicated above, a miRNA expression profile of TCam-2 cells 
was determined and compared to the EC cell lines. The different miRNAs included in the 
study were grouped into three classes based on their relative expression level compared to 
the normalized control: high expression (more than 2 SD), intermediate (-2 SD to 2 SD) 
and low (under -2 SD) (Table 1). The hsa-miRNA 371-373 cluster is specific for embryonic 
germ cells as well as for TGCTs, was highly expressed in TCam-2 indicating its TGCT 
origin (data not shown), and matching the presence of a wild type TP53 (Voorhoeve et al., 
2006, see below). Comparison of the miRNA expression profile of TCam-2 to the various 
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EC cell lines showed a number of differentially expressed miRNAs. Especially, miRNA 
145 and 324-5p are of interest here, because of their high expression relative to the EC cell 
lines and SOX2 as their predicted target. 
 
FIGURE 3. Expression of embryonic stem cell markers in TCam-2 and clinical germ cell tumor samples. A) 
left panel: Nuclear staining for pluripotency factor OCT3/4 in TCam-2 cells grown in a culture dish; middle 
panel: TCam-2 cells are positive for PLAP on cytospin preparation; right panel: dotted cytokeratin 8 
(CAM5.2) staining in TCam-2 cells on cytospin preparation, as can be observed in seminoma; B) left upper 
panel: Western blot analysis shows expression of SOX2 in the embryonal carcinoma cell line NTera-2 and 
absence of SOX2 in TCam-2; left lower panel: Immunoprecipitation (IP) for c-KIT shows the expected band 
in TCam-2 and in F36P control total cell lysate, while c-KIT expression is very weak in total cell lysate of 
TCam-2; middle and right panel: immunohistochemistry for c-KIT and SCF on TCam-2 cells on cytospin 
preparations; C) Expression results of TCam-2 and primary human germ cell tumor samples based on 
genome wide (Affymetrix) expression profiling (log2 transformed data), left panel: OCT3/4 (expressed in all 
samples); middle panel: SOX2, and right panel: CD30, both expressed in embryonal carcinoma and low in 
seminoma and TCam-2. EC: embryonal carcinoma; DG: dysgerminoma; SE: seminoma. (Figure 3 colour 
image on page 186) 
 
Mutation screening 
Unlike other solid tumors, type II TGCTs have a low mutation rate in proto-oncogenes, 
including BRAF and KRAS2 (Sommerer, et al. 2005), as well as the tumor suppressor gene 
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FIGURE 4. Unsupervised hierarchical clustering based on the top 100 differentiating genes between 
seminoma (SE)/dysgerminoma (DG) and embryonal carcinoma (EC) based on Affymetrix expression 
profiling to cluster the TCam-2 cell line (see supplementary data). TCam-2 clusters in the seminoma branch, 
separate from the  EC samples. (Figure 4 colour image on page 187) 
 
 
TABLE 1. MicroRNA expression profile of TCam-2  
High 
 let-7e, let-7g, 9, 15b, 17-5p, 19a, 20a, 20b, 26a, 26aN, 28, 29a, 30a-5p, 30b, 30d, 31, 32, 92, 92N, 93, 99b, 
124a, 126, 126#, 130b, 134, 135b, 142-5p, 145, 151, 154, 181a, 181b, 181d, 182, 186, 199a, 199a*, 199-s, 
200bN, 200c, 205, 216, 217, 222, 301, 302a, 302d, 330, 342, 367, 371, 372, 373, 517a, 517c 
Intermediate 
 7, 9*, 10a, 15a, 18a, 19b, 21, 23b, 23bN, 25, 26b, 27a, 27bN, 30a-3p, 30a-5pN, 34aN, 34b, 105, 106a, 108, 
124b, 125b,  132, 135a, 139, 141, 142-3p, 152N, 183, 184, 187, 192, 196a, 197, 200b, 203, 218, 224, 220, 
296, 302b, 302c#, 324-5p, 320, 321, 326, 328, 331, 337, 339, 340, 362, 365, 375, 380-3p, 381, 383, 423, 
425, 452*,512-3p, 517b, 518a, 518b, 518c, 518f, 519c, 519d, 520g, 520h, 522, 525* 
Low 
 let-7a, let-7c, let-7d, let-7i, 1, 10b, 16, 17-3p, 22, 23a, 24, 26bN, 27b, 29b, 29c, 30c, 30e-5p, 33, 34a, 34c, 
34cN, 95, 96, 98, 99a, 100, 101, 103, 104, 106b, 107, 122a, 125a, 127, 129, 130a, 130aN, 133a, 133b, 137, 
138, 140, 143, 144, 146a, 146b, 147, 148a, 148b, 149, 150, 152, 153, 154*, 155, 181c, 182*, 189, 190, 191, 
193a, 193b, 194, 195, 196b, 198, 199b, 200a, 200a#, 200cN, 202, 202#, 204, 206, 208, 210, 210N, 211, 212, 
213, 213, 214, 215, 219, 221, 223, 302a#, 302c, 323, 324-3p, 325, 325N, 299-3p, 299-5p, 335, 338, 345, 
346, 361, 363, 368, 369-3p, 369-5p, 370, 373#, 374, 376a, 377, 378, 379, 380-5p, 382, 384, 409-5p, 412, 
422a, 422b, 424, 429, 432, 432*, 433, 448, 449, 450, 451, 452, 453, 485-3p, 485-5p, 488, 489, 490, 491, 
492, 493, 494, 496, 497, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512-5p, 514, 515-
3p, 515-5p, 516-5p, 517*, 518a-2*, 518c*, 518d, 518e, 519a, 519e, 520a, 520a*, 520b, 520c, 520d, 520d*, 
520e, 520f, 521, 523, 524, 524*, 525, 526a, 526b, 526b*, 526c, 527 
A panel of 300 mature human miRNAs were divided in groups of high (more than 2SD), intermediate (-2SD 
to 2SD) and low (under -2SD) expression level. MiRNAs specific for GCTs are underlined. 
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TP53 (Kersemaekers, et al. 2002). In addition, TGCTs seldom have mutations in genes 
encoding receptor kinases (Bignell, et al. 2006; Greenman, et al. 2007). In contrast, 
mutations can be found in the stem cell factor receptor c-KIT, in particular in bilateral 
tumors (Looijenga, et al. 2003a). Mutation analysis of these aforementioned genes in 
TCam-2 cells showed a mutation in the proto-oncogene BRAF gene due a thymine to 
adenine transversion at nucleotide 1796 (T1796A), leading to a substitution of glutamic 
acid for valine at amino acid 600 (V600E)(data not shown). No mutations in TP53, KRAS2 
and c-KIT were found. 
 
 
DISCUSSION 
 
TGCTs are the result of erronous development of early germ cells during migration or 
upon their arrival in the gonad. In stead of progressing through the maturation process 
that will eventually form spermatozoa around puberty, these cells retain their embryonic 
phenotype and acquire malignant potential (Oosterhuis and Looijenga 2005). The 
transformation from the precursor lesion CIS to invasive TGCTs, seminoma and 
nonseminoma, is accompanied by gain of the short arm of chromosome 12, this feature 
being the genomic hallmark of all TGCTs irrespective of histology (Looijenga, et al. 2003c; 
van Echten, et al. 1995). The embryonic origin of TGCTs is reflected in their pluripotent 
potential: CIS and seminoma can progress to the undifferentiated EC – a process called 
reprogramming - , and these cells can recapitulate normal development by differentiation 
to embryonic (teratoma) and extra-embryonic tissues (yolk sac tumor and 
choriocarcinoma), as well as the germ lineage (Honecker, et al. 2006). Besides their 
pluripotency, TGCTs harbour a defined set of features of embryonic development, some of 
which have been used for diagnostic purposes. The most striking example is the 
identification and current use as diagnostic marker of OCT3/4 (de Jong, et al. 2005). 
In this study we characterized the cell line TCam-2, supposedly derived from a seminoma, 
by determining whether it harbours the genomic and embryonic hallmarks of invasive 
TGCTs. Our results showed specific gain of 12p in TCam-2 cells by SKY, array CGH and 
FISH. Expression of the (embryonic) miRNA cluster hsa-miR 371-373, as well as protein 
and mRNA expression of embryonic stem cell markers OCT3/4 and NANOG, together 
with biallelic expression of imprinted genes IGF2 and H19 proved the TGCT origin of 
TCam-2. The seminomatous origin of TCam-2 was reflected by the expression of c-KIT, 
SCF and PLAP, and by the absence of SOX2 and CD30. In addition, the tetraploidy of 
TCam-2 cells was close to the hypertriploid number of chromosomes found in primary 
seminomas, in contrast to the hypotriploidy of nonseminomas (Oosterhuis, et al. 1989). 
Our results are consistent with the recent array CGH data and the reported OCT3/4 
protein expression in TCam-2 (Goddard, et al. 2007). 
The proven seminomatous origin of TCam-2 paves the way to research that could not be 
undertaken previously because of lack of a valid model for seminomas. Seminomas are 
considered the default developmental pathway of CIS cells, or stated otherwise: a 
proliferation of CIS cells that have acquired invasiveness, possibly related to gain of 12p. 
Therefore, the availability of a seminoma cell line offers opportunities to study earlier 
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steps in germ cell tumorigenesis than in the EC derived cell lines. Especially the 
transformation step of CIS/seminoma cells to EC cells, which results in the clinically 
unfavorable nonseminomas, could not be explored until now. This process called 
reprogramming is a black-box during which the CIS/seminoma cells acquire the 
expression of stem cell markers SOX2, CRIPTO-1/TDGF1 and CD24 (Korkola, et al. 2006; 
Looijenga, et al. 2007), resulting in the undifferentiated EC cells. Artificial upregulation of 
these genes in TCam-2, combined with downregulation of CIS/seminoma specific genes 
by siRNA, can be used to mimic the process of reprogramming and break it down into a 
molecular biological sequence. Interestingly, the miRNAs 145 and 324-5p might be 
gatekeepers in this process, by preventing translation of SOX2 mRNA in TCam-2. In 
addition, the proposed role of TSPY in the development of these tumors can be 
investigated (Kersemaekers, et al. 2005; Li, et al. 2007a; Li, et al. 2007b) 
The favorable treatment outcome in most TGCTs, even after metastasizing, is tightly 
linked to the exceptional sensitivity to chemotherapy and radiation (Kollmannsberger, et 
al. 2006). The absence of G1 arrest in response to DNA damage, is another feature that 
reflects their embryonic origin (Aladjem, et al. 1998). The sensitivity of TCam-2 to 
different chemotherapeutics and different radiation dosis regiments can now be tested in 
vitro. Besides in vitro, TCam-2 can also be studied in vivo as xenografts in SCID mice, as 
was demonstrated in the original article (Mizuno, et al. 1993). In this way, behavior of the 
cells injected in the testis and other locations can be used to study, for instance, 
metastasizing capacity. 
Although the establishment of TCam-2 creates a new research area to be explored, the 
fact that it is the only proven seminoma cell line, is reason for caution. If TCam-2 was 
derived from a typical seminoma, then it is expected that it could not have been 
established by a traditional culture method, as has been done. Therefore, the initial tumor 
cells probably had an advantage that helped them escape from the anoikis that normally 
awaits seminoma cells upon disruption of their microenvironment (Olie, et al. 1996). A 
possible explanation for the succesfull establishment of this unique cell line was found in 
the mutation analysis of TCam-2. Although primary GCTs generally have a low mutation 
frequency in well-known tumor suppressor and oncogenes as TP53, KRAS2 and BRAF, 
GCT-derived cell lines show a relatively high proportion of mutations. For example, TP53 
is mutated in NCCIT (Burger, et al. 1998), GCT85 has mutated BRAF, and 833KE has 
mutant KRAS2 (unpublished observations). In TCam-2, BRAF was mutated, leading to a 
constitutively activated RAS-pathway (McIntyre, et al. 2005). This mutation could be the 
explanation that these cells could be propagated in vitro. Because of the lack of the 
primary tumor, it could not be determined whether this mutation was present in the 
original tumor, or generated due to in vitro culturing. Our hypothesis that in vitro growth 
of TCam-2 cells is possible due to the BRAF mutation finds support in our own experience 
of trying to establish seminoma cell lines. Typically seminoma cells go rapidly into 
apoptosis upon disruption of their microenvironment (Olie, et al. 1996). However, the 
presence of either a RAS mutation or high level amplification of 12p sequences results in 
prolonged in vitro survival (Roelofs, et al. 2000). Both events make the tumor cells more 
resistent to apoptosis, supposedly in a similar way as the BRAF mutation in TCam-2.  
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In conclusion, this study demonstrates that the TCam-2 cell line has all the essential 
features to qualify as a valid model for seminomatous tumors. The presence of an 
activating mutation in the BRAF oncogene provides a possible explanation why this cell 
line could be established. 
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ABSTRACT 
 
Embryonic development is characterized by a spacial and temporal sequence of tightly 
regulated differentation, starting from a population of pluripotent stem cells. The 
combined action of SOX and POU families of transcription factors plays major roles in this 
regulation by forming heterodimers consisting of a SOX protein and a POU protein bound 
to the target DNA sequence. In embryonic stem cells the protein interaction between 
SOX2 and POU5F1 (also known as OCT3/4 and OCT4) is essential for maintaining the 
undifferentiated state by activating pluripotency-linked genes, and inhibition of genes 
involved in the various differentiation pathways. Besides embryonic stem cells, POU5F1 is 
also present during normal development in migrating primordial germ cells and the 
undifferentiated germ cells in the gonad, the gonocytes. However, the target genes of 
POU5F1 in germ cells and how these genes are regulated remains to be studied. Here we 
show that SOX2 is absent in germ cells of human fetal gonads, carcinoma in situ (CIS), i.e. 
the precursor lesion of testicular germ cell tumors of adolescents and adults (TGCTs), and 
seminoma, the latter confirming other studies. Based on genome wide expression 
profiling, SOX17 was found to be the alternative protein partner for POU5F1 in early 
germ cells and their malignant counterparts, CIS and seminoma. Immunohistochemistry, 
Western blot analysis and quantitative RT-PCR showed that SOX17 is a suitable marker to 
distinguish seminoma from embryonal carcinoma, the latter being the malignant 
counterpart of embryonic stem cells, and SOX2 positive. This is confirmed in 
representative cell lines. Furthermore, we show that aberrant SOX2 expression in Sertoli 
cells is strongly associated with the presence of CIS in the seminiferous tubules. 
In conclusion, this study demonstrates the absence of SOX2 in human embryonic and 
malignant germ cells, which express SOX17 in conjunction with POU5F1. This finding 
has both diagnostic as well as developmental biological implications. 
 
 
 
 
 
submitted for publication 
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INTRODUCTION 
 
The SOX family of transcription factors is involved in orchestrating development from the 
early cells in the embryo to differentiated lineages of specialized cells. Currently, twenty 
SOX proteins have been identified in humans, and all have a high-mobility group domain 
(HMG), a 79-amino acid protein motif, that binds into the minor groove of the DNA helix 
and will induce DNA bending, involved in expression regulation 1. SOX proteins have at 
least 50% amino acid similarity to the HMG domain of SRY, the testis-determining factor 
in mammals excluding monotremes 2, and are therefore named SRY-related HMG box 
(SOX) proteins. Although different SOX proteins can bind highly similar DNA sequences 
in vitro, they are expressed in a cell-type specific manner in which they regulate their 
target genes 3. This regulation is achieved by the collaboration of SOX proteins in 
association with other proteins 4. Abundantly represented among the protein partners are 
the POU homeodomain proteins 5, 6. Like SOX proteins, these transcription factors are 
expressed in a cell-specific way and interact simultaneously with the DNA and stabilizing 
partner proteins 7, 8. The joined action of SOX and POU proteins has been confirmed in 
various cell-types, for example the activation of PAX6 by SOX2 and POU2F1 in lens 
placode formation 9, and the combined action of SOX10, POU3F2 (also known as BRN-2 
and N-OCT3) and POU3F1 (OCT6) in expression control of KROX20 in the myelination 
of Schwann cells 10. In oligodendrocytes the interaction between SOX11 and POU3F3 
(BRN-1) has been proven, however the first target gene of this couple remains to be 
identified 11. 
The most extensively studied SOX-POU partnership is that of SOX2 and POU5F1 (also 
known as OCT3/4 and OCT4) in the inner cell mass of early embryonic development and 
the in vitro counterpart, i.e., embryonic stem (ES) cells. These proteins have been shown 
to dimerize in a target-specific conformation onto the DNA 12, and regulate their own 
gene expression as well as that of their protein partner 13-15. Both factors are in the center 
of an intricate network required to maintain pluripotency 16-18 for review, where feedback 
mechanisms control the appropriate level of the transcription factors 19, and deviation will 
promote differentiation 20, 21. Genome wide screens in human and mouse ES cells have 
identified a large number of target genes that are activated or repressed by simultaneous 
binding of POU5F1 and SOX2 depending on their involvement in pluripotency or 
differentiation 22, 23. However, a substantial number of target genes in ES cells are only 
bound by either POU5F1 or SOX2, and no cooperative action in the control of these target 
genes is expected. 
Besides ES cells, POU5F1 is present in primordial germ cells (PGCs) which arise from the 
proximal epiblast cells of the bi-layered embryo 24, 25. During migration of PGCs, POU5F1 
remains highly expressed 26 and after arrival at the gonadal ridge (the PGCs are now called 
gonocytes) these cells progressively lose POU5F1 upon maturation during gametogenesis. 
Interestingly, knock-out of POU5F1 in mouse PGCs results in induction of apoptosis, 
instead of differentiation as in ES cells 27. Normally, one year after birth no POU5F1 
positive cells are present either in the gonads or any other organs and tissues. The 
mechanistic basis of the different function between POU5F1 in PGC and ES cells remains 
to be elucidated.  
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In humans prolonged expression of POU5F1 is strongly associated with development of 
malignant testicular germ cell tumors (TGCTs), clinically manifest after puberty. These so 
called type II TGCT, i.e., seminomas and nonseminomas, arise from a malignantly 
transformed PGC/gonocyte and this dormant precursor lesion is named carcinoma in situ 
(CIS) or intratubular germ cell neoplasia unclassified (IGCNU) 28, for review. The precursor 
lesion of dysgenetic gonads is known as gonadoblastoma 29, 30. After puberty, proliferation 
of these precursor cells will give rise to invasive seminoma (known as dysgerminoma in 
the ovary and dysgenetic gonad), the default pathway for CIS cells, or – by acquiring 
additional expression of ES cell markers - to invasive embryonal carcinoma (EC), the 
undifferentiated cells of nonseminoma, representing the inner cell mass during normal 
embryogenesis. Furthermore, EC cells can differentiate into teratoma (the somatic 
lineage) and the different extra-embryonal lineages, i.e., yolk sac tumor and 
choriocarcinoma, as well as the germ cell lineage. During the past years, POU5F1 has 
proven to be a specific marker in TGCT diagnostics with 100% of CIS, seminoma and EC 
cells, showing  a profound nuclear staining 31-33. 
The physiological function that POU5F1 exerts in different cell types, is dependent on the 
cell-specific target genes and therefore, on the selected POU5F1 protein partner in that 
specific cell type. The role of SOX2 interaction with POU5F1 in maintaining pluripotency 
and preventing differentiation is well established 13, however, how POU5F1 expression is 
involved in apoptosis control in PGC is not clear. To gain more insight into this process, 
we studied the expression of SOX2 in germ cells in early embryonic gonads to adult testis 
and ovary, and in pre-invasive and invasive TGCTs by immunohistochemistry. This shows 
that SOX2 is not present during normal human germ cell development and the malignant 
counterpart, CIS and seminoma cells, but indeed present in EC, as well as heterogeneously 
in different derivatives. Furthermore, we show that SOX2 can be expressed in Sertoli cells 
associated with the presence of CIS cells in seminiferous tubules, which is a significant 
observation, because it may result in overdiagnosis of intratubular EC. Based on genome 
wide mRNA expression profiling and quantitative RT-PCR of patient-derived TGCT 
samples, we identified another SOX family member, SOX17, as the most obvious 
candidate to interact with POU5F1 in CIS and seminoma cells. SOX17 plays a role in 
endoderm formation, oligodendrocyte differentiation and has been reported to function as 
a transcriptional activator in mouse pre-meiotic germ cells 34-36. Moreover, most recently, 
it has been found to distinguish embryonic from adult hematopoietic stem cells 37. 
Immunohistochemistry of SOX17 demonstrated nuclear co-expression with POU5F1 in 
fetal gonocytes, CIS and seminoma cells, as well as in the recently characterized 
seminoma cell line TCam-2, but not in EC and derived-cell lines. This finding allows 
distinction between seminoma and EC in a diagnostic setting, for which so far no absolute 
marker for seminoma is available. In addition, this knowledge will deepen our 
understanding of the progression of TGCTs from CIS to either seminoma or EC.  
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MATERIALS AND METHODS 
 
Immunohistochemistry 
The presence of SOX2 in normal and pathological gonadal development was studied by 
immunohistochemistry using a monoclonal antibody (AF2018, R&D Systems, Abingdon, 
UK) in a 1:750 dilution incubated for 2 hours at RT. As a secondary antibody, a 
biotinylated rabbit anti-mouse antibody was applied (1:200; E0413, Dako, Glostrup, 
Denmark) and bound antibody complex was visualized using the horseradish peroxidase 
avidin-biotin complex (HRP-ABC) method. The samples examined are listed in Table 1. In 
addition, double staining was performed using a monoclonal antibody directed against 
POU5F1 (1:1000; sc-Santa Cruz Biotechnology, Santa Cruz, CA, USA) and SOX2, 
respectively, with 3-amino-9-ethyl-carbazole (A5754: Sigma, Steinheim, Germany)/H2O2 
for a red staining and Fast Blue/Naphtol AS-MX phosphate (F3378 and N500: Sigma) for a 
blue staining. Detection of SOX17 in gonadal development, normal spermatogenesis and 
TGCTs was done with a goat polyclonal antibody (GT15094, Neuromics) in a 1:3000 
dilution for 2 hours at RT. Subsequently, a biotinylated horse anti-goat secondary 
antibody (1:200; BA-9500, Vector) was used, and detection was done using the HRP-ABC 
method. Antibodies against SOX17 from Santa Cruz (sc-17355) and R&D Systems 
(MAB1924) were also tested, but these gave non-specific and cytoplasmic staining. 
Therefore, these antibodies were not used for further experiments. 
 
TABLE 1. Gonadal samples used for SOX2 immunohistochemistry 
Fetal testis: N=16 (age in weeks) 60: 15, 16, 16, 16, 17, 17, 18, 18, 21, 21, 23, 24, 27, 30, 38, 40 
Fetal ovary: N=5 (age in weeks)61: 18, 20, 26, 33, 41 
Adult testis: N=1: 42 years (additional samples are included in the TGCT TMA (see below)) 
Post-natal ovary: N=5 (age in years): 11, 31, 33, 36, 50 
Type II  TGCTs: (tissue micro array; TMA): 
CIS (N=39), seminoma (N=50), EC (N=42), yolk sac tumor (N=8), choriocarcinoma (N=13), teratoma (N=26)
Dysgenetic gonads and GCTs N=9 62: 
Published 
code 
age (years) Tissue Tumor 
32r 16 undifferentiated gonadal tissue (UGT) gonadoblastoma (GB) 
5l** 14 UGT GB+dysgerminoma (DG) 
31l 14 Streak - 
31r 14 Streak - 
39r 19 UGT GB+DG 
39l 19 UGT GB 
3l 1 month testis+ovary - 
3r 1 month ovary+UGT - 
29r 14 Streak GB 
 
In addition to fetal gonads indicated in Table 1, a series of Bouin fixed early fetal gonads 
(57 to 63 days) was obtained from Phillipa Saunders and Richard Anderson (Centre for 
Reproductive Biology, Queen's Medical Research Institute, The University of Edinburgh, 
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UK). Extensive testing using an appropriate positive control showed that the SOX2 
antibody (AF2018, R&D Systems) did not work on Bouin fixed material, and therefore 
only SOX17 (GT15094, Neuromics) immunohistochemistry could be performed on these 
samples.  
 
Cell culture 
The cell line TCam-2, recently confirmed to be a seminoma cell line (De Jong, submitted 
for publication), was obtained from Sohei Kitazawa (Division of Molecular Pathology, 
Kobe University, Japan). The cells were cultured in RPMI 1640 (Invitrogen, Breda, The 
Netherlands) supplemented with 10% fetal calf serum (Hyclone, Thermo Fisher Scientific, 
Etten-Leur, The Netherlands) and penicillin/streptomycin (Invitrogen, Breda, The 
Netherlands) at 37°C in a humidified cell culture incubator with 5% carbon dioxide. The 
EC cell lines Tera-1 38, NTera-2 39, 2102Ep 40, 833KE 41 and NCCIT 42 were cultured as 
described before 43. The cell line JKT-1, recently demonstrated to be not a seminoma cell 
line was cultured as described before 44. These cells likely represent a later stage of germ 
cell development. Cells were trypsinized and harvested for the different experiments. 
Cytospins were prepared and RNA was isolated (see below).  
 
Protein isolation and Western blot analysis 
Isolation of protein and Western blot analysis were performed as described previously32. 
 
Quantitative RT-PCR for SOX2 and SOX17 in normal testis and TGCTs 
High-quality total RNA was extracted from normal testis (n=4) and patient derived TGCT 
samples containing either CIS (n=4), seminoma (n=12) or EC (n=11) using RNAqueous-
4PCR kit (Ambion Europe, Huntingdon, United Kingdom) according to the 
manufacturer’s instructions. In addition, RNA from cell lines JKT-1, TCam-2 and the EC 
cell lines Tera-1, NTera-2, 2102Ep, and NCCIT was used. Samples were treated with 
DNase and checked for residual DNA contamination by PCR. Quantitative PCR was done 
using the real-time PCR ABI PRISM 7700 sequence detector system (Applied Biosystems, 
Foster City, CA). For detection of SOX2 expression the following primers-set was used: 
SOX2-F 5’-CACACTGCCCCTCTCACACAT-3’ and SOX2-R 5’-CATTTCCCTCGTTT-
TTCTTTGAA-3’. Quantitative values were obtained from the Ct.  SOX2 mRNA was 
quantified relative to HPRT ( SOX2 mRNA value = 2 ( mean Ct HPRT – mean Ct SOX2 ) ) 45. For 
detection of SOX17 the following primers were used: SOX17-F (exon 1) 5’-
GATGCGGGATACGCCAGTGAC-3’ and SOX17-R (exon 2) 5’-GCTCTGCCTCC-
TCCACGAAG-3’ and quantified by the formula described above. 
 
Micro-array expression profiling 
Expression profile of frozen TGCTs (five spermatocytic seminomas, three dysgerminomas, 
being the ovarian counterpart of seminoma 45 four seminomas, and five ECs), cell line 
JKT-1 and the seminomatous TCam-2 cell line was determined using Affymetrix 
GeneChip Human Genome U133 plus 2.0 array as described before 45. Analysis was done 
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using Omniviz and SAM software as reported in the same manuscript. Expression levels of 
each SOX family member were analyzed for all samples and plotted in a graph. 
 
 
RESULTS 
 
SOX2 is not expressed in normal human gonadogenesis 
The gate-keeper of pluripotency in ES cells, POU5F1, switches its function to a survival 
factor in early migrating germ cells, and loss of POU5F1 in these cells induces apoptosis 46. 
In ES cells and their malignant counterpart, EC cells, SOX2 is regarded as the well-
established protein partner of POU5F1. To elucidate whether SOX2 plays a role in germ 
cell development and gonadogenesis, immunohistochemistry was done on gonads from 
early fetal life (15 weeks) to adult ovary and testis. The SOX2 protein was not expressed in 
germ cells regardless of their state of maturation (data not shown). Occasionally, SOX2 
positive Sertoli cells were present in normal adult testis, however, the expression level of 
SOX2 mRNA was very low (Figure 1A). 
 
SOX2 in testicular germ cell tumors 
The differential expression of SOX2 between seminoma and EC cells is used as an 
argument to explain the differences in pluripotency between these cells 47, 48. The relative 
overexpression of several core “stemness” genes, like EBAF, TDGF1, and SOX2, reflects 
the undifferentiated state of EC cells and is the starting point of their differentiation 
potential, analogous to the ES cells derived from the inner cell mass of early embryonic 
development. 
To study SOX2 expression in the development of TGCTs, tissue micro-arrays (TMA) of 
the various invasive histological subtypes and the precursor lesion CIS were used (see 
Table 1). As expected, all EC cells were positive for SOX2, while CIS, seminoma, yolk sac 
tumor and choriocarcinoma were consistently negative. In teratoma a small number of 
SOX2 positive cuboidal or columnar epithelium cells of endodermal origin were present as 
was recently also reported in teratomas of the central nervous system 49. However, in the 
seminiferous tubules containing CIS cells (always POU5F1 positive) a large number of 
SOX2 positive cells were seen more luminal situated than the CIS cells (Figure 1B). 
Detailed morphological study of these cells and double staining for SOX2 and vimentin 
showed that they are Sertoli cells (Figure 1C). Quantitative RT-PCR confirmed the 
elevated expression of SOX2 in samples containing CIS cells, compared to normal testis 
(Figure 1A). 
 
SOX17 is expressed in CIS, gonadoblastoma and seminomatous cells and not EC 
With the absence of SOX2 expression in germ cells and their malignant counterparts, CIS 
and seminoma cells, the question arises whether POU5F1 is interacting with another SOX 
member, and thereby regulating its target genes in these cells. To gain insight in this 
possibility, we screened the expression profiles of all SOX family members in TGCT 
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FIGURE 1. A) Quantitative RT-PCR for SOX2 on TGCT samples. Tested are the cell line JKT-1, the 
seminomatous cell line TCam-2 and the EC cell lines (NTera-2, NCCIT, Tera-1, and 2102Ep). A high 
expression of SOX2 is observed in the EC samples and cell lines. In testis parenchyma containing CIS 
(percentage is indicated in the bars) the SOX2 mRNA expression is elevated compared to normal testis; the 
level of expression parallels the amount of CIS containing seminiferous tubules. TCam-2 and JKT-1 show a 
level of expression in between normal testis/seminoma and EC samples and cell lines. B) Double 
immunohistochemistry for SOX2 (red) and POU5F1 (blue) shows that SOX2 is not expressed in the POU5F1 
positive CIS cells, but in a cell type more luminally located, being Sertoli cells. C) Double staining for 
Vimentin (blue) and SOX2 (red) combined with morphology and the position in the seminiferous tubule 
shows that the SOX2 positive cells are Sertoli cells. (Figure 1 colour image on page 188) 
 
samples and the cell lines JKT-1 and TCam-2 (Figure 2). The expression pattern of SOX2 
was confirmed on the mRNA level, being specifically expressed in EC. Most of the SOX 
members gave a non-specific pattern for the different histological elements investigated, 
including the cell lines, with one interesting exception. SOX17 is highly expressed in all 
seminoma/dysgerminoma samples, as well as the seminoma cell line TCam-2, and 
virtually absent in EC cells (absolute value for specific probe sets below 30). The mRNA 
expression profile of SOX17 in POU5F1 positive TGCTs (seminoma/dysgerminoma and 
EC) is exactly complementary to that of SOX2. Therefore, we subsequently focused on 
this specific SOX member for the rest of the study. Quantitative RT-PCR confirmed the 
elevated SOX17 expression in seminoma samples and seminoma cell line TCam-2 
compared to EC samples and EC cell lines (Figure 3A). Immunohistochemistry using a 
specific antibody showed the nuclear expression of SOX17 in all CIS/gonadoblastoma and 
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FIGURE 2. Expression results of all 20 human SOX family members in TGCT samples and cell lines JKT-1 
and TCam-2 based on genome wide (Affymetrix) expression profiling (log2 transformed data). The following 
samples were used: five spermatocytic seminomas, four seminomas, three dysgerminomas and five EC (also 
indicated in the legend in the lower right corner of the figure explaining the different bar colors). Main 
findings are the well-known high SOX2 expression in EC and low expression in seminoma/dysgerminoma. 
The profile of SOX17 shows an inverse relation with low expression in EC and high expression in 
seminoma/dysgerminoma samples and the seminoma cell line TCam-2 (indicated by an asterix). 
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seminoma/dysgerminoma cells, being therefore co-expressed with POU5F1 (Figure 3B 
and 3C). In addition, the seminoma cell line TCam-2 – expresses SOX17 protein (Figures 
3D and 3E), while no SOX17 was detected on cytospins of EC cell lines (data not shown) 
and by Western blot analysis (Figure 3E). The specific nuclear staining for SOX17 can be 
of diagnostic value in discriminating seminoma/dysgerminoma from EC. However, SOX17 
is not a suitable marker for the diagnosis of CIS, because it is found in different maturation 
stages of spermatogenesis (Figure 3F). In addition, SOX17 expression is present in fetal 
male and female gonocytes (earliest sample tested was 57 days old gonad) and stays 
present in these cells throughout fetal life (Figure 3G). No staining was identified in either 
Sertoli cells or granulosa cells. In contrast to male spermatogenesis, SOX17 is not detected 
in oogenesis beyond the stage of the gonocyte. However, SOX17 protein is detected in the 
epithelium of the Fallopian tube and rete testis (data not shown). Therefore POU5F1 is 
still the best marker for detection of CIS in the adult testis 32. 
 
FIGURE 3. A) Quantitative RT-PCR 
for SOX17 on TGCT samples, cell line 
JKT-1, seminomatous cell line TCam-2 
and EC cell lines (NTera-2, NCCIT, 
Tera-1, and 2102Ep) demonstrates a 
high expression of SOX17 in the 
seminoma samples and cell line TCam-
2, whereas the expression is low in all 
other samples. Nuclear SOX17 signal 
(brown) in B) CIS, C) seminoma and D) 
the seminomatous cell line TCam-2. 
Inset: nuclear POU5F1 staining in 
TCam-2 cells. E) Western blotting 
shows a complementary expression 
pattern for SOX2 and SOX17 in TCam-
2 and EC cell lines with high SOX17 
expression in TCam-2 and no SOX17 
expression in the EC cell lines NTera-2, 
NCCIT and 833KE. SOX2 is highly 
expressed in the EC cell lines and not 
in TCam-2. The embryonic stem cell 
marker OCT3/4 is expressed in all 
samples. As a loading control β-actin 
was used. F) SOX17 protein is present 
in various maturation stages of 
spermatogenesis: spermatogonium 
(black arrow), secondary spermatocyte 
(white arrow) and spermatid (black 
arrowhead), while primary 
spermatocytes, spermatozoa and Sertoli 
cells are negative. G) Nuclear SOX17 in 
gonocytes of an 18 week old fetus. 
(Figure 3 colour image on page 189) 
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DISCUSSION 
 
Transcription factors act as pathway switches in embryonic development and 
commitment to the differentiation lineages. Specific combinations of transcription factors 
belonging to the SOX and POU families are known to establish tissue and cell specific 
expression of target genes. In this paper we focused on the protein partners of POU5F1 
which are subsequently expressed during embryonic development in cells of the inner cell 
mass, the epiblast and PGCs. In ES cells the intimate relationship between POU5F1 and 
SOX2 is most extensively studied and binding of both proteins to adjacent sites on the 
DNA with simultaneous physical protein interaction controls a large number of target 
genes involved in pluripotency and differentiation. 
Besides ES cells, SOX2 is abundantly expressed in differentiating and differentiated cells 
and is found in endodermal cells of the primitive foregut 50, the developing inner ear 51 
and the central nervous system 52. However, it is never detected in combination with 
POU5F1, which is likely related to the absence of pluripotency. It has been reported that 
SOX2 is expressed in mouse fetal germ cells and neonatal ovine gonads 53, 54, but the actual 
data were not shown. These reports were confirmed by RNA in situ detecting SOX2 in 
male E12.5 to E15.5 gonad/mesonephros tissues, however no protein detection was done 
55. Recently, the expression of SOX2 in the establishment and early migration of mouse 
PGCs was identified by quantitative single-cell gene expression profiling 56. These results 
indicated that SOX2 expression is not immediately lost upon commitment to the germ cell 
lineage. However, the timing of SOX2 downregulation in gametogenesis remains to be 
clarified. Our results show that SOX2 is not expressed in human gonadogenesis from 15 
weeks of gestation onwards, as well as in normal adult testis and ovary. 
The study in early mouse PGCs also investigated the expression pattern of SOX3 and 
SOX17 56. Both genes were transiently expressed in migrating PGCs at developmental 
stage E7.25 dpc. Here we demonstrated for the first time that SOX17 is expressed and the 
protein is present in CIS and seminoma cells, and not in EC cells, either in vivo tumors or 
cell lines. The absence of SOX3 expression in seminoma (Figure 2) could be related to the 
timing of the maturation block that has occurred in the precursor cells of TGCTs, or the 
result of species specific differences. So far, the existing evidence for a role of SOX17 in 
gametogenesis is fragmented. Heterozygous SOX17 knock-out mice are normal and fertile, 
while homozygous knock-out mice are deficient of gut endoderm and after 10.5 dpc no 
homozygous mutants are found 57. This lethality due to endoderm deficiency is prior to 
gonad development and therefore the role of SOX17 absence during gametogenesis can 
only be studied in conditional knock-outs. Furthermore, two isoforms (1 without HMG-
domain) have been isolated from an adult mouse testis library. Analysis of these isoforms 
suggest that SOX17 may function as a transcriptional activator in pre-meiotic germ cells, 
and that a splicing switch into a truncated SOX17 protein may lead to loss of its function 
in post-meiotic germ cells 35. So far, no human SOX17 splice variants have been identified. 
The co-expression of SOX17 and POU5F1 in CIS and seminoma cells in the absence of 
SOX2, qualifies SOX17 as a potential protein partner in these cells. In addition, SOX17 is a 
repressed target gene of the POU5F1 protein and not of SOX2 in human ES cells 22. It 
remains to be investigated whether this is also the case in PGC. The co-expression of 
SOX17 and SOX2 in (malignant) stem and germ cells 
 141
SOX17 and POU5F1 in the seminoma cell line TCam-2 compared to established EC cell 
lines, being SOX2 positive and SOX17 negative, can be used as an experimental model to 
study this hypothesis, and to identify common target genes in CIS and seminoma. Possibly 
factors of the WNT pathway are involved in the transcriptional activity of POU5F1 and 
SOX17 in normal and malignant germ cells, as it has been shown in ES cells58 and 
embryonic endoderm59 that the proteins can physically interact with β-CATENIN. A 
recent observation is that SOX17 is essential for fetal and neonatal hematopoietic stem 
cells (HSC), but not for adult HSCs 37. Knock-out studies and expression data of SOX17 in 
primitive endoderm, fetal HSCs and early germ cells indicates an crucial role of this 
transcription factor in a number of lineages during embryonic and fetal development. The 
origin of PGCs from the primitive endoderm, like fetal HSC, is of high interest in this 
context. 
As suggested, the presence of expression of SOX17 in CIS could indicate the timing of the 
first step in the development of TGCTs. Whether these cells are already malignantly 
transformed at the time of this maturation arrest, or acquire malignant potential later in 
development as a result of an unfavorable micro-environment for immature germ cells is 
not clear. Therefore, analysis of these markers in patients with Disorders of Sex 
Development (DSD) will be informative, because some of them show a significant 
increased risk for type II GCTs 30. Our study of SOX2 expression in normal gonadogenesis 
and TGCTs demonstrated that SOX2 can be present in Sertoli cells in CIS-containing 
seminiferous tubules, whereas this was rarely observed in tubules without CIS. SOX2 is 
not expressed in fetal gonads from 15 weeks of gestation onwards, indicating either 
aberrant expression of SOX2 in Sertoli cells in CIS-positive tubules, or possibly persistent 
expression assuming SOX2 is expressed in Sertoli cells before 15 weeks. Either way, SOX2 
expression in CIS-positive tubules reflects an abnormal micro-environment which may 
have contributed to the initiation of TGCT development or has a later origin under the 
influence of the aberrant germ cells. An important implication of this result is that SOX2 
expression in seminiferous tubules should not be mistaken for intratubular EC known to 
be SOX2 positive. 
The differential and complementary expression of SOX2 and SOX17 in normal and 
malignant germ cell development and identification of SOX17 as the alternative protein 
partner for POU5F1 in CIS and seminoma cells provides an important lead to elucidate 
the cell specific function of POU5F1 in embryonic germ and ES cells. The recently 
characterized seminoma cell line TCam-2 can be used to study the mechanisms and 
identify the involved target genes of joined POU5F1 and SOX17 action. 
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GENERAL DISCUSSION 
 
The pluripotency of the first stages of embryogenesis is inherited by the future generation 
via the gametes. Paradoxically, in order to transmit pluripotency, the gametes have to give 
up their own pluripotent potential and have to differentiate along the path of 
spermatogenesis or oogenesis including meiosis, which reduces their chromosome content 
from diploid to haploid. During this initial maturation process embryonic markers 
involved in pluripotency are progressively downregulated reflecting loss of pluripotent 
potential. In contrast, germ cells that retain their embryonic features will interfere with 
fertility and can acquire malignant potential culminating in a germ cell tumor. The 
expression of embryonic markers in these tumors can be used as a powerful diagnostic tool 
in clinical pathology. The transcription factor OCT3/4 is currently regarded as one of the 
key regulators of pluripotency, and has been intensively studied in the research fields of 
stem cells and germ cell tumors. 
 
 
A POUERFUL DIAGNOSTIC MARKER IN TYPE II GERM CELL TUMORS 
 
Expression of OCT3/4 was initially found in a mouse embryonal carcinoma (EC) cell line1, 
and shortly after that in early stem cells and germ cells of the mouse embryo2-5. In human 
testicular GCTs the presence of OCT3/4 mRNA was reported in 20026, and a year later an 
extensive study on OCT3/4 protein expression in a multi-tumor tissue micro-array 
analysis was published7. This immunohistochemical study using a goat polyclonal 
antibody showed that OCT3/4 is specifically expressed in CIS/gonadoblastoma, 
seminomatous and EC cells of type II GCTs and not in other tumors. These findings were 
confirmed by a large number of other studies on samples collected from various archives8-
15. The first prospective study on the value of OCT3/4 as a diagnostic marker in TGCTs 
was done on a consecutive series of more than 200 testicular cancers (Chapter 2)16. Next to 
the polyclonal antibody used in all previous studies, the value of a mouse monoclonal 
antibody was demonstrated. This monoclonal antibody gave comparable results to the 
polyclonal antibody in immunohistochemistry and Western blotting. Both antibodies 
were shown to be robust and highly stable, and the immunohistochemical detection 
method applied was relatively insensitive to pretreatment or quality of the tissue samples. 
The strong and reproducible nuclear staining of OCT3/4 was present in 100% of CIS, 
seminoma and EC cells. This study demonstrated that OCT3/4 is a valuable and reliable 
marker in the diagnostics of TGCTs. However, evaluation of immunohistochemistry 
should always be performed in the context of cell morphology and proper controls. This is 
exemplified by subsequent studies on the expression pattern of OCT3/4 in metastatic EC 
and seminoma. Sung et al 17 reported on OCT3/4 staining of metastatic EC after 
chemotherapy. Six out of 25 cases (24%) were negative for both CD30 and OCT3/4. This 
unexpected result was proven to be erroneous, because five out of six cases were identified 
as yolk sac tumors based on a positive AFP staining (reviewed in Cheng et al 18 and own 
unpublished results) and the remaining case was a non-germ cell malignancy judged by 
morphology. In other words, all EC, even after chemotherapy, are proven to be OCT3/4 
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 positive. In seminoma metastases Biermann et al 19 found a very heterogeneous staining of 
seminoma cells using OCT3/4 immunohistochemistry. The percentage of OCT3/4 positive 
tumor cells ranged from 5 to over 90%. In addition, 10 cases of testicular seminoma also 
showed a major variation from 25% to over 90%. Because of the discordance of these 
results with previous findings, immunohistochemistry for OCT3/4 was performed by the 
same group with a new batch of monoclonal antibodies and adjusted protocol, as used in 
our study.16 The results showed a consistent, intense and homogeneous staining of all 
tumor cells. Therefore, the initial results must be due to sub-optimal staining conditions. 
This finding is in preparation to be submitted for publication (Biermann and coworkers). 
In diagnostic challenging cases we have shown that OCT3/4 can be crucial to come to a 
final diagnosis (Chapter 2 and 3). Especially when other markers as PLAP and c-KIT are 
negative, small biopsies having a limited number of neoplastic cells are present and tissue 
samples of poor quality due to necrosis, the consistent strong nuclear staining of OCT3/4 
can be the decisive diagnostic clue. 
OCT3/4 is not only a valuable marker in diagnosis of overt TGCTs, but can also 
significantly contribute in screening for occult tumors and their precursor cells (Chapter 2 
and 4). In a series of 81 open surgical testicular biopsies from 56 adults with primary 
infertility or a history of TGCT, CIS cells were identified in four patients (7%) based on 
morphology and OCT3/4 immunohistochemistry16. Of importance is our observation of 
the occasional presence of OCT3/4 positive cells lacking typical CIS morphology in 
seminiferous tubules that contain normal spermatogenesis through all maturation stages. 
Because the normal adult testis including spermatogenesis is OCT3/4 negative and these 
normal appearing tubules were adjacent to tubules with typical CIS cells and without 
spermatogenesis, the OCT3/4 positive cells in normal seminiferous tubules were diagnosed 
as CIS. These reports and the difficulty to morphologically identify all CIS cells based on 
formalin-fixed tissue demonstrate that screening for OCT3/4 positive cells in populations 
of patient with risk factors for TGCTs, like infertility, cryptorchidism and a (familial) 
history of TGCT, is mandatory when these patients are biopsied (Chapter 4). Chances of 
finding CIS or an early occult tumor are significantly raised in comparison to the general 
population in which the incidence is 6-11 per 100.000. In nation-wide search of invasive 
TGCTs with a previous negative testicular biopsy, obtained because of infertility studies, 
we could prove the presence of CIS cells by positive OCT3/4 immunohistochemistry in 10 
out of 21 cases. 
 
 
MULTIPLE OCT3/4 PSEUDOGENES ARE TRANSCRIBED 
 
Several reports on OCT3/4 protein expression in differentiated cells have been 
published.20-22 A report on bladder cancer by Atlasi et al 23 demonstrated OCT3/4 mRNA 
expression using a non-specific primer set (see below) and in addition OCT3/4 protein 
expression by immunohistochemistry and Western blotting using both OCT3/4 antibodies 
that were validated by us 16. The Western blot images shown for both antibodies appeared 
genuine and specific, although the signal in the bladder sample lanes had a slightly larger 
mass than the NTera-2 control lane. These results could not be confirmed in a series of 
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bladder cancers of our own institute (unpublished results). The immunohistochemistry in 
the report by Atlasi and coworkers provide no clear images of evident nuclear OCT3/4 
staining, and they even show cytoplasmic staining which is incompatible with functional 
OCT3/4. In most other report on OCT3/4 immunohistochemistry in differentiated normal 
or tumor cells, the presumably OCT3/4 positive nucleus is morphologically not well 
defined nor visibly surrounded by a cell. Therefore, we regard these staining spots as non-
specific artefacts in contrast to the specific nuclear staining in ES cells, PGCs, and their 
malignant counterparts. 
 
TABLE 1 Chromosomal location and name of human OCT3/4 (POU5F1) pseudogenes* 
Chromosomal 
location 
Approved 
gene symbol 
Alias Name in 
Pain et al 24 
Name in 
Suo et al 25 
1q22 POU5F1 pseudogene LOC645682 Pg4 Pg3 
3q21** - - Pg6 Pg4 (Pg5 in table) 
8q22 - - Pg2 Pg6 
8q24 POU5F1P1 OTF3C; OTF3P1; 
POU5FLC8 
Pg1 Pg1 
10q21 - - Pg5 Pg5 (Pg4 in table) 
12p13 POU5F1L OTF3L Pg3 Pg2 
*Not all pseudogenes have an official NCBI name. In addition, the articles reporting the pseudogenes 
assigned different names to the pseudogenes. The article from Suo et al 25 uses  inconsistent pseudogene 
names in text and table. 
**The pseudogene on chromosome 3q21 is the only non-processed pseudogene, the others are processed and 
therefore intron-less pseudogenes. 
 
Besides OCT3/4 protein expression, an alarming number of articles on OCT3/4 mRNA 
expression in a wide variety of cells have been published during the last few years, 
especially in the haunt for adult stem cell and cancer stem cell markers. However, reports 
from OCT3/4 expression in normal adult tissues but also in cancer have to be interpreted 
with caution because of the existence of a number of OCT3/4 pseudogenes. Pseudogenes 
are defined as genomic sequences with close similarities to the paralogous gene, either 
originating from duplication of the genomic sequence of the gene (non-processed 
pseudogene) or alternatively by insertion into the genome of double stranded sequence 
generated from single-stranded RNA (processed or retro-pseudogene).26 These 
pseudogenes can be transcribed, but a protein will never be formed, however the 
functional relevance of these pseudogene transcripts is unclear. In the case of the OCT3/4 
gene, Takeda et al 27 identified one pseudogene as a retrotransposon on chromosome 8 and 
predicted at least four related sequences in the human genome. Now that the entire 
human genome has been sequenced, OCT3/4 related sequences can be identified more 
easily. In 2005, Pain et al 24 reported on multiple pseudogenes from embryonic stem cell 
specific genes. Ten highly homologous pseudogenes for NANOG, 16 for STELLAR/DPPA3 
and six for OCT3/4 (Table 1) were identified by nucleotide BLAST searches against the 
mRNA transcripts of the respective gene. One of the OCT3/4 pseudogenes was localized 
near the NANOG and STELLAR/DPPA3 gene on 12p13 and this region was found to be 
evolutionary conserved between human and mouse chromosome 6, possibly indicating a 
functional role of this pseudogene. In this analysis only the long splice variant (isoform A)  
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of the OCT3/4 mRNA was used. We repeated this query for both OCT3/4 transcripts and 
the OCT3/4 partner SOX2. The pseudogenes for OCT3/4 isoform A were confirmed, 
however no pseudogenes for isoform B and SOX2 were identified in the genome. The first 
and thus far only report on the expression of the pseudogenes in a panel of normal tissue, 
tumors and cell lines came from Suo et al 25. In this study a screening for OCT3/4 related 
transcripts was done by using universal primers which should detect transcripts from the 
OCT3/4 gene as well as from all pseudogenes (NB: these primers do not detect the 
pseudogene on 8q22). Transcripts from the true OCT3/4 gene on 6p21, from the 
pseudogene on 10q21 and from 8q24 were confirmed by sequencing cloned PCR products. 
No transcripts were identified in the normal tissues examined. However, some data with 
(pseudo)gene specific primers conflicted with the data from the universal primers. In 
addition, they showed that the primers used by Monk et al 28 detected transcripts in 
almost all tissues and cell lines tested, even including normal tissues. The study of Suo et 
al 25 demonstrates that previous and future results need to be interpreted with caution 
because of the existence of transcribed pseudogenes. The use of specific primers for PCR, 
followed by cloning and sequencing is mandatory. Both studies described above do not 
give the exact location and use different names for the pseudogenes. Not all pseudogenes 
have been exactly mapped and given an official name, and therefore the current status on 
position and name is presented in Table 1. For consistency and clarity we refer to the 
pseudogenes by their chromosomal location and recommend others to do so in future 
publications until official names have been assigned. 
 
TABLE 2. Non-specific primer sets used in RT-PCR*.  
 Pseudogenes detected  
 
 
Article  1
q2
2 
 3
q2
1 
 8
q2
2 
 8
q2
4 
 1
0q
21
 
 1
2p
13
   
 
Tissue/cells in which OCT3/4 expression was found 
Takeda27 +   +  + heart, kidney, liver, placenta, spleen, pancreatic islets 
Jin29 +   +   primary breast carcinomas, breast carcinoma cell lines 
Monk28    +  + breast-, pancreas- and colon carcinoma cell line 
Tai22    +  + various normal and tumor cell lines, various normal tissues 
Ezeh30 +   +   primary breast carcinomas, breast carcinoma cell lines, seminomas 
Matthai21    +  + endometrium 
Raman31    +  + normal and tumor renal tissue 
Hoffmann32 +   +  + primary prostate tumors and cell lines, prostate and testis 
Mongan33    +  + cultured human epidermal keratinocytes 
*These primers will detect not only OCT3/4 (POU5F1) mRNA but also transcribed OCT3/4 pseudogenes and 
genomic sequences of intron-less pseudogenes. This results in a large number of reports claiming OCT3/4 
expression in normal and neoplastic differentiated tissues and cell lines. 
We designed a primer set that is specific for mRNA of the true OCT3/4 gene: F 5’-tcccttcgcaagccctcat-3’ and 
R 5’-tgatgtcctgggactcctc-3’. 
 
All studies so far have used non-specific primers that detect transcripts from the OCT3/4 
gene as well as from pseudogenes and this can be a major reason for finding expression of 
OCT3/4 in a broad gamut of cells and tissues. In addition, because five OCT3/4 
pseudogenes are processed intron-less pseudogenes, DNA contamination will give a false 
positive result. A selection of studies is presented in Table 2 to illustrate the non-
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specificity of primers, the sequence of a specific primer pair we designed is added in the 
legend. A worrying finding is that probe sets used in micro array expression profiling like 
Affymetrix are not specific for the true gene but also detect some of the pseudogenes. 
 
 
EPIGENETIC REGULATION OF THE OCT3/4 GENE 
 
As stated above, the true OCT3/4 gene is only expressed in stem cells, germ cells and their 
malignant counterparts, i.e. EC and CIS/seminoma. During normal development the 
promoter region of OCT3/4 undergoes significant methylation and this process has been 
extensively studied in vitro by differentiation of human and mouse ES and EC cells34-37. 
The progressive methylation of OCT3/4 and NANOG sequences has recently been 
proposed as barometers to determine the extent of human ES cell differeniation38. We 
showed that the methylation status of patient-derived TGCTs of various histologies 
corresponds to the in vitro obtained results (Chapter 5). Differentiated tumor components 
as yolk sac tumor and teratoma had heavily methylated upstream regions of the OCT3/4 
gene, whereas samples primarily composed of seminoma or EC cells had a considerably 
lower level of methylation. In addition, micro-dissection of seminoma and EC cells 
showed the virtual absence of methylation. This is in agreement with the difference in 
overall methylation status of these various histological tumor types, likely reflecting 
normal development 39. 
The developmental dynamics of shut down of OCT3/4 expression follow a multi-step 
program of inactivation40. Binding of GCNF to the RA receptor element (RARE) causes 
transient transcriptional repression. This causes recruitment of histone deacetylase 
(HDAC) molecules and subsequently histone methylases. Finally, DNA methyltransferases 
DNMT3A and perhaps DNMT3B catalyse the de novo methylation of the OCT3/4 
regulatory sequences. Under normal circumstances this last step appears to be 
irreversible40, but artificial removal of methylation by demethylating agent 5-azacytidine 
was shown to revert differentiation of mouse ES cells in vitro 41. Dedifferentiation of cells 
is particularly of interest in the current attempts to generate cells with a stem cell 
phenotype from terminal differentiated somatic cells. The ultimate goal is to create 
autologous stem cells that can be used to replace injured or damaged tissues in patients 
suffering from different diseases, e.g., degenerative neurological diseases, diabetes, as well 
as ischemic heart disease42-44. 
 
DEDIFFERENTIATION, REPROGRAMMING AND CELL LINE MODELS 
 
The first hurdles along this pathway has been taken by showing that forced re-expression 
of a small set of genes is sufficient to create cells with a stem cell phenotype, so-called 
induced pluripotent stem (iPS) cells45. Induction of pluripotency was achieved in adult 
mouse fibroblasts by retroviral introduction of transgenes expressing OCT3/4, SOX2, c-
MYC and KLF4. The dominant role of OCT3/4 and SOX2 in pluripotency is well 
established, while c-MYC and KLF4 are known to contribute to rapid proliferation of ES 
cells in culture46,47 and are frequently upregulated in tumors. Recently, viable and fertile 
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chimaeras were obtained by injection of iPS cells into blastocysts48,49. However, in one 
study approximately 20% of the offspring developed tumors attributable to reactivation of 
the c-MYC transgene. This negative side-effect is a major concern in the clinical 
application of iPS cells. 
Dedifferentiation of cells into undifferentiated cells with an embryonic phenotype that 
are pluripotent and can differentiate into all cell lineages is exactly what happens in 
TGCTs in vivo. CIS and seminoma cells, the malignant counterparts of PGC/gonocytes, 
are blocked in the process of gametogenesis and have limited differentiation capacity. In 
seminomatous tumors hCG positive trophoblastic giant cells can be present which 
suggests that these cells originated from a seminoma cell. In almost half of TGCTs, CIS 
and seminoma cells can acquire the expression of ES cell markers and become pluripotent 
EC cells by a process called reprogramming. The trigger for this dedifferentiation and 
underlying molecular mechanisms are still unknown. 
To study the process of reprogramming, an in vitro model that allows controlled 
manipulation of CIS or seminoma cells would be valuable. During the last two decades, 
considerable effort has been made to establish seminoma cell lines. However, seminoma 
cells rapidly undergo programmed cell death (apoptosis) upon disruption of their micro-
environment and can only be cultured for a short period of time. In contrast to the large 
number of EC cell lines, there are only single reports on seminomatous cell lines50-52. One 
of these cells lines, JKT-1, described to originate from a  testicular seminoma of a 40-year-
old Japanese male, has been used for various investigations consistently as representative 
for seminoma53-58. We showed that JKT-1 does not have the essential hallmarks of a 
seminoma, like gain of 12p sequences and expression of OCT3/4 and NANOG amongst 
others, and therefore cannot be used as a model for seminoma59 (Chapter 6). In addition, it 
was demonstrated that the tumor of which the cell line was supposed to be generated 
from was genetically unrelated. This indicates that a thoroughful characterization of a cell 
line is required before it can be accepted as informative. Another cell line, TCam-2, was 
reported in a Japanese paper to be established from a testicular seminoma of a 35-year-old 
Japanese male by the traditional explant culture method51. In an extensive 
characterization of this cell line, genomic constitution, imprinting status and 
immunohistochemical marker profile were determined, as well as genome wide mRNA 
and miRNA expression profiling (Chapter 7). The results showed that TCam-2 cells 
contain all the typical features of seminoma. In addition, an activating mutation of the 
BRAF gene, a downstream factor of the RAS pathway, was found, providing an 
explanation for successful establishment of this cell line. 
One of the unique features of TGCT is that the initial steps in tumor development, already 
take place in utero. This makes it difficult to study the early steps in malignant 
transformation of the germ cells because of the inaccessibility of this cell population in the 
early embryo. During the past years, major progress has been made in establishing in vitro 
models for gametogenesis by generating PGCs from ES cells60-63. Recently, viable 
transgenic offspring was produced from sperm differentiated from mouse ES cells64. These 
results pave the way to a model system for the early phases of germ cell tumorigenesis. 
Currently, the pre-invasive CIS cells are the earliest available stage for research in TGCT 
development, but there are no cell lines for CIS. After puberty, these cells start 
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proliferating, acquire additional chromosomal aberrations including gain of 12p, and 
become invasive, giving rise to a seminoma or – via reprogramming – to embryonal 
carcinoma65. Because seminoma is the default pathway, resembling CIS cells 
morphologically and expressing the same markers, the availability of the seminomatous 
cell line TCam-2 provides a model system for earlier steps in TGCT development than the 
EC cell lines. 
 
 
PROTEIN PARTNERS AND MICRO-ENVIRONMENT 
 
During normal development OCT3/4 is expressed in the inner cell mass, the epiblast, 
PGCs and gonocytes. The function OCT3/4 exerts is not the same in these cell types: in 
the inner cell mass/ES cells OCT3/4 expression will keep these cells in an undifferentiated 
pluripotent state, while in PGCs it is implicated in survival of these cells66. As OCT3/4 is a 
transcription factor, this differential function can be achieved by selection of cell specific 
target genes using cell specific co-factors. Sumoylation of OCT3/4 at the end of the N-
terminal transactivation domain by SUMO-1 enhances the protein stability and increases 
DNA binding67. This mechanism is the first post-translational modification known to 
regulate OCT3/4 activity in vitro and in vivo. A limited number of proteins involved in 
selection of OCT3/4 target genes has been identified68. Another group of developmental 
regulators in early development are the polycombs. These proteins form multiple 
Polycomb Repressive Complexes (PRC) that can modify chromatin structure. After initial 
gene repression by transcription factors as OCT3/4, PRCs are brought to the site of initial 
repression and act through epigenetic modification of chromatin structure to maintain 
these genes in a repressed state69.  The target genes of PRC2 in ES cells, become activated 
during ES cell differentiation when the repressive effect of PRC2 is released. The 
observation that OCT3/4, SOX2 and NANOG are bound to a significant subset of 
developmental genes occupied by PRC2 links this polycomb complex to the maintenance 
of stem cell pluripotency70. The molecular mechanism by which OCT3/4 and PRC2 are 
connected, remains to be elucidated. 
In ES cells and also in EC cells, SOX2 is the well established protein partner for OCT3/4. 
SOX2 knock-out embryos are embryonic lethal71 and the joined binding of OCT3/4 and 
SOX2 to enhancers of pluripotency genes was shown to be essential for maintaining 
pluripotency. However, a recent article72 by the same group that reported on the role of 
the level of OCT3/4 expression in maintaining pluripotency73 shows that SOX2 is 
redundant in regulating other pluripotency genes. Other SOX proteins present in ES cells 
like SOX 4, SOX11 and SOX15 can also bind to the enhancers of these genes and 
substitute for SOX272. Indirectly, SOX2 is necessary for maintaining pluripotency by 
regulating multiple transcription factors that affect OCT3/4 expression72. In TGCTs 
functional studies on the role of SOX2 are lacking. To characterize the SOX2 expression 
profile in TGCTs we performed immunohistochemistry on tissue micro-arrays of the 
various histological subtypes of TGCTs. CIS, seminoma, yolk sac tumor and 
choriocarcinoma were negative for SOX2; EC was positive and also some components of 
teratoma were positive as can be expected because SOX2 is expressed in various 
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differentiated tissues in normal development (Chapter 8). Surprising was the presence of 
SOX2 positive Sertoli cells in seminiferous tubules containing CIS. This phenomenon was 
shown to be aberrant SOX2 expression, as it was not present in normal Sertoli cell 
maturation during fetal and adult life. Whether SOX2 expression in Sertoli cells is a 
consequence of derailment of germ cell maturation in TGCTs or is inherent to an 
abnormal micro-environment in the seminiferous tubules that contributes to TGCT 
initiation is unknown. In search of an alternative protein partner for OCT3/4 in cells 
devoid of SOX2, we identified SOX17 as the candidate protein partner for OCT3/4 in 
gonocytes, CIS and seminoma based on quantitative PCR, mRNA expression profiling and 
immunohistochemistry on fetal gonads, clinical TGCT samples, seminomatous cell line 
TCam-2 and several EC cell lines (Chapter 8). The presence of SOX17 in seminoma and 
absence in EC indicates potential diagnostic value in discriminating seminoma from EC. 
 In ES cells SOX17 expression is repressed by joined action of OCT3/474 and PRC270. The 
switch from SOX2 to SOX17 as a protein partner for OCT3/4 might be a lead to explaining 
the functional switch from keeper of pluripotency in undifferentiated cells to survival 
factor in PGCs. During migration of PGCs in the mouse embryo, there is a peak in SOX17 
mRNA expression after which the expression ceases to virtually zero75. Our results show 
that in humans SOX17 protein is present from early fetal gonocytes to mature stages of 
spermatogenesis. In the female gonad SOX17 expression in only present in gonocytes and 
not in later stages of oogenesis. Of interest is the concurrent SOX3 peak in migrating 
mouse PGCs as SOX3 mRNA expression is not observed in clinical seminoma samples and 
the TCam-2 cell line. This initiates the question whether absence of SOX3 expression 
contributes to germ cell tumorigenesis? In favor of this hypothesis is the observation that 
absence of SOX3 expression in a mouse knock-out leads to impaired spermatogenesis and 
increased expression of OCT3/476.  
 
 
ROLE IN ONCOGENESIS 
 
Aberrant expression of OCT3/4 has been suggested to play an oncogenic role in 
tumorigenesis.8,22,28 In order to act as an oncogene, OCT3/4 protein has to be present at 
least in the initial tumor cells. Thus far, OCT3/4 protein expression has only consistently 
and repeatedly been found in type II (T)GCTs.7 However, it is highly questionable if the 
expression in these tumors can be regarded as aberrant. The cell of origin of these tumors 
is an embryonic PGC or gonocyte, which normally expresses OCT3/4.65 In the invasive 
tumors, the seminoma and EC cells, which are the OCT3/4 positive cells in (T)GCTs, can 
be considered the malignant equivalents of respectively PGCs and ES cells as explained 
before. In addition, OCT3/4 expression is rapidly lost in type II (T)GCTs upon 
differentiation into teratoma along the three germ lineages of the embryo and into extra-
embryonic tissues as yolk sac tumor and choriocarcinoma.7 Based on these observations, 
OCT3/4 expression in (T)GCTs can be regarded as inherent to the embryonic phenotype 
of these cells, instead of the result of an activated oncogene with aberrant expression. 
Future studies need to address the presence of mutations or amplifications in the OCT3/4 
gene in GCTs. 
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The potential of OCT3/4 to act as an oncogene has been studied in several mouse models. 
Gidekel et al 8,77 injected mouse ES cells with various levels of induced OCT3/4 expression 
subcutaneously in nude mice. The highest percentage of tumor formation was seen after 
injection of ES cells expressing physiological levels of OCT3/4, whereas elevated (150%) 
or lower levels of expression (0, 50 or 75%) gave rise to less tumor formation. This 
indicates that non-physiological levels of OCT3/4 possibly impair cell proliferation or 
survival. In the tumors derived from OCT3/4 showing overexpression ES cells a significant 
higher percentage of primitive neuronal tissue was present, presumably indicating a 
higher grade of malignancy. However, from these results OCT3/4 cannot be designated as 
a classical oncogene. In the same article, Gidekel and coworkers showed that mouse 
fibroblasts expressing transgenic OCT3/4 gave rise to morphological high-grade 
fibrosarcomas that can invade adjacent tissues after subcutaneous injection into nude 
mice. This indicates that ectopic expression of OCT3/4 can give a tumor-like phenotype. 
This hypothesis was tested by Hochedlinger et al 77 in a mouse model with inducible 
ubiquitously OCT3/4 expression in adult mice. Activation of OCT3/4 resulted in dysplastic 
growths in epithelial tissues with an expansion of progenitor cells and a morphologically 
invasive phenotype. However, the lesions were dependent on continuous OCT3/4 
expression and upon removal of this expression the dysplasia and even invasive growth 
disappeared completely. These studies illustrate that non-physiological expression of 
OCT3/4 can lead to dysplasia and even morphologically invasive behavior of cells in an 
artificial setup. However, OCT3/4 expression has never been consistently proven in 
human solid tumors other than (T)GCTs. 
The only report possibly indicating a role of OCT3/4 in human non-GCTs is the 
identification of an EWSR1-OCT3/4 fusion gene in an undifferentiated sarcoma derived 
from the pelvis bone of a 39-year old woman.78 This fusion gene resulted from 
chromosomal translocation t(6;22)(p21;q12) creating a chimeric transcript composed of 
the transcriptional activation domain of the Ewing’s sarcoma protein (EWSR1/EWS) gene 
and POU DNA-binding domain derived from OCT3/4. Although the functional relevance 
of the EWSR1-OCT3/4 fusion gene is unclear as the presence of a fusion protein in the 
tumor cells was not examined, there is a strict relationship between tumor types and 
EWSR1 fusion partners in Ewing’s family tumors, suggesting a functional role of these 
EWSR1 chimeras.79 Of major interest is that EWSR1 is normally present in human and 
mouse ES cell lines where it co-activates transcription by binding directly to the OCT3/4 
protein (Figure 1).80  
The activity of the OCT3/4 gene in type II TGCTs has been confirmed on DNA level as 
OCT3/4 promoter hypomethylation together with expression of mRNA from the true 
gene and nuclear protein expression.6,7,39 The presence of OCT3/4 and other stem cell 
markers in type II GCTs is likely to reflect the embryonic origin of these tumors instead of 
an initiating oncogenic event. In all other tumor types OCT3/4 expression still has to be 
consistently confirmed on the gene level, as well as on the mRNA- and protein level. 
Therefore, although OCT3/4 has oncogenic capacity in experimental systems, its role in 
oncogenesis of these tumors remains to be elucidated. 
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MAIN FINDINGS OF THIS THESIS AND FUTURE PERSPECTIVES 
 
The results obtained in this thesis focus on the role of the transcription factor OCT3/4 in 
the development of TGCTs and provide a detailed analysis on the value of this factor in 
the diagnosis of these tumors. Based on a large series of consecutive tumors we conclude 
that OCT3/4 is a robust and reliable marker in type II TGCT diagnostics, by positive 
nuclear immunohistochemistry of all (100%) CIS, seminoma and EC cells. In challenging 
cases as poor tissue quality due to necrosis or a limited number of tumor cells in a 
histological biopsy, OCT3/4 immunohistochemistry was decisive in coming to a final 
diagnosis. Furthermore, a retrospective nation-wide analysis of invasive TGCTs with a 
previous negative testicular biopsy, showed the presence of CIS cells in these biopsies 
amid almost normal spermatogenesis. This finding exemplifies the need for OCT3/4 
immunohistochemistry on testicular biopsies taken for infertility. 
Germ cell tumorigenesis and embryogenesis parallel each other and their features can be 
compared to come to a better understanding of aberrant and normal aspects of the 
development of GCTs. We showed that the expression of OCT3/4 in the various 
histological components of clinical TGCT samples is associated with specific changes in 
methylation of the promoter region and follows the same pattern as in embryogenesis. 
This adds to the view that OCT3/4 is expressed in TGCTs because it is inherent to its cell 
of origin, and not because of oncogenic activation. Analysis of the epigenetic state of the 
OCT3/4 promoter, mRNA and protein expression was also used to validate whether the 
cell lines JKT-1 and TCam-2 could be used as a model for seminomatous tumors. Partly 
based on these results we showed that JKT-1 is not a seminomatous cell line, while TCam-
2 is the first cell line that is available as a model for seminoma. In addition, we 
demonstrated the presence of an activating BRAF mutation in TCam-2, an exceptional 
event in in vivo TGCTs. 
The relationship between OCT3/4 and its protein partner SOX2 has been extensively 
studied in ES and EC cells. We showed the presence of SOX2 positive Sertoli cells in 
seminiferous tubules containing CIS, the latter SOX2 negative. This knowledge is essential 
to prevent misdiagnosis of intratubular EC based on positive SOX2 staining. Furthermore, 
SOX17 is proposed as the alternative OCT3/4 protein partner in gonocytes, CIS and 
seminoma cells. 
 
The findings presented above have generated new questions. In addition, longer existing 
questions can now be explored. The proven existence of a cell line representative for 
seminoma provides opportunities to mimic and study the process of reprogramming 
during TGCT development resulting in the clinically unfavorable non-seminomas. The 
switch from SOX17 as a potential OCT3/4 protein partner to SOX2 is likely to be essential 
during this transformation and this can be induced in vitro. In addition, target genes that 
are under joined SOX17 and OCT3/4 control can be identified in TCam-2. Recent progress 
in generating germ cells from ES cells has significantly enhanced the available research 
tools to investigate the earliest steps in germ cell tumorigenesis. Improved knowledge on 
the malignant transformation of the germ cell lineage is vital to mimic this process in vitro 
and eventually create an animal model for the type II GCTs. 
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Regarding diagnosis and treatment of TGCTs, future research should focus on an early 
diagnosis of these tumors as their precursor cells are already present from birth onwards. 
The long dormant phase at least till puberty should be taken advantage of to select and 
treat the carriers of the malignant cells before the tumors become invasive. OCT3/4 
immunohistochemistry on testicular biopsy specimens will have to be implemented in 
clinical pathology routine. Screening tools for highly specific factors like OCT3/4 in blood 
and semen are being developed and will be applied to individuals at risk. 
Pluripotency literally means to be able to do more. To beat the malignant germ cells, we 
have to increase our own pluripotency in diagnosis and treatment of these fascinating 
tumors. 
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SUMMARY 
 
Genesis of a new individual starts by fusion of the female egg and male sperm forming the 
fertilized egg called the zygote. This single cell will divide and the repeated division of its 
daughter cells will eventually give rise to approximately 100 million million cells that 
constitute an adult human being. Along this path of development the cells will acquire 
specialized features and skills necessary for performing their specific function within the 
organism; the cells have differentiated. If and how a cell will differentiate is dependent on 
the potency of the cell and the stimuli it receives from the environment. The first cell(s) 
of the embryo can differentiate to the complete gamut of somatic cells and germ cells, and 
are therefore pluripotent. The process of differentiation of germ cells starts in the first 
weeks of embryonal development and culminates in the formation of highly specialized 
germ cells, i.e. egg and spermatozoon, around puberty. Germ cells that fail to properly 
differentiate during development can give rise to germ cell tumors. Depending on the 
time point of derailment of normal germ cell development, different types of germ cell 
tumors can arise. This thesis focuses on germ cell tumors of adolescents and young adults 
that derive from an early germ cell that has not yet differentiated to a cell committed to 
male or female germ cell development. Reminiscent of their origin these tumors are 
pluripotent and have features that are only present in cells of early embryonic 
development. This includes the presence of proteins involved in regulation of 
pluripotency like OCT3/4, also known as POU5F1. Because OCT3/4 is unique to stem cells 
and germ cells in the early embryo and normally not present in the adult human, we can 
use OCT3/4 in diagnosis of germ cell tumors in adults. 
Chapter 1 provides an extensive overview of the current knowledge of OCT3/4. The 
discovery of OCT3/4 and the recognition of its central role in the early steps of normal 
embryonic development as well as in germ cell tumor development is described. 
Furthermore, other genes and proteins involved in OCT3/4 regulation are grouped to 
provide a framework for future research. 
In chapter 2 the value of OCT3/4 in the diagnosis of a large consecutive series of germ cell 
tumors of the testis was examined. Two different antibodies to detect the OCT3/4 protein 
were used and both demonstrated the presence of OCT3/4 in the nucleus of specific tumor 
cell types. For clarity, a concise overview of the different cell types in germ cell tumors is 
provided here (see also figure 2 on page 20). Carcinoma in situ, the earliest known cell 
type of testicular germ cell tumors, is very similar to an early germ cell and has OCT3/4 
protein in the nucleus of the cells. These cells are present in the seminiferous tubules 
where sperm is made from puberty onwards. When carcinoma in situ cells divide, become 
invasive and grow through the wall of the tubule they are referred to as seminoma cells. 
Fifty percent of all testicular germ cell tumors are composed of seminoma cells, which 
have also the OCT3/4 protein in their nucleus. The malignant germ cells - carcinoma in 
situ and seminoma - can transform by an unsolved mechanism (reprogramming) to a cell 
type that mimics the inner cells of the initial embryo. These malignant cells are called 
embryonal carcinoma, which is in principle pluripotent and can differentiate to all 
possible cell types of the embryo (teratoma tumor cells and malignant germ cells), 
placenta (the tumor cells are called choriocarcinoma), and yolk sac (yolk sac tumor). As
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opposed to the seminomatous tumors (seminomas), tumors composed of embryonal 
carcinoma cells or any of their derived differentiated cells are referred to as 
nonseminomatous tumors (nonseminomas). The pluripotent potential of embryonal 
carcinoma is reflected by the presence of OCT3/4 in these cells. In the series of testicular 
germ cell tumors we examined, 100% of carcinoma in situ, seminoma and embryonal 
carcinoma cells were positive for the OCT3/4 protein, whereas all other cell types were 
negative. 
In chapter 3 the clinical history of a 40-year-old woman is presented who suffered from 
severe progressive neurological symptoms. On MRI scan a large diffuse area of aberrant 
intensity was seen. A stereotactic biopsy of this intracerebral lesion showed tumor cells on 
which no diagnosis could be made initially despite use of a large series of 
immunohistochemical markers. We showed that the neoplastic cells were positive for 
OCT3/4 and the final diagnosis was a diffusely infiltrating germinoma, which is a 
seminoma of the brain. 
In chapter 4 a retrospective study on patients who developed an invasive testicular germ 
cell tumor after an initial tumorcell negative biopsy is presented. Revision of the biopsies 
ans performing immunohistochemistry for OCT3/4 and other diagnostic markers revealed 
the presence of carcinoma in situ in ten out of 19 cases. This study shows that 
morphological examination is not sufficient and screening of all testicular biopsies by 
immunohistochemistry is mandatory to identify carcinoma in situ. 
In chapter 5 the methylation status of the upstream region of the OCT3/4 gene in normal 
and neoplastic testicular tissues was examined. The cell line JKT-1, supposedly seminoma-
derived, was included in this survey. We showed that all differentiated cell types, 
including JKT-1, had a consistent hypermethylation of the OCT3/4 promoter. In contrast, 
seminoma and embryonal carcinoma were hypomethylated, confirmed by analyses after 
tumor micro-dissection. Our results from in vivo derived samples are in accordance to the 
previously generated in vitro data and show that expression of OCT3/4 is associated with 
specific changes in methylation. 
In chapter 6 the origin of the cell line JKT-1 and its value as a model for germ cell tumors 
was investigated. This cell line was reported to be derived from a seminoma of a Japanese 
male. However, attempts to culture seminoma cells have failed in the past because these 
cells go into apoptosis (programmed cell death) after disruption of their micro-
environment. We showed by analysis on chromosomal, DNA, RNA and protein level that 
JKT-1 lacks all the essential characteristics of seminoma cells and cannot be used as a 
model for these tumors. In addition, molecular analysis proved that the JKT-1 cell line and 
the supposedly primary tumor were not related. 
Chapter 7 describes the characterization of another cell line, TCam-2, also reported to be 
derived from a seminoma of a Japanese male. The same approach as for the cell line JKT-1 
was taken and all essential features of seminomas were present, including OCT3/4 mRNA 
and nuclear protein. A possible explanation for the successful establishment of this cell 
line was that TCam-2 had an activating mutation of the BRAF gene, a rare event in germ 
cell tumors. 
In embryonic stem cells and embryonal carcinoma OCT3/4 exerts its function by physical 
interaction with SOX forming a heterodimer to activate and repress target genes. In these 
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undifferentiated cells OCT3/4 is regarded as the gatekeeper of pluripotency. However, in 
embryonic germ cells loss of OCT3/4 leads to programmed cell death instead of 
differentiation, implicating OCT3/4 as a survival factor in these cells. In chapter 8 we 
show that SOX2 is not present in early fetal germ cells, carcinoma in situ and seminoma 
cells, and we propose SOX17 as an alternative protein partner for OCT3/4 in these cells. 
SOX17 mRNA and protein is present in patient derived seminoma samples and the 
seminoma cell line TCam-2, but not in embryonal carcinoma cell lines and patient 
samples. This indicates that SOX17 can be used as a diagnostic marker to differentiate 
between seminoma and embryonal carcinoma. Furthermore, SOX17 is present in early 
fetal germ cells, carcinoma in situ, and in almost all stages of spermatogenesis. 
In chapter 9 the findings of this thesis are discussed in a broader perspective and 
additional data are provided on the molecular biology of OCT3/4. In humans different 
variants of the OCT3/4 protein can be formed and there are several OCT3/4 pseudogenes, 
highly similar to the OCT3/4 gene, but not suitable to make a protein. These OCT3/4 
pseudogenes and protein variants can hamper the interpretation of research results. 
Finally, we conclude that lack of OCT3/4 mutations and the presence of OCT3/4 and 
other stem cell markers in germ cell tumors are likely to reflect the embryonic origin of 
these tumors instead of an initiating oncogenic event. 
 
 
SAMENVATTING 
 
Het ontstaan van een nieuw organisme begint met de bevruchting waarbij een zaadcel de 
eicel binnendringt. Deze bevruchte eicel, de zygote, deelt zich herhaaldelijk en de 
gevormde dochtercellen vormen uiteindelijk de ongeveer 100 biljoen cellen waaruit een 
volwassen mens bestaat. Tijdens deze delingen krijgen de cellen speciale eigenschappen en 
taken die nodig zijn om hun specifieke functie in het lichaam te vervullen; de cellen zijn 
gedifferentieerd. Wanneer en op welke manier een cel differentieert hangt af van de cel 
zelf én van signalen uit de omgeving. De eerste cellen van het zich ontwikkelende embryo 
kunnen in elk denkbare andere lichaamscel differentiëren, bijvoorbeeld een spiercel, een 
zenuwcel of een rode bloedcel, en daarom worden deze eerste cellen pluripotent (“meer 
kunnend”) genoemd. Ook de voorlopers van de geslachtscellen, genaamd kiemcellen, 
ontstaan uit deze pluripotente cellen tijdens de eerste weken van de embryonale 
ontwikkeling. Rond de puberteit rijpen de kiemcellen uit tot uiterst gespecialiseerde 
kiemcellen, de zaadcel en de eicel, waarvan de enige functie het vormen van een nieuwe 
generatie is. Kiemcellen met een verstoorde uitrijping kunnen zich ontwikkelen tot 
kiemceltumoren. Afhankelijk van het tijdstip waarop de normale kiemcelontwikkeling 
verstoord raakt, kunnen verschillende typen kiemceltumoren ontstaan. Dit proefschrift 
beperkt zich tot kiemceltumoren die zich vanaf de puberteit openbaren en voornamelijk 
bij jonge volwassenen voorkomen. Deze tumoren ontstaan uit vroege kiemcellen en 
hebben eigenschappen die normaal gesproken alleen bij cellen in het embryo voorkomen, 
zoals pluripotentie. Pluripotentie van een cel is afhankelijk van de aanwezigheid van 
bepaalde eiwitten, zoals OCT3/4, waarvan de officiële naam POU5F1 is. Dit eiwit speelt 
een sleutelrol bij de vroege ontwikkeling in het embryo. Het is bekend dat het aanwezig 
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blijven van dit eiwit in kiemcellen samenhangt met het ontstaan van kiemceltumoren. In 
het onderzoek dat beschreven wordt in dit proefschrift staat OCT3/4 en zijn rol in 
kiemceltumoren centraal. De onderzoeksresultaten vergroten onze kennis van 
kiemceltumoren en dragen bij aan optimalisering van diagnostiek waardoor de 
behandeling van patienten verder zal verbeteren. 
In hoofdstuk 1 wordt een uitgebreid overzicht gegeven van de huidige kennis over 
OCT3/4. De ontdekking van OCT3/4 en zijn centrale rol zowel in het begin van de 
normale embryonale ontwikkeling als in de ontwikkeling van kiemceltumoren wordt 
beschreven.  
De waarde van OCT3/4 in het stellen van de diagnose kiemceltumor wordt beschreven in 
hoofdstuk 2. Hiervoor is gebruik gemaakt van kiemceltumoren die oorspronkelijk in een 
zaadbal ontstaan zijn. De aanwezigheid van het OCT3/4 eiwit in de kern van bepaalde 
tumorcellen kon worden aangetoond met twee specifieke antilichamen. Elk antilichaam 
herkent een ander gedeelte van het OCT3/4 eiwit. Beide antilichamen geven een duidelijk 
signaal in de celkern als het OCT3/4 eiwit aanwezig is. Voor een beter begrip van de 
verschillende celtypen in kiemceltumoren volgt hier een beknopt overzicht (zie ook 
figuur 2 op bladzijde 20). Het vroegst bekende celtype waaruit alle kiemceltumoren in de 
zaadbal van (jonge) mannen ontstaan is carcinoma in situ. Deze kwaadaardige kiemcellen 
lijken qua uiterlijk op vroege kiemcellen en hebben het OCT3/4 eiwit in hun celkern. 
Carcinoma in situ cellen liggen in de buizen van de zaadbal waar vanaf de puberteit de 
zaadcellen worden aangemaakt. Zodra carcinoma in situ cellen zich gaan delen en dwars 
door de wand van de zaadbuizen het omgevende weefsel binnendringen worden ze 
seminoomcellen genoemd. Van alle kiemceltumoren van (jong) volwassenen bestaat 
vijftig procent uit seminoomcellen die ook het OCT3/4 eiwit in hun celkern hebben. 
Kwaadaardige kiemcellen – carcinoma in situ en seminoom – kunnen veranderen in een 
cel die sterk lijkt op de eerste cellen van het embryo, de embryonale stamcellen. Dit 
veranderingsproces wordt reprogrammering genoemd, maar hoe dit verloopt, is nog een 
raadsel. De kwaadaardige embryonale stamcellen die via reprogrammering ontstaan 
worden embryonaal carcinoomcellen genoemd. Embryonaal carcinoom is pluripotent en 
heeft OCT3/4 eiwit in de celkern. Als het OCT3/4 eiwit verdwijnt, gaat embryonaal 
carcinoom differentiëren en kan dan veranderen in alle mogelijke celtypen in de mens en 
weefsels die om het embryo heenliggen tijdens de vroege ontwikkeling, zoals placenta 
(choriocarcinoom) en dooierzak (dooierzaktumor). Ondanks dat grotendeels het patroon 
van normale ontwikkeling gevolgd wordt, blijven deze cellen kwaadaardig. Als 
tegenhanger van de tumoren die uit seminoomcellen bestaan (seminomen), worden de 
tumoren van embryonaal carcinoom en daaruit ontstane cellen nonseminomen genoemd. 
In de grote verzameling kiemceltumoren van de zaadbal die geanalyseerd is, bevatten 
100% van alle carcinoma in situ cellen, seminoomcellen en embryonaal carcinoomcellen 
het OCT3/4 eiwit. Alle andere celtypen missen het eiwit. Hieruit blijkt dat het aantonen 
van de aanwezigheid van OCT3/4 zeer geschikt is om kiemceltumoren te herkennen en 
daarom gebruikt kan worden door de patholoog om de diagnose kiemceltumor te stellen. 
Hoofdstuk 3 beschrijft de ziektegeschiedenis van een vrouw van 40 jaar die verschillende 
neurologische symptomen kreeg waaronder wazig zien en vermindering van spierkracht 
en tastgevoel. Een MRI scan liet een onscherp afwijkend gebied in de hersenen zien en 
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hieruit werd een weefselbiopt genomen. In het weefsel waren tumorcellen aanwezig, 
maar het soort tumor kon niet vastgesteld worden, ondanks weefselkleuringen met een 
uitgebreid panel van specifieke antilichamen (immuunhistochemische kleuringen). Het 
nut van OCT3/4 voor de diagnostiek van kiemceltumoren was net bekend en uiteindelijk 
werd deze marker ook gebruikt op het weefselbiopt van de hersenafwijking. Alle 
tumorcellen waren positief voor OCT3/4 en de uiteindelijke diagnose was een diffuus 
groeiend germinoom, ook wel seminoom van de hersenen genoemd. De patiënte werd 
bestraald en haar lichamelijke klachten verminderden sterk door de behandeling. 
In hoofdstuk 4 is een studie gedaan naar patiënten die een kiemceltumor van de zaadbal 
kregen, hoewel er in een eerder afgenomen zaadbalbiopt geen tumorcellen gezien waren. 
Het opnieuw bekijken van de biopten en immuunhistochemische kleuring tegen het 
OCT3/4 eiwit toonde aan dat er in de biopten carcinoma in situ cellen aanwezig waren in 
tien van de negentien patiënten. Deze resultaten geven aan dat carcinoma in situ cellen 
niet altijd goed te herkennen zijn en dat OCT3/4 kleuring op alle zaadbalbiopten 
noodzakelijk is om een kiemceltumor uit te sluiten. 
Hoofdstuk 5 beschrijft onderzoek naar het verband tussen de activiteit van het OCT3/4 
gen en de aanwezigheid van OCT3/4 eiwit in een (tumor)cel. Hieruit blijkt dat als er veel 
methylgroepen aan het DNA van het OCT3/4 gen zitten, het OCT3/4 gen uitstaat en er 
geen OCT3/4 eiwit gemaakt wordt. Dit is het geval in gedifferentieerde cellen. In 
tegenstelling tot gedifferentieerde cellen zitten er in seminoomcellen en embryonaal 
carcinoomcellen weinig methylgroepen aan het DNA van het OCT3/4 gen en staat het 
gen aan waardoor OCT3/4 eiwit aangemaakt wordt. Het nieuwe van deze studie is dat in 
plaats van gekweekte tumorcellen (cellijnen), tumorweefsel gebruikt is van patiënten 
waardoor een directer inzicht wordt gekregen in de werkelijke situatie van de tumorcel in 
het menselijk lichaam. 
Zoals eerder gezegd, bestaat vijftig procent van de kiemceltumoren uit de zaadbal uit 
seminomen. Van de nonseminomen zijn meerdere cellijnen gemaakt, die we in het 
laboratorium kunnen kweken en manipuleren om zo meer te weten te komen over de 
werkelijke tumoren. In het verleden zijn vele pogingen gedaan om ook seminoomcellen te 
kweken in het laboratorium en er een stabiele cellijn van te maken. Dit is echter nooit 
gelukt omdat deze cellen een zelfmoord programma (apoptose) aanschakelen als ze uit de 
tumor losgemaakt worden en vervolgens allemaal doodgaan. Hoofdstuk 6 gaat over de 
cellijn JKT-1 die verondersteld werd afkomstig te zijn van een seminoom uit de zaadbal 
van een Japanse man. De afkomst van JKT-1 werd onderzocht en de eigenschappen van de 
JKT-1 cellen werden vergeleken met seminoomcellen uit tumorweefsel van patiënten. Uit 
analyse van de chromosomen, het DNA, RNA en eiwit van de JKT-1 cellen, blijkt dat een 
JKT-1 cel niet op een seminoomcel lijkt. Daarbij kon ook met DNA analyse worden 
aangetoond dat de JKT-1 cellen en het oorspronkelijke seminoom niet van dezelfde 
persoon afkomstig zijn. Deze resultaten laten zien dat de JKT-1 cellijn niet geschikt is als 
model voor het seminoom. 
Hoofdstuk 7 is op dezelfde wijze opgezet als het voorgaande hoofdstuk. In hoofdstuk 7 is 
de cellijn TCam-2 onderzocht. Van deze cellijn is ook beschreven dat hij afkomstig is van 
een seminoom uit de zaadbal van een Japanse man. Uitgebreide analyse van TCam-2 
cellen laat zien dat deze cellijn alle eigenschappen heeft die ook in seminoomcellen 
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aanwezig zijn, zoals OCT3/4 eiwit in de celkern. Hiermee is TCam-2 de eerste en – voor 
zover bekend – de enige cellijn die als model voor seminomen gebruikt kan worden. Een 
mogelijke verklaring voor het bestaan van deze unieke cellijn is dat TCam-2 cellen een 
mutatie in het DNA hebben op de plaats van het BRAF gen. Dit gen is vaak gemuteerd in 
verschillende soorten tumoren, maar zelden in kiemceltumoren. 
De manier waarop het OCT3/4 eiwit zorgt dat cellen pluripotent blijven, is door binding 
op specifieke plaatsen in het DNA. Het OCT3/4 eiwit heeft hierbij hulp van andere 
eiwitten nodig, waarvan SOX2 het meest onderzocht is. In embryonale stamcellen en 
tumorcellen van embryonaal carcinoom binden het OCT3/4 eiwit en het SOX2 eiwit naast 
elkaar aan het DNA en wordt er ook een onderlinge verbinding gemaakt tussen de 
eiwitten. Hierdoor worden genen geactiveerd die nodig zijn voor pluripotentie, en genen 
uitgeschakeld die betrokken zijn bij differentiatie. In hoofdstuk 8 wordt beschreven dat 
het SOX2 eiwit niet aanwezig is in vroege kiemcellen, carcinoma in situ en seminoom. 
Het OCT3/4 is wel aanwezig in deze cellen en heeft een partner nodig om zijn functie uit 
te oefenen. SOX17, een ander eiwit uit de SOX familie, is een zeer goede kandidaat 
hiervoor. Dit eiwit zit in de celkern van vroege kiemcellen, carcinoma in situ en 
seminoomcellen, zowel van tumoren als de cellijn TCam-2. Embryonaal carcinoomcellen 
bevatten geen SOX17 eiwit. Hierdoor kan SOX17 ook gebruikt worden om onderscheid te 
maken tussen seminoom en embryonaal carcinoom bij het stellen van een diagnose. 
Omdat SOX17 ook voorkomt in andere celtypen onder andere tijdens de uitrijping van de 
normale zaadcel, is het belangrijk om niet alleen naar de aanwezigheid van het SOX17 
eiwit te kijken maar ook naar het uiterlijk van de cellen,  
In hoofdstuk 9 worden de resultaten van dit proefschrift besproken en vergeleken met 
wat bekend is in de huidige literatuur. Interessant daarbij is dat er in mensen 
verschillende varianten van het OCT3/4 eiwit bekend zijn, waarbij niet altijd duidelijk is 
wat de functie van zo’n eiwitvariant is én of dit wel een functie heeft. Naast het 
werkelijke OCT3/4 gen in het DNA zijn er op een aantal chromosomen ook genen 
aanwezig die hier heel erg op lijken, pseudogenen genoemd, waarvan geen OCT3/4 eiwit 
gevormd kan worden. Door hun grote gelijkenis met het werkelijke gen kunnen ze voor 
verwarring zorgen. 
De slotconclusie van het proefschrift is dat het OCT3/4 eiwit in kiemceltumoren een 
normaal eiwit is. Er zijn geen mutaties in het OCT3/4 gen in kiemceltumoren bekend en 
de aanwezigheid van OCT3/4 verwijst naar de embryonale afkomst van deze tumoren. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
 
 
FIGURE 1. Transcriptional regulation of the OCT3/4 gene and targets of OCT3/4 protein. For clarity the 
well-established name OCT3/4 is used in this figure, however the official gene name is POU5F1. 
Transcription of the OCT3/4 gene is regulated by a large number of proteins that bind to conserved regions 
(CR1 to CR4) in the upstream region of the gene. Which factors will bind depends on the stage of 
embryonic development, cell type and environment of the cells involved. The binding site for NOBOX 
(between CR1 and CR2) is only present in the murine OCT3/4 gene, whereas, in theory, the other factors 
can bind in both the mouse and human gene. However, most of the functional studies have been performed 
in mouse and await confirmation in human cells. Activation of OCT3/4 expression will generate mRNA that 
can be alternatively spliced in human generating two proteins, OCT3/4A and OCT3/4B. The biological role 
of OCT3/4B is unknown at the moment. The OCT3/4A protein can bind to several other proteins, but so far 
again most of these interactions have only been studied in mouse. In addition, OCT3/4A binds to 
transcriptional control elements and activates or represses expression of a large number of genes. Besides 
regulating its own expression by binding to conserved region four (CR4) upstream the OCT3/4 gene, 
OCT3/4A regulates genes involved in differentiation and pluripotency of which a selected number from 
human and mouse data is presented here. Finally, OCT3/4A binds in the vicinity of a number of miRNAs 
and is therefore likely to influence their expression. (Original position Figure 1 on page 16) 
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FIGURE 1. OCT3/4 immunohistochemistry using different embedding, fixation, and detection methods. (A) 
Nuclear staining (brown) of seminoma cells with a mono-clonal antibody. (B) Embryonal carcinoma and 
seminoma incubated with a polyclonal antibody. Note the cytoplasmic staining in the angio-invasive 
embryonal carcinoma (arrows) compared with the clear cytoplasm of intratubular seminoma cells. Both 
slides are from formalin-fixed and paraffin wax-embedded tissue. Images C–F show FITC-labelled 
fluorescence with the monoclonal antibody as the primary step. Nuclear staining is in blue (DAPI) and 
OCT3/4 localization in green (FITC). (C) Frozen tissue from a seminoma. (D) Frozen tissue from an 
embryonal carcinoma. Note the difference in cytoplasmic staining pattern between seminoma and 
embryonal carcinoma cells. Cytospin preparations of (E) pluripotent embryonal carcinoma-derived cell line 
NT2 and (F) nullipotent 2102Ep. Note the OCT3/4-negative cells located at the periphery of the aggregates.  
(Original position Figure 1 on page 40) 
  179
CHAPTER 2: DIAGNOSTIC VALUE OF OCT3/4 IN GERM CELL TUMORS 
 
 
FIGURE 2. (A) Western blot analysis for OCT3/4 in different testicular germ cell tumours, derived cell lines, 
and normal testis. Note the specificity for seminoma and embryonal carcinoma. (B) OCT3/4 immuno-
histochemistry on Bouin-fixed tissue showing  positive staining of CIS. (C, D) Retroperitoneal tumour with 
extensive necrosis from patient 1 showing weak cytoplasmic, focally membranous staining for c-KIT in red 
(C, positive cells indicated with arrows) and distinct brown nuclear staining for OCT3/4 (D). (E, F) Tumour 
localized in the brain of patient 2, with scattered cells with clear cytoplasm and prominent nucleoli (E) with 
positive staining for OCT3/4 (F). (Original position Figure 2 on page 43) 
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FIGURE 2. A stereotactic biopsy of the intracerebral lesion showed blast-like neoplastic cells within a 
mononuclear infiltrate (Figure 2A). A wide panel of markers including those for carcinoma, melanoma and 
primary central nervous system lymphoma was applied: CD3, CD4, CD5, ALK-1, CD19, CD20, CD79a, 
CD45, CD30, S-100, MELAN-A, HMB45, CD68, CD43, PLAP, hCG, AFP and CD56, all found to be negative; 
there was some punctuated NCL5D3 (low molecular weight keratins 8 and 18) positivity (Figure 2B). No 
final diagnosis could be made. Subsequently, the marker OCT3/4 became available, and 100% of tumor cell 
nuclei present in the biopsy clearly stained positive for OCT3/4 (Figure 2C). Recently, the stem cell factor 
receptor c-KIT was applied on a previously negative slide and the cytoplasm of some tumor cells was stained 
positive (Figure 2D). (Original position Figure 2 on page 52) 
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FIGURE 1. A) Histology of an open surgical biopsy of the testis stained with H&E (25x) (patient 7, Table 1). 
It was identified as suspected, but not proven to contain CIS; B) Higher power of suspected lesion (H & E 
100x); C) Histology of the same biopsy stained immunohistochemical for OCT3/4 (25x). The region with 
positive cell is indicted in the square; D) Higher power of suspected lesion (OCT3/4, 100x); Only three 
tubules contained OCT3/4 positive cells (brown); E) PLAP immunohistochemistry of the same region, 
confirming the presence of CIS cells (red). (Original position Figure 1 on page 62) 
 
 
 
 
 
CHAPTER 5: OCT3/4 METHYLATION IN TESTICULAR GERM CELL TUMORS 
 
 
FIGURE 1. Embryonal carcinoma (black arrows) before (A) and after (B) micro-dissection. Enzymatic 
alkaline phosphatase stains embryonal carcinoma as well as the carcinoma in situ cells (white arrows). 
(Original position Figure 1 on page 75) 
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FIGURE 1. (A) Immunohistochemistry of the primary tumour for OCT3 ⁄ 4; immunohistochemistry of JKT-1 
cells: (B) double staining for VASA (red color) and DAZL (blue color). Note the more intensive DAZL 
staining in the cells positive for VASA; (C) XPA; (D) SYCP3; (E) Western blot analysis of a seminoma, the 
EC-derived cell line NT2, and the three subclones of the JKT-1 cell lines (I, II, and III), for SYCP3, SYCP1, 
XPA, OCT3 ⁄ 4, NANOG and VASA, ß-actin was used as a loading control; (F) clonality analysis of the 
supposed primary tumour and the three JKT-1 cell lines, designated I, II and III. The following markers 
were applied: D9S156, D9S157, D17S786, D8S133, and D8S136. Note that the different sub-lines show the 
same pattern, meaning a monoclonal origin, but these were clonally unrelated to the primary tumour. The 
limited number of bands per marker indicate that both cell lines and primary tumour have no micro-
satellite instability. (Original position Figure 1 on page 94) 
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FIGURE 2 (A) Representative 
metaphase of spectral karyo-
typing analysis of JKT-1. 
Characteristic aberrations are 
loss of chromo-somes 4, 13, 
18, 22 and Y; gain of X; and 
isochromosome 5p. The 
clonal chromosomal consti-
tution based on nine meta-
phases is: 61-68, XX, +der(X) 
t(X;3)(q22;?)[7]-Y,der(1)t(1;9) 
(q21;q?)[8], der(1;3) (q10;p10) 
[8], der(2) t(2;3) (q21;q2) [2], 
der(2) t(2;5) (q21;?), der(3) 
del(3) (p?) del(3) (q?) [2], 
der(3;5), (p10; q10)[8],-4,+i(5) 
(p10), der(6) t(3;6) (?;q22)[7], 
del(7)(p21)[3],-9,add(9) (p11) 
[4], -10[3], del(10)(p1) [2], 
der(10) t(3;10) (?;p1?2) [6], 
der(11) dup(11) (p?p?) t(3;11) 
(?;p14) dup(11) (q?q?) t(3;11) 
(?;q24) [3], der(11) dup(11) 
(p?p?) t(9;11) (?;p14) dup(11) 
(q?q?) t(9;11) (?;q24) [6], -13, 
+der(16) t(15;16) (?;q23), -18 
[7],der(18)-del(18)(p1) del(18) 
(q?1)[2],der(19)(19::11::13)[8], 
der(19)t(19;20)(?;?)[2],der(20)
t(18;20) (?;?) [5], -22, +der(?) 
(5::9::X) [8], +der(?) (5::9::X) 
[2], +der(?) (?;3)[2] [cp9]. 
(B) Results of the 3.6 K BAC ⁄ 
PAC array CGH analysis of 
the JKT-1 cells. 
(C) Methylation-sensitive 
single nucleotide primer 
extension (MS-SNuPE) of the 
IGF2 ⁄ H19 imprinting control 
region of JKT-1 shows a very 
low methylation level by two independent primers (7% for primer A and 0% for primer B). In contrast, the 
sperm DNA control has a 30% methylation level; (D) Sequencing of the CTCF core binding domain on 
bisulfite treated DNA of JKT-1 confirms the MS-SNuPE data. All cytosines (initial sequence on top) have 
been converted to thymine because they were unmethylated (bisulfate treated DNA sequence below); (E). 
Results of Affymetrix expression profiling. Unsupervised clustering of JKT-1, 5 spermatocytic seminomas 
(SS), 4 seminomas (SE) and 3 dysgerminomas (DG) using Omniviz. The SE and DG could not be separated, 
in contrast to the SE ⁄ DG and SS. JKT-1 does not cluster with any of the tumour samples. (Original position 
Figure 2 on page 96) 
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FIGURE 1. Genomic constitution of TCam-2 cells was determined by SKY analysis, array CGH and FISH. In 
addition, the EC-cell lines Tera-1, NTera-2, 2102Ep and NCCIT were analysed by array CGH. A) A 
representative metaphase of SKY analysis of TCam-2. The majority of chromosomes contains anomalies, and 
a large number of marker chromosomes is present; B) 3.6 K BAC/PAC array CGH analysis of TCam-2 cells 
and four EC-cell lines. Gain of 12p is present in all cell lines, while for example the Y chromosome is lost; C) 
FISH analysis confirmed the increased number of 12p copies (green signal) compared to the centromeric 
region of chromosome 12 (red signal) in TCam-2. (Original position Figure 1 on page 117) 
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FIGURE 2. The status of genomic imprinting in the IGF2/H19 locus was determined by polymorphic 
restriction enzyme digestion and the methylation status of the imprinting control region (ICR) in this locus. 
A) In TCam-2 both H19 and IGF2 genes were informative as shown by RsaI and ApaI digestion on DNA 
derived PCR products (DNA+). The same restriction enzyme digestions of PCR products from TCam-2 
mRNA showed biallelic expression of both H19 and IGF2 (cDNA+), indicated by both the A and B allele; B) 
Bisulfite sequencing reveals that the ICR in the IGF2/H19 locus was completely unmethylated and all 
cytosines were converted to thymines (indicated in red compared to the original sequence as shown below). 
(Original position Figure 2 on page 118) 
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FIGURE 3. Expression of embryonic stem cell markers in TCam-2 and clinical germ cell tumor samples. A) 
left panel: Nuclear staining for pluripotency factor OCT3/4 in TCam-2 cells grown in a culture dish; middle 
panel: TCam-2 cells are positive for PLAP on cytospin preparation; right panel: dotted cytokeratin 8 
(CAM5.2) staining in TCam-2 cells on cytospin preparation, as can be observed in seminoma; B) left upper 
panel: Western blot analysis shows expression of SOX2 in the embryonal carcinoma cell line NTera-2 and 
absence of SOX2 in TCam-2; left lower panel: Immunoprecipitation (IP) for c-KIT shows the expected band 
in TCam-2 and in F36P control total cell lysate, while c-KIT expression is very weak in total cell lysate of 
TCam-2; middle and right panel: immunohistochemistry for c-KIT and SCF on TCam-2 cells on cytospin 
preparations; C) Expression results of TCam-2 and primary human germ cell tumor samples based on 
genome wide (Affymetrix) expression profiling (log2 transformed data), left panel: OCT3/4 (expressed in all 
samples); middle panel: SOX2, and right panel: CD30, both expressed in embryonal carcinoma and low in 
seminoma and TCam-2. EC: embryonal carcinoma; DG: dysgerminoma; SE: seminoma. (Original position 
Figure 3 on page 120) 
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FIGURE 4. Unsupervised hierarchical clustering based on the top 100 differentiating genes between 
seminoma (SE)/dysgerminoma (DG) and embryonal carcinoma (EC) based on Affymetrix expression 
profiling to cluster the TCam-2 cell line (see supplementary data). TCam-2 clusters in the seminoma branch, 
separate from the  EC samples. (Original position Figure 4 on page 121) 
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FIGURE 1. A) Quantitative RT-PCR for SOX2 on TGCT samples. Tested are the cell line JKT-1, the 
seminomatous cell line TCam-2 and the EC cell lines (NTera-2, NCCIT, Tera-1, and 2102Ep). A high 
expression of SOX2 is observed in the EC samples and cell lines. In testis parenchyma containing CIS 
(percentage is indicated in the bars) the SOX2 mRNA expression is elevated compared to normal testis; the 
level of expression parallels the amount of CIS containing seminiferous tubules. TCam-2 and JKT-1 show a 
level of expression in between normal testis/seminoma and EC samples and cell lines. B) Double 
immunohistochemistry for SOX2 (red) and POU5F1 (blue) shows that SOX2 is not expressed in the POU5F1 
positive CIS cells, but in a cell type more luminally located, being Sertoli cells. C) Double staining for 
Vimentin (blue) and SOX2 (red) combined with morphology and the position in the seminiferous tubule 
shows that the SOX2 positive cells are Sertoli cells. (Original position Figure 1 on page 137) 
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 CHAPTER 8: SOX17 AND SOX2 IN (MALIGNANT) GERM AND STEM CELLS 
 
FIGURE 3. A) Quantitative RT-PCR for SOX17 on TGCT samples, cell line JKT-1, seminomatous cell line 
TCam-2 and EC cell lines (NTera-2, NCCIT, Tera-1, and 2102Ep) demonstrates a high expression of SOX17 
in the seminoma samples and cell line TCam-2, whereas the expression is low in all other samples. Nuclear 
SOX17 signal (brown) in B) CIS, C) seminoma and D) the seminomatous cell line TCam-2. Inset: nuclear 
POU5F1 staining in TCam-2 cells. E) Western blotting shows a complementary expression pattern for SOX2 
and SOX17 in TCam-2 and EC cell lines with high SOX17 expression in TCam-2 and no SOX17 expression 
in the EC cell lines NTera-2, NCCIT and 833KE. SOX2 is highly expressed in the EC cell lines and not in 
TCam-2. The embryonic stem cell marker OCT3/4 is expressed in all samples. As a loading control β-actin 
was used. F) SOX17 protein is present in various maturation stages of spermatogenesis: spermatogonium 
(black arrow), secondary spermatocyte (white arrow) and spermatid (black arrowhead), while primary 
spermatocytes, spermatozoa and Sertoli cells are negative. G) Nuclear SOX17 in gonocytes of an 18 week old 
fetus. (Original position Figure 3 on page 139) 
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ABBREVIATIONS 
 
AFP  α-fetoprotein 
CGH  comparative genomic hybridization 
CHC  choriocarcinoma 
CIS  carcinoma in situ 
DNA  deoxyribonucleic acid 
EC  embryonal carcinoma 
ES(C)  embryonic stem (cell) 
FISH  fluorescent in situ hybridization 
GCT  germ cell tumor 
hCG  human chorionic gonadotrophin 
H&E  hematoxylin & eosin staining 
HMG  high mobility group 
ICM  inner cell mass 
ICR  imprinting control region 
I(T)GCNU intratubular germ cell neoplasia unclassified 
MRI  magnetic resonance imaging 
miRNA microRNA 
mRNA  messengerRNA 
NANOG derived from a Celtic legend: Tir na nOg is the land of the ever young 
NS  nonseminoma 
OCT3/4 octamer binding transcription factor 3/4 
PALGA pathologisch anatomisch landelijk geautomatiseerd archief 
PCR  polymerase chain reaction 
PGC  primordial germ cell 
PLAP  placental alkaline phosphatase 
POU5F1 Pit-Oct-Unc family of transcription factors, class 5, factor 1 
RNA(i) ribonucleic acid (interference) 
RT-PCR reverse transcriptase polymerase chain reaction 
SE  seminoma 
siRNA  small interfering RNA 
SKY  spectral karyotyping 
SOX  SRY-related HMG box 
SRY  sex determining region on the Y chromosome 
SS  spermatocytic seminoma 
TE  teratoma 
TGCT  testicular germ cell tumor 
TMA  tissue micro array 
TSPY  testis-specific protein, Y-encoded 
WHO  world health organization 
YST  yolk sac tumor 
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De laatste bladzijde van mijn boekje. Geen spannende ontknoping, maar wel het stukje 
tekst waar iedereen benieuwd naar is. Dit boekje is het eindresultaat van het onderzoek 
van de afgelopen jaren waar ik met veel plezier aan heb gewerkt en waarschijnlijk ook in 
de toekomst mijn blik op zal richten. 
Zoals een cel in het lichaam niet kan functioneren zonder de juiste stimulatie uit zijn 
omgeving, zo is ook dit proefschrift tot stand gekomen. Als eerste wil ik daarom mijn 
ouders bedanken. Pa en ma, de eigenschappen die ik van jullie geërfd heb en de steun die 
jullie me altijd gegeven hebben tijdens de vele omwegen die ik tijdens mijn opleiding 
gemaakt heb, vormen de basis van wie ik nu ben en wat ik bereikt heb. Bedankt voor 
alles! 
Dit project is voor mij begonnen tijdens mijn sollicitatiegesprek met Wolter Oosterhuis en 
Theo van der Kwast voor een opleidingsplaats pathologie. Wolter informeerde of ik 
onderzoek wilde doen en voor ik het goed en wel doorhad zat ik met Leendert om de tafel 
over dit project te praten. Wolter, tijdens het onderzoek kon ik altijd bij je terecht om 
coupes onder de microscoop te bekijken of een artikel te laten corrigeren, ook al had je 
het razend druk en stonden er meerdere mensen voor je deur te wachten. Bedankt voor al 
je tijd en aandacht; de komende jaren zal ik nog vaak bij je aankloppen. 
Leendert, vanaf de eerste keer dat ik met jou om tafel zat, werd ik gegrepen door je 
enthousiasme. Wanneer ik zelf het grote verband tussen mijn onderzoekslijnen niet 
helder voor ogen had, was je altijd bereid het nog een keer uit te leggen. Hierbij schetste 
je dan mogelijkheden voor verder onderzoek genoeg voor de komende jaren. In het begin 
werd ik hierdoor overdonderd, omdat ik dacht dat het allemaal direct moest gebeuren. 
Mede door jouw stimulerende persoonlijkheid is het onderzoek redelijk soepel verlopen 
en wordt zelfs nog voortgezet. Je bent niet alleen mijn baas geweest, maar ook een fijne 
collega en dat je geen humor hebt, zal ik zeker niet meer beweren. Bedankt voor de 
aangename begeleiding en opleiding van de afgelopen jaren. 
Het LEPO lab waar het zich allemaal heeft afgespeeld, heeft een harde kern die bestaat uit 
Hans, Ad en Ruud. Zoals bij vele promovendi voor mij hebben jullie bergen werk verzet 
om mij de eindstreep te laten halen. Ook jullie humor die aan een buitenstaander niet uit 
te leggen is, heeft mij een onvergetelijke tijd op het LEPO lab gegeven. Daar kan ik jullie 
in woorden niet genoeg voor bedanken, maar misschien is het in bier uit te drukken en 
kan ik op mijn promotiefeest iets voor jullie terugdoen. 
De huidige en voorgaande LEPO generatie: Remko, Gert-Jan, Claudia, Niels, Maria, 
Hendrik, Bertie, Wil, Martine P, Imke, Amy, Martine C, Annemarie, Marjan, Ester, Joris, 
Tim en Koen. Bedankt voor de goede sfeer en samenwerking! 
Sannah, mijn eerste en enige student. Bedankt voor je (radio)actieve inzet. 
De pathologen uit Delft: Antoine, Juliëtte en Hedda. Bedankt voor de ruimte die jullie me 
gaven om dit boekje af te ronden. 
Anoek, mijn zusje, samen hebben we een mooie kaft gemaakt, bedankt voor je hulp! 
Ruud, een paar jaar hebben we op het lab en achter de pc naast elkaar gezeten. Bedankt 
dat je tijdens mijn promotie naast me staat. 
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Kirsten, jij ben de vrouw die mij het beste kent en op jouw huwelijk was ik 
ceremoniemeester. Bedankt dat jij mijn paranimf wil zijn. 
Leo, jouw geduld en liefde zijn belangrijk geweest voor het slagen van mijn promotie 
onderzoek. Zoals altijd vullen we elkaar perfect aan met de verschillende keuzes die we 
maken. De tijd dat je me hebt moeten missen toen ik boven in de kast achter de pc zat, 
gaan we vanaf nu inhalen! 
 
 
 
The author and the Sajama vulcano (6542 meters) in Bolivia. 
 
